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Cover:  The illustration shows Nuclear Receptors and their control of diverse 
physiologic pathways (provided by Ronald Evans). 
 
The relationship between receptor's function and physiology illustrates how 
receptors are both controlled by environmental, physiologic and pathologic 
changes as well as illustrating the potential of receptors to impact on both 
the progression and treatment of disease. 
  
  
NUCLEAR RECEPTORS & DISEASE 
Tuesday, August 31 – Saturday, September 4, 2010 
 
Tuesday 7:30 pm 1  Keynote Speakers 
   
Wednesday 9:00 am 2  Physiology and Metabolism  
   
Wednesday 2:00 pm 3  Poster Session I 
   
Wednesday 4:30 pm Wine and Cheese Party * 
   
Wednesday 7:30 pm 4  Inflammation and Metabolic Disease 
   
Thursday 9:00 am 5  Ligands and Cofactors 
   
Thursday 2:00 pm 6  Poster Session II 
   
Thursday 7:30 pm 7  Cancer 
   
Friday 9:00 am 8  Mechanisms of Insulin Resistance and 
Adipogenesis 
   
Friday 2:00 pm 9  Inflammation II 
   
Friday 6:00 pm Concert 
 7:00 pm Banquet 
   
Saturday 9:00 am 10  Chromatin and Transcription 
 
Poster sessions are located in Bush Lecture Hall 
* Airslie Lawn, weather permitting 
Mealtimes at Blackford Hall are as follows:   
Breakfast   7:30 am-9:00 am 
Lunch       11:30 am-1:30 pm 
Dinner       5:30 pm-7:00 pm 
Bar is open from 5:00 pm until late 
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PROGRAM 
 
 
TUESDAY, August 31—7:30 PM 
 
 
SESSION 1 KEYNOTE SPEAKERS 
 
Chairperson: K. Yamamoto, University of California, San Francisco 
 
 
Nuclear receptor modulators (NuRMs) in worms 
Steven A. Kliewer, David J. Mangelsdorf. 
Presenter affiliation: University of Texas Southwestern Medical School, 
Dallas, Texas. 
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PPARγ and the anti-diabetic PPARγ ligands—A new look at an old 
friend 
Bruce Spiegelman. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts. 
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WEDNESDAY, September 1—9:00 AM 
 
 
SESSION 2 PHYSIOLOGY AND METABOLISM 
 
Chairperson: A. Saltiel, University of Michigan, Ann Arbor 
 
  
Integrating metabolic control by NAD+ sensors 
Johan Auwerx. 
Presenter affiliation: Ecole Polytechnique Federale de Lausanne 
(EPFL), Lausanne, Switzerland. 
 
 
 
3 
  
The nuclear bile acid receptor FXR and SIRT1 deacetylase form a 
dynamic interactive regulatory network controlling hepatic lipid 
metabolism 
Jongsook K. Kemper. 
Presenter affiliation: University of Illinois at Urbana-Champaign, 
Urbana, Illinois. 
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 vi 
NHR-49 as chief economist 
Mark Van Gilst. 
Presenter affiliation: Fred Hutchinson Cancer Research Center, 
Seattle, Washington. 
 
 
 
5 
  
Gene/environment influence on skeletal muscle insulin sensitivity 
in type 2 diabetic patients. 
Juleen Zierath. 
Presenter affiliation: Karolinska Institutet, Stockholm, Sweden. 
 
 
 
6 
  
PPARα orchestrates sexual dimorphism in hepatic functions 
Walter Wahli, Gianpaolo Rando, Nicolas Leuenberger. 
Presenter affiliation: University of Lausanne, Lausanne, Switzerland. 
 
 
7 
  
Oxysterols are ligands for the orphan nuclear receptor RORγt, a 
key regulator of Th17 cell development 
Katherine Rouleau, Xiaoshan Min, Zhulun Wang, Anke Konrad, John 
E. Sims, Antony Symons. 
Presenter affiliation: Amgen Inc., Seattle, Washington. 
 
 
 
 
8 
  
Circadian transcriptional repressors Cry1 and Cry2 mediate 
transrepression by the glucocorticoid receptor 
Katja A. Lamia, Grant D. Barish, Ruth T. Yu, N Henriette Uhlenhaut, 
Johan W. Jonker, Jamie Whyte, Michael Downes, Ronald M. Evans. 
Presenter affiliation: The Salk Institute for Biological Studies, La Jolla, 
California; The Scripps Research Institute, La Jolla, California. 
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WEDNESDAY, September 1—2:00 PM 
 
 
SESSION 3 POSTER SESSION I 
 
  
Promoter elements and protein function of the atypical 
corepressor TNIP1 indicate an expression feedback loop 
Igor Gurevich, Carmen Zhang, Priscilla Encarnacao, Vincent Ramirez, 
Brian Aneskievich. 
Presenter affiliation: University of Connecticut, Storrs, Connecticut. 
 
 
 
 
10 
  
Image-based analysis of ligand-specific coregulator recruitment 
to an estrogen receptor α-occupied promoter—An application for 
high content screening 
Felicity J. Ashcroft, Michael Bolt, Michael A. Mancini. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
11 
  
 vii 
Conditional knockdown of p70S6 kinase in liver protects against 
hepatic steatosis and systemic insulin resistance 
Eun Ju Bae, Jianfeng Xu, Jin-Long Chen, Jerrold M. Olefsky. 
Presenter affiliation: UCSD, La Jolla, California. 
 
 
 
12 
  
Loss of ER-regulated microRNAs is fundamental to hormone-
independent breast cancer cells 
Shannon T. Bailey, Housheng He, Myles Brown. 
Presenter affiliation: Dana-Farber Cancer Institute/Harvard Medical 
School, Boston, Massachusetts. 
 
 
 
 
13 
  
Effects of the selective glucocorticoid receptor modulator 
Compound A on Hsp70’s expression and functionality in the 
combat of inflammation 
Ilse M. Beck, Ruben Hoya Arias, Wim Vanden Berghe, Ali Adem 
Bahar, Guy Haegeman, Karolien De Bosscher. 
Presenter affiliation: University of Ghent, Gent, Belgium. 
 
 
 
 
 
14 
  
Structure elucidation of endogenous ligands of nuclear hormone 
receptors and other signaling molecules through Differential 
Analysis by 2D NMR Spectroscopy 
Parag Mahanti, Neelanjan Bose, Axel Bethke, Joshua C. Judkins, 
Joshua Wollam, Adam Antebi, Frank C. Schroeder. 
Presenter affiliation: Cornell University, Ithaca, New York. 
 
 
 
 
 
15 
  
The immunomodulatory glycan LNFPIII attenuates metabolic 
syndrome in HFD-induced obesity 
Prerna Bhargava, Changlin Li, Sihao Liu, Kristopher J. Stanya, Donald 
A. Harn, Chih-Hao Lee. 
Presenter affiliation: Harvard School of Public Health, Boston, 
Massachusetts. 
 
 
 
 
 
16 
  
Structural studies of transcriptional nuclear receptor complexes 
involving ERR and PGC-1α 
Isabelle M L. Billas, Maria Takács, Maxim Petoukhov, Borries Demeler, 
Javier Perez, Dmitri I. Svergun, Dino Moras. 
Presenter affiliation: IGBMC (Institut de Génétique et de Biologie 
Moléculaire et Cellulaire), Illkirch, France. 
 
 
 
 
 
17 
 
 
 
 viii 
In vitro biotools for NR research—From whole cell biosensors 
and –omics based methods to use of precision cut organ slices 
and ussing chambers 
Toine F. Bovee, Peter J. Hendriksen, Jeroen C. Rijk, Ad A. 
Peijnenburg, Ron L. Hoogenboom, Michel W. Nielen. 
Presenter affiliation: RIKILT-Institute of Food Safety, WUR, 
Wageningen, the Netherlands. 
 
 
 
 
 
 
18 
  
Glucocorticoids enhance the expression and function of the 
NLRP3 inflammasome 
John M. Busillo, John A. Cidlowski. 
Presenter affiliation: Molecular Endocrinology Group, Laboratory of 
Signal Transduction, Research Triangle Park, North Carolina. 
 
 
 
 
19 
  
Loss of IKKξ improves energy expenditure, diet-induced 
inflammation and hepatic steatosis independently of body weight 
Shian-Huey Chiang, Jonathan Hung, Lynn Geletka, Xiaoling Peng, 
Nathan Qi, Alan Saltiel. 
Presenter affiliation: University of Michigan, Ann Arbor, Michigan. 
 
 
 
 
20 
  
Regulation of the histone demethylase LSD1 by nuclear hormone 
receptors. 
Erin A. Clark, Yujiang Shi. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
 
 
 
21 
  
Progesterone receptor activity maintains uterine quiescence 
through direct regulation of caspase-3 action in the pregnant 
uterus. 
Pancharatnam Jeyasuria, Kalpana Subedi, Arvind Suresh, Jennifer 
Condon. 
Presenter affiliation: Magee Womens Research Institute, Pittsburgh, 
Pennsylvania. 
 
 
 
 
 
 
22 
  
The DLK gene is a target for PPARγ-mediated transcriptional 
activation during both adipogenesis and neurogenesis. 
Jean-Philippe Couture, Richard Blouin. 
Presenter affiliation: Université de Sherbrooke, Sherbrooke, Canada. 
 
 
 
23 
  
Selective modulation of GR can distinguish between 
transrepression of NF-κB and AP-1 
Karolien De Bosscher, Ilse M. Beck, Nadia Bougarne, Debby Bracke, 
Ine Vanherpe, Wim Vanden Berghe, Guy Haegeman. 
Presenter affiliation: University of Gent, Gent, Belgium. 
 
 
 
 
24 
  
 ix 
Increased glucocorticoid receptor expression and activity 
mediate the LPS resistance of SPRET/Ei mice 
Lien Dejager, Iris Pinheiro, Leen Puimege, Ye-Dong Fan, Claude 
Libert. 
Presenter affiliation: VIB, Zwijnaarde (Ghent), Belgium; UGent, 
Zwijnaarde (Ghent), Belgium. 
 
 
 
 
 
25 
  
GRIP1 as a target for glucocorticoid-induced phosphorylation 
Jana Dobrovolna, Yurii Chinenov, Inez Rogatsky. 
Presenter affiliation: Hospital for Special Surgery, New York, New 
York. 
 
 
 
26 
  
Nur77-dependent deregulation of PPARγ2 in fasted white adipose 
tissue 
Kalina Duszka, Anne M. Krogsdam, Juliane Bogner-Strauss, Andreas 
Prokesch, Zlatko Trajanoski. 
Presenter affiliation: Innsbruck Medical University, Innsbruck, Austria. 
 
 
 
 
27 
  
The role ERK1/2 and androgen receptor phosphorylation at serine 
81 in the progression to castrate resistant prostate cancer. 
Pamela McCall, Claire Orange, Morag Seywright, Mark Underwood, 
Joanne Edwards. 
Presenter affiliation: University of Glasgow, Glasgow, United Kingdom. 
 
 
 
 
28 
  
Genome-wide effects of RNAi-mediated knockdown of 
steroidogenic factor-1 in adrenocortical cells 
Anna Ehrlund, Cecilia Williams, Jan-Åke Gustafsson, Eckardt Treuter. 
Presenter affiliation: Karolinska Institutet, Stockholm, Sweden. 
 
 
 
29 
  
PGC1α-independent regulation of VEGF and vascularization by 
ERRγ 
Vihang A. Narkar, Weiwei Fan, Michael Downes, Ruth T. Yu, Johan W. 
Jonker, Ronald M. Evans. 
Presenter affiliation: Howard Hughes Medical Institute, The Salk 
Institute, La Jolla, California. 
 
 
 
 
 
30 
  
FoxO1 regulates Tlr4 inflammatory pathway signaling in 
macrophages 
WuQiang Fan, Jerrold M. Olefsky. 
Presenter affiliation: University of California, San Diego, La Jolla, 
California. 
 
 
 
 
31 
  
 x 
USP7/HAUSP stabilizes Tip60 in adipogenesis 
Yuan Gao, Olivier van Beekum, Arjen Koppen, Nicole Hamers, Aukje 
Veenstra, Ruud Berger, Aart G. Jochemsen, Arjan B. Brenkman, Huib 
Ovaa, Eric Kalkhoven. 
Presenter affiliation: UMC Utrecht, Utrecht, Netherlands; Netherlands 
Metabolomics Centre, Utrecht, Netherlands. 
 
 
 
 
 
32 
  
Cactin, a novel regulator of TLR signalling pathways 
Siobhan Gargan, Paola Atzei, Paul Moynagh. 
Presenter affiliation: Institute of Immunology, Maynooth, Republic of 
Ireland. 
 
 
 
33 
  
Expression profiling defines a universal glucocorticoid response 
program in airway smooth muscle, including non-inflammatory 
targets that alter airway function 
Kiriko Masuno, Sarah K. Sasse, Mukesh Jain, Anthony N. Gerber. 
Presenter affiliation: National Jewish Health, Denver, Colorado. 
 
 
 
 
34 
  
Genome-wide binding of estrogen receptor α in response to 
bisphenol A, genistein or estradiol exposure is cell-type specific 
and associates with FOXA1 binding 
Jason Gertz, Timothy E. Reddy, Katherine E. Varley, Rebekka O. 
Sprouse, Kimberly M. Newberry, Stephanie L. Parker, Richard M. 
Myers. 
Presenter affiliation: HudsonAlpha Institute, Huntsville, Alabama. 
 
 
 
 
 
 
35 
  
JMJD3 regulates Bcl-2 transcription in ERα-dependent breast 
cancer cells 
Amy Svotelis, Gabrielle Huppé, Stéphanie Bianco, Nicolas Gévry. 
Presenter affiliation: Université de Sherbrooke, Sherbrooke, Canada. 
 
 
 
36 
  
RBCK1 regulates proliferation in breast cancer cells potentially 
through control of ERα gene expression 
Nina Gustafsson, Chunyan Zhao, Jan-Åke Gustafsson, Karin 
Dahlman-Wright. 
Presenter affiliation: Karolinska Institute, Huddinge, Sweden. 
 
 
 
 
37 
  
Plasma cholesterol lowering by FXR agonist Px20350 is likely due 
to increased export as well as decreased uptake of cholesterol 
Eva Hambruch, Thomas Schlueter, Ulrich Abel, Michael Burnet, Ulrich 
Deuschle, Claus Kremoser. 
Presenter affiliation: Phenex Pharmaceuticals AG, Heidelberg, 
Germany. 
 
 
 
 
 
38 
  
 xi 
Potentiation of glucocorticoid signaling by chloroquine via 
inhibition of lysosomes 
Yuanzheng He, Yong Xu, Chenghai Zhang, Xiang Gao, H. Eric Xu. 
Presenter affiliation: Van Andel Institute, Grand Rapids, Michigan. 
 
 
 
39 
  
Orphan receptor NR2F6 represses autoimmunity 
Natascha Hermann-Kleiter, Thomas Gruber, Gottfried Baier. 
Presenter affiliation: Medical University, Innsbruck, Austria. 
 
 
40 
  
Her2-mediated down-regulation of SMRT in tamoxifen-resistant 
breast cancer 
Kuo-Sheng Hsu, Hung-Ying Kao. 
Presenter affiliation: Case Western Reserve University, Cleveland, 
Ohio. 
 
 
 
 
41 
  
Genome wide analysis of factors affecting androgen receptor 
function reveals new therapeutic targets in prostate cancer 
Keren Imberg, Susan Ha, Susan K. Logan, Michael J. Garabedian. 
Presenter affiliation: NYU School of Medicine, New York, New York. 
 
 
 
42 
  
Transcriptional Mediator subunit MED1 in stromal cells is 
involved in hematopoietic stem/progenitor cell support through 
VDR- and Runx2-mediated osteopontin expression 
Ruri Ishino, Akiko Sumitomo, Norinaga Urahama, Robert G. Roeder, 
Mitsuhiro Ito. 
Presenter affiliation: Kobe University Graduate School of Health 
Sciences, Kobe, Japan; The Rockefeller University, New York, New 
York. 
 
 
 
 
 
 
 
43 
  
Development of a novel pharmacokinetic approach for the use of 
glucocorticoids in the treatment of inflammatory diseases 
Maryam Jangani, David W. Ray, Rachelle P. Donn. 
Presenter affiliation: University of Manchester, United Kingdom. 
 
 
 
44 
  
Williams-Beuren syndrome chromosome region 22 (WBSCR22) is 
a novel modulator of glucocorticoid sensitivity. 
Maryam Jangani, Laura M. Green, Laura Elsby, David W. Ray, 
Rachelle P. Donn. 
Presenter affiliation: University of Manchester, United Kingdom. 
 
 
 
 
45 
  
BDNF and glucocorticoid receptor signaling and crosstalk 
Freddy D. Jeanneteau, Marcus Lambert, Thomas A. Neubert, Francis 
S. Lee, Michael J. Garabedian, Moses V. Chao. 
Presenter affiliation: NYU-Skirball Institute of Biomolecular Medicine, 
New York, New York. 
 
 
 
 
46 
  
 xii 
The actin-binding protein, α actinin alpha 4 (ACTN4), is a nuclear 
receptor coactivator that is required for estrogen receptor-
mediated transcriptional activation in MCF-7 breast cancer cells 
Simran Khurana, Sharmistha Chakraborty, Xiwen Cheng, Yu-Ting Su, 
Hung-Ying Kao. 
Presenter affiliation: Case Western Reserve University, Cleveland, 
Ohio. 
 
 
 
 
 
 
47 
  
Targeting EGFR-associated signaling pathways in non-small cell 
lung cancer cells—Implication in radiation response 
In Ah Kim. 
Presenter affiliation: Seoul National University, Seoul, South Korea. 
 
 
 
48 
  
Modeling of the aryl hydrocarbon receptor ligand binding pocket 
and identification of new ligands by virtual ligand screening 
Daniel C. Koch, William H. Bisson, Edmond F. O'Donnell, Prasad R. 
Kopparapu, Nancy I. Kerkvliet, Ruben Abagyan, Robert L. Tanguay, 
Siva K. Kolluri. 
Presenter affiliation: Oregon State University, Corvallis, Oregon. 
 
 
 
 
 
49 
  
In silico analysis in combination with high-throughput 
interactomics identifies putative novel brown/white specific 
PPARγ coregulators 
Arjen Koppen, Rene Houtman, Eric Kalkhoven. 
Presenter affiliation: University Medical Centre Utrecht, Utrecht, 
Netherlands. 
 
 
 
 
 
50 
  
Hairless—A novel transcriptional regulator of adipocyte 
differentiation 
Susann Kumpf, Arne Ittner, Romeo Ricci. 
Presenter affiliation: ETH Zurich, Zurich, Switzerland. 
 
 
 
51 
  
Mechanisms of glucocorticoid-induced muscle atrophy and 
insulin resistance 
Taiyi Kuo, Michelle J. Lew, Oleg Mayba, Terry Speed, Jen Chywan 
Wang. 
Presenter affiliation: University of California, Berkeley, Berkeley, 
California. 
 
 
 
 
 
52 
  
Modulation of glucocorticoid receptor transcriptional activity via 
BDNF-dependent phosphorylation 
W. Marcus Lambert, Freddy Jeanneteau, Thomas Neubert, Moses V. 
Chao, Michael J. Garabedian. 
Presenter affiliation: NYU School of Medicine, New York, New York. 
 
 
 
 
53 
  
 xiii 
Liver X receptor (LXR) regulates human adipocyte lipolysis 
Britta M. Stenson, Mikael Rydén, Nicolas Venteclef, Dominique Langin, 
Peter Arner, Jurga Laurencikiene. 
Presenter affiliation: Karolinska Institute, Stockholm, Sweden. 
 
 
 
54 
  
High throughput phage display identified novel ERβ interactors 
Thien Le, Matthew Walker, Benjamin Casterline, Geoffrey Greene. 
Presenter affiliation: University of Chicago, Illinois. 
 
 
55 
  
The role of the retinoid x receptors in stem cell differentiation 
Melanie C. Le May, Chenchen Hou, Natascha Lacroix, Hymn Mach, 
Qiao Li. 
Presenter affiliation: University of Ottawa, Ottawa, Canada. 
 
 
 
56 
  
PPARγ2 controls bone mass, marrow mesenchymal stem cell 
differentiation and energy metabolism in bone 
Beata Lecka-Czernik, Clifford Rosen, Masanobu Kawai, Piotr Czernik, 
Amrei Krings. 
Presenter affiliation: University of Toledo Medical Center, Toledo, 
Ohio. 
 
 
 
 
 
57 
  
Antiinflammatory effects of a novel agonist ligand for the nuclear 
receptor LRH-1 in inflammatory bowel disease 
Jae M. Lee, Jennifer Mamrosh, Charity M. Mills, David D. Moore. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
58 
  
The coactivator SRC-1 is an essential coordinator of hepatic 
glucose production 
Jean-Francois Louet, Atul Chopra, Jorn V. Sagen, Brian York, Chris B. 
Newgard, Bert W. O'Malley. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
 
 
 
 
59 
 
 
 
WEDNESDAY, September 1—4:30 PM 
 
Wine and Cheese Party 
 
 
 xiv 
WEDNESDAY, September 1—7:30 PM 
 
 
SESSION 4 INFLAMMATION AND METABOLIC DISEASE 
 
Chairperson: B. Desvergne, University of Lausanne, Switzerland  
 
 
Non-invasive imaging of pancreatic inflammation in models and 
patients 
Diane J. Mathis. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
 
 
 
60 
  
Cryo-electron microscopy structure of the 100kDa full nuclear 
receptor RXR/VDR heterodimer complex with its target DNA 
Igor Orlov, Natacha Rochel, Dino Morals, Bruno Klaholz. 
Presenter affiliation: IGBMC, Illkirch, France. 
 
 
 
61 
  
Inflammatory links between obesity, diabetes and energy 
expenditure 
Alan Saltiel 
Presenter affiliation: University of Michigan, Ann Arbor. 
 
 
 
62 
  
Identification of novel targets for PPARγ using transcriptional 
promoter ontology 
Johan W. Jonker, Michael Downes, Ronald M. Evans. 
Presenter affiliation: Salk Institute, La Jolla, California; University 
Medical Center Groningen, Groningen, Netherlands. 
 
 
 
 
63 
  
GPR120 is an Omega-3 fatty acid receptor mediating potent anti-
inflammatory and insulin sensitizing effects 
Da Young Oh, Saswata Talukdar, Jerrold M. Olefsky. 
Presenter affiliation: University of California, San Diego, La Jolla, 
California. 
 
 
 
 
64 
  
Structural mechanisms of signal integration in RXR heterodimers 
John Bruning, Andrew I. Shulman, German Gil, Nowak Jason, David J. 
Mangelsdorf, Michael Chalmers, Patrick R. Grififn, Kendall Nettles. 
Presenter affiliation: Scripps Research Institute, Jupiter, Florida. 
 
 
 
65 
  
Metabolic flexibility, stress and inflammation 
Philipp E. Scherer. 
Presenter affiliation: University of Texas Southwestern Medical Center, 
Dallas, Texas. 
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 xv 
THURSDAY, September 2—9:00 AM 
 
 
SESSION 5 LIGANDS AND COFACTORS 
 
Chairperson: R.M. Evans, The Salk Institute, La Jolla, California 
 
  
Mechanistic and physiological roles of coregulators in 
transcriptional regulation by steroid receptors 
Michael R. Stallcup. 
Presenter affiliation: University of Southern California, Los Angeles, 
California. 
 
 
 
 
67 
  
In vitro identification of selective androgen receptor modulators 
using an AR conformation change assay 
Jeremy O. Jones. 
Presenter affiliation: City of Hope Beckman Research Institute, Duarte, 
California. 
 
 
 
 
68 
  
Genome-wide chromatin remodeling during adipogenesis 
Susanne Mandrup. 
Presenter affiliation: University of Southern Denmark, Odense M, 
Denmark. 
 
 
 
69 
  
A distinct class of nuclear receptor alternate site modulators 
(NRAMs) that target a novel androgen receptor regulatory 
mechanism involving FKBP52 and β-Catenin 
Johanny Meneses De Leon, Aki Iwai, Jane Trepel, Clementine Feau, 
R. Kip Guy, Robert Fletterick, Leaonard M. Neckers, Marc B. Cox. 
Presenter affiliation: University of Texas at El Paso, El Paso, Texas. 
 
 
 
 
 
70 
  
Variation in glucocorticoid receptor binding sequence and its 
effect on structure 
Miles A. Pufall, Samantha Cooper, Lisa Watson, Keith R. Yamamoto. 
Presenter affiliation: University of California-San Francisco, San 
Francisco, California; University of Iowa-Carver College of Medicine, 
Iowa City, Iowa. 
 
 
 
 
 
71 
  
NR coactivators—Physiology and disease 
Bert O'Malley. 
Presenter affiliation: Baylor College of Medicine, Houston, Texas. 
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 xvi 
THURSDAY, September 2—2:00 PM 
 
 
SESSION 6 POSTER SESSION II 
 
  
Identification and mechanism of decanoic acid as a natural 
modulating ligand of PPARγ 
Raghu R. V. Malapaka, Sok Kean Khoo, Yong Xu, James H. Resau, 
Eugene Chen, Eric Xu. 
Presenter affiliation: Van Andel Institute, Grand Rapids, Michigan. 
 
 
 
 
73 
  
Multiple nuclear export signals in the thyroid hormone receptor—
Implications for resistance to thyroid hormone syndrome 
Manohara S. Mavinakere, Jeremy Powers, Vincent R. Roggero, 
Lizabeth A. Allison. 
Presenter affiliation: College of William & Mary, Williamsburg, Virginia. 
 
 
 
 
74 
  
The role of androgen receptor phosphorylation in castrate 
resistant prostate cancer 
Pamela McCall, Claire Orange, Morag Seywright, Joanne Edwards. 
Presenter affiliation: University of Glasgow, Glagow, United Kingdom. 
 
 
 
75 
  
Regulation of androgen receptor mediated transcription by RPB5 
binding protein (RMP/URI) 
Paolo Mita, Susan Ha, Susan K. Logan. 
Presenter affiliation: New York University School of Medicine, New 
York, New York. 
 
 
 
 
76 
  
Screening patients with severe insulin resistance identifies a 
novel FPLD-associated PPARγ mutation (Y151C) 
Maartje E. Visser, Elise Kropman, Mariëtte E. Kranendonk, Arjan 
Koppen, Erik S. Stroes, Eric Kalkhoven, Houshang Monajemi. 
Presenter affiliation: UMC Utrecht, Utrecht, Netherlands. 
 
 
 
 
77 
  
Ligand-independent transcriptional actions of human ERβ splice 
variants on ERE, AP-1 and human arginine vasopressin (hAVP) 
promoters in neuronal cells 
Natasha N. Mott, Toni R. Pak. 
Presenter affiliation: Loyola University Medical Center, Maywood, 
Illinois. 
 
 
 
 
 
78 
  
 xvii 
Estrogen: estrogen receptor alpha activated negative regulators 
of growth factor signaling in breast cancer. 
Harikrishna Nakshatri, Hitesh Appaiah, AJ Sood, Jennifer Sondhi, Sunil 
Badve, Poornima Bhat-Nakshatri. 
Presenter affiliation: Indiana University School of Medicine, 
Indianapolis, Indiana. 
 
 
 
 
 
79 
  
Dexamethasone (DEX), cortisol (COR), and aldosterone (ALD) 
generate common and unique patterns of gene expression in 
human trabecular meshwork cells 
Alissar Nehme, Stefanie J. Kirwin, W D. Stamer, Jeffrey L. Edelman. 
Presenter affiliation: Allergan Inc, Irvine, California. 
 
 
 
 
80 
  
AHR-mediated immunosuppression by alternative AHR ligands—
A novel strategy for treatment of autoimmune disease 
Ed F. O'Donnell, Prasad Kopurapu, Diana Rohlman, Dan Koch, Siva K. 
Kolluri, Nancy I. Kerkvliet. 
Presenter affiliation: Oregon State University, Corvallis, Oregon. 
 
 
 
 
81 
  
Estrogen receptor β is a potential therapeutic target to suppress 
lymphoid tumor growth 
Konstantin Yakimchuk, Maryam Iravani, Stefan Nilsson, Mikael Jondal, 
Sam Okret. 
Presenter affiliation: Karolinska Institutet, Huddinge, Sweden. 
 
 
 
 
82 
  
Androgen- and glucocorticoid-induced activation of FKBP51 
locus through long-range interactions 
Ville Paakinaho, Harri Makkonen, Tiina Jääskeläinen, Jorma Palvimo. 
Presenter affiliation: University of Eastern Finland, Kuopio, Finland. 
 
 
 
83 
  
Identification of a novel estrogen responsive estrogen receptor α 
(ESR1) variants in the pregnant uterus. 
Clifton R. Moore, Steve N. Caritis, Christina M. Kachulis, Jennifer C. 
Condon, Pancharatnam Jeyasuria. 
Presenter affiliation: University of Pittsburgh, School of Medicine, 
Pittsburgh, Pennsylvania. 
 
 
 
 
 
84 
  
Opposite roles of additional sex comb-like (ASXL) 1 and 2 in 
adipogenesis via differential regulation of PPARγ 
Ui-Hyun Park, Na-ra Shin, Eun-Joo Kim, Soo-Jong Um. 
Presenter affiliation: Sejong University, Seoul, South Korea. 
 
 
 
85 
  
 xviii 
NHR-49 influences mitochondrial physiology by regulating 
distinct aspects of lipid metabolism 
Pranali P. Pathare, Marc Van Gilst. 
Presenter affiliation: Fred Hutchinson Cancer Research Center, 
Seattle, Washington. 
 
 
 
 
86 
  
Warfarin enantiomers interactions with Pregnane X nuclear (PXR) 
receptor in gene regulation of cytochrome P450 CYP3A4 enzyme 
Alice Rulcova, Lucie Svecova, Radim Vzal, Michal Bitman, Zdenek 
Dvorak, Petr Pavek. 
Presenter affiliation: Charles University in Prague, Hradec Kralove, 
Czech Republic. 
 
 
 
 
 
87 
  
Glucocorticoid receptor transcriptional regulation of the circadian 
clock gene PER1 
Marlisa L. Pillsbury, Keith R. Yamamoto. 
Presenter affiliation: University of California, San Francisco, San 
Francisco, California. 
 
 
 
 
88 
  
LXR activation induces Arginase 1 expression in macrophages 
Benoit Pourcet, Ines Pineda-Torra. 
Presenter affiliation: University College London, London, United 
Kingdom. 
 
 
 
89 
  
Effects of free fatty acids on the expression of PGC1-α and 
insulin signaling in skeletal muscle cells 
Larysa Yuzefovych, Lyudmila Rachek. 
Presenter affiliation: University of South Alabama, Mobile, Alabama. 
 
 
 
90 
  
A network of regulatory elements directs the glucocorticoid 
receptor to express Period 1 at low doses of corticosteroid 
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FRIDAY, September 3—6:00 PM 
 
CONCERT 
Grace Auditorium 
 
Di Wu, piano 
 
Praised in The Wall Street Journal as “a most mature and sensitive pianist,” 
Chinese-born Di Wu’s reputation as an elegant yet exciting musician 
continues to grow, and 2009 has been a banner year: During the spring and 
summer she made her New York Alice Tully Hall recital debut as winner of 
Juilliard’s William Petschek Piano Debut Recital Award, was named Artist of 
the Month by MusicalAmerica.com, and was awarded a Vendome Virtuosi 
prize at Lisbon’s prestigious Vendome Competition as well as one of the 
coveted prizes at the Thirteenth Van Cliburn International Piano Competition. 
In September she made her Philadelphia Orchestra debut at a gala benefit 
concert under Charles Dutoit. 
Ms. Wu made her professional debut at 14 with the Beijing Philharmonic, 
since then she has toured widely in Asia, Europe and the United States, 
where her recent orchestral engagements have included appearances with 
Washington’s National Symphony, the Pittsburgh Symphony, the New Jersey 
Symphony Orchestra, and twice in Carnegie Hall with the New York Pops. 
During the 2009-10 season, Ms. Wu is scheduled for a 40-concert tour which 
will take her from California to Germany.  
 
Di Wu came to the United States in 1999 to study at the Manhattan School 
of Music with Zenon Fishbein. From 2000 to 2005 she studied at the Curtis 
Institute with Gary Graffman, subsequently earning a Master of Music degree 
at The Juilliard School under Yoheved Kaplinsky and, in 2009, an Artist 
Diploma under the guidance of Joseph Kalichstein and Robert McDonald. 
Ms. Wu is currently represented by Astral Artists.  
 
 
FRIDAY, September 3 
 
BANQUET 
 
Cocktails  7:00 PM Dinner  7:45 PM 
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NUCLEAR RECEPTOR MODULATORS (NURMS) IN WORMS 
 
Steven A Kliewer, David J Mangelsdorf  
 
University of Texas Southwestern Medical School, Departments of 
Pharmacology, Molecular Biology, and Howard Hughes Medical Institute, 
Dallas, TX, 75390 
 
The ability to regulate nutrient metabolism under conditions of excess (i.e., 
after a big meal) or deprivation (i.e., starvation) is a physiologic process that 
coincided with the evolution of nuclear receptors in all multi-cellular 
organisms. In mammals, nuclear receptor systems have evolved to respond 
to cholesterol, bile acids, and fatty acids and thereby govern nutrient 
metabolism in the fed and fasted state. Recently, we have discovered that 
this process is conserved in nematodes, and this has led to the discovery that 
nuclear receptor regulated pathways may be exploited therapeutically to 
target two unexpectedly related human diseases: type 2 diabetes and 
nematode parasitism. 
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PPARγ AND THE ANTI-DIABETIC PPARγ LIGANDS: A NEW LOOK 
AT AN OLD FRIEND 
 
Bruce Spiegelman  
 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115 
 
 The nuclear receptor PPARγ is the dominant regulator of fat cell 
differentiation and development. Expression and agonist activation of 
PPARγ is sufficient for adipose cell differentiation in most fibroblastic 
cells, and loss of function blocks fat development. Humans with dominant-
negative mutations in PPARγ have a form of lipodystrophy with severe 
insulin resistance and hypertension. In addition to these roles in adipose 
formation, PPARγ is the functioning receptor for the TZD anti-diabetic 
ligand drugs. These drugs such as rosiglitazone are full agonists for PPARγ. 
In new work, we show that obesity induced in mice by high-fat feeding 
activates the protein kinase cdk5 in adipose tissues. This results in 
phosphorylation of PPARγ at serine 273. This modification of PPARγ does 
not alter its adipogenic capacity, but leads to dysregulation of a large 
number of genes whose expression is altered in obesity, including a 
reduction in the expression of the insulin-sensitizing adipokine, adiponectin. 
The phosphorylation of PPARγ by cdk5 is blocked by anti-diabetic PPARγ 
ligands, such as rosiglitazone and MRL24. This inhibition works bothin 
vivo and in vitro, and surprisingly, is completely independent of classical 
receptor transcriptional agonism. Similarly, inhibition of PPARγ 
phosphorylation in obese patients by rosiglitazone is very tightly associated 
with the anti-diabetic effects of this drug.  These data strongly suggest that 
cdk5-mediated phosphorylation of PPARγ may be involved in the 
pathogenesis of insulin-resistance, and present an opportunity for 
development of an improved generation of anti-diabetic drugs through 
PPARγ.
 3 
INTEGRATING METABOLIC CONTROL BY NAD+ SENSORS 
 
Johan Auwerx  
 
Ecole Polytechnique Federale de Lausanne (EPFL), SV/IBI1/NCEM/LISP, 
Lausanne, 1015, Switzerland 
 
A century after the identification of a co-enzymatic activity for NAD+, 
NAD+ metabolism has come in the spotlight again due to the potential 
therapeutic relevance of a set of enzymes whose activity is tightly regulated 
by the balance between the oxidized and reduced forms of this metabolite. 
In fact, the actions of NAD+ have been extended from being an 
oxidoreductase cofactor for single enzymatic activities to acting as a 
substrate for a wide range of proteins. These include NAD+-dependent 
sirtuin protein deacetylase, poly(ADP-ribose) polymerases, and 
transcription factors that affect a large array of cellular functions. Through 
these effects NAD+ provides a direct link between the cellular redox status 
and the control of signaling and transcriptional events. Of particular interest 
within the metabolic/endocrine arena are the recent results, which indicate 
that the regulation of these NAD+-dependent pathways may have a major 
contribution to oxidative metabolism and lifespan extension. I will provide 
an integrated view on how the control of NAD+ production and cycling, as 
well as its cellular compartmentalization, alters transcriptional pathways via 
NAD+’s commanding role on cofactor networks that involve and SIRT1, 
GCN5, and PGC-1α. As such the modulation of NAD+-producing and -
consuming pathways have a major physiological impact and hold promise 
for the prevention and treatment of metabolic disease. 
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THE NUCLEAR BILE ACID RECEPTOR FXR AND SIRT1 
DEACETYLASE FORM A DYNAMIC INTERACTIVE REGULATORY 
NETWORK CONTROLLING HEPATIC LIPID METABOLISM  
 
Jongsook K Kemper 
 
University of Illinois at Urbana-Champaign, Molecular and Integrative 
Physiology, Urbana, IL, 61801 
 
Imbalance in metabolic equilibrium and accumulation of lipid metabolites, bile 
acids, cholesterol, and fat, play causative roles in metabolic disorders. The 
nuclear bile acid receptor FXR plays an important role in maintaining lipid 
levels by activating or repressing its numerous target genes. The NAD+-
dependent SIRT1 deacetylase also plays a critical role in cellular metabolism by 
modulating the activity of key metabolic regulators including PGC-1a. 
Although both FXR and SIRT1 are critical for hepatic metabolism and 
activation of these proteins lead to beneficial transcriptional profiling and 
metabolic outcomes in metabolic disease states, it is not clear whether these two 
proteins are coordinately regulated. Our published and current studies provide 
evidence that FXR and SIRT1 positively regulate each others’ levels and 
activities to maintain metabolic homeostasis. FXR activation positively 
regulates hepatic SIRT1 protein levels by inhibiting expression of the non-
coding small microRNA34a (miR-34a), which inhibits SIRT1 by binding to its 
3’UTR. Levels of miR-34a are elevated and SIRT1 protein levels are decreased 
in obese mice, and interestingly, FXR activation by daily treatment for 1 week 
with GW4064, a synthetic FXR agonist, reverses these effects. It has been 
shown that SIRT1 levels are substantially reduced in diet-induced obese mice 
but how SIRT1 levels are reduced remains unclear. Our studies explain, at least 
in part, decreased SIRT1 protein levels are due to elevated miR34a levels as a 
result of deregulated FXR activity in obese mice. Conversely, SIRT1 also 
increases transactivation potential of FXR because acetylation dampens FXR 
activity by inhibiting heterodimerization with RXRa and binding to 
DNA/chromatin. Remarkably, FXR acetylation is dramatically elevated in 
obese mice and SIRT1 activation in these mice by treatment of resveratrol, a 
natural SIRT1 activator, or adenoviral-mediated overexpression of SIRT1 
decreases FXR acetylation levels with beneficial lipid metabolic outcomes. To 
elucidate functional roles of FXR acetylation, we have identified K157 and 
K217 as FXR acetylation sites and developed antibodies specific for FXR 
acetylated at these sites. Using these antibodies, we found that acetylation 
specifically at K217 is dramatically elevated in obese mice and interaction with 
SIRT1 is substantially decreased in these mice. We are currently investigating 
transcriptional and metabolic effects of FXR acetylation at K217 in vivo. Our 
studies suggest that FXR and SIRT1 constitute an interactive regulatory 
network dynamically controlling hepatic lipid metabolism and that deregulation 
of these networks is associated with metabolic disease states. Manipulation of 
this regulatory network may be useful for treating metabolic diseases, such as 
fatty liver, obesity, and diabetes (Supported by grants from NIH and the 
American Diabetes Association). 
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NHR-49 AS CHIEF ECONOMIST 
 
Marc Van Gilst  
 
Fred Hutchinson Cancer Research Center, Basic Sciences Division, Seattle, 
WA, 98109 
 
In nematodes, NHR-49 acts as a functional homolog of the mammalian 
PPARs, directing energy storage and expenditure in response to food intake 
and withdrawal. Using the unique methodological strengths of C. elegans, 
we have been able to comprehensively characterize and dissect the NHR-49 
regulatory network. Our studies show that, at the global level, NHR-49 
partners with other C. elegans NRs to coordinate food supply with 
reproductive demand, while at the local level NHR-49 directs the assembly 
and modification of cellular infrastructure to accommodate changes in 
nutrient accessibility or demand. The cellular functions of NHR-49 are 
elegantly modeled by the basic principles of supply side economics. In such 
a model, NHR-49 acts as a chief economist charged with stabilizing global 
supply and demand. At the local level, NHR-49 works with a team of NR 
“specialists” that allow NHR-49 to independently control multiple links in 
the supply side chain. Finally, in addition to subtle modifications, the NHR-
49 regulatory mechanism can bring the entire economy of reproduction to a 
halt if even a simple commodity is missing. This state of reproductive arrest 
can extend adult longevity by nearly 20-fold, suggesting that the challenges 
of running a highly productive economy may be causative factors in the 
aging process. Moving forward, stable isotope labeling strategies provide a 
unique opportunity to measure economic parameters in a live organism, and 
to relate these parameters to the genetics of aging and disease. 
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GENE/ENVIRONMENT INFLUENCE ON SKELETAL MUSCLE 
INSULIN SENSITIVITY IN TYPE 2 DIABETIC PATIENTS 
 
Juleen R Zierath  
 
Karolinska Institutet, Physiology, Stockholm, Sweden 
 
Skeletal muscle is an important site of insulin-mediated glucose uptake and 
defects in this insulin target tissue precede the manifestation of Type 2 
diabetes. Our central hypothesis is that activation of insulin-independent 
pathways to glucose transport in skeletal muscle may overcome the 
profound impairment in whole body glucose homeostasis associated with 
Type 2 diabetes. Intensive research efforts have been directed towards 
understanding the regulation of insulin-dependent and insulin-independent 
pathways governing glucose metabolism and the factors causing insulin 
resistance in Type 2 diabetes. Physical exercise/muscle contraction elicits 
an insulin-independent increase in glucose transport and perturbation of this 
pathway may bypass defective insulin signaling. To date, the exercise-
responsive signaling molecules governing glucose metabolism in skeletal 
muscle are largely unknown. Epigenetic modification through DNA 
methylation is implicated in metabolic disease and may play a role in the 
mechanism by which environmental factors influence metabolic responses 
in diabetes. Using whole genome promoter methylation analysis of skeletal 
muscle from normal glucose tolerant and Type 2 diabetic subjects, we 
identified cytosine hypermethylation of Peroxisome Proliferator-Activated 
Receptor γ Coactivator-1 α (PGC-1α) in diabetic subjects. Methylation 
levels were negatively correlated with PGC-1α mRNA and mitochondrial 
DNA (mtDNA). Bisulfite sequencing revealed that the highest proportion of 
cytosine methylation within PGC-1α was found within non-CpG 
nucleotides. Non-CpG methylation was acutely increased in human 
myotubes by exposure to tumor necrosis factor-α (TNF-α) or free fatty 
acids, but not insulin or glucose. Selective silencing of the DNA 
methyltransferase 3B (DNMT3B), but not DNMT1 or DNMT3A, prevented 
palmitate-induced non-CpG methylation of PGC-1α and decreased mtDNA 
and PGC-1α mRNA. We provide evidence for PGC-1α hypermethylation, 
concomitant with reduced mitochondrial content in Type 2 diabetic patients, 
and link DNMT3B to the acute fatty-acid induced non-CpG methylation of 
PGC-1α promoter. By identifying the molecular mechanisms controlling 
insulin sensitivity, future development of pharmacological and 
physiological (exercise and diet) intervention strategies aimed to improve 
glucose homeostasis may be possible.  
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PPARα ORCHESTRATES SEXUAL DIMORPHISM IN HEPATIC 
FUNCTIONS  
 
Walter Wahli1, Gianpaolo Rando1, Nicolas Leuenberger2  
 
1University of Lausanne, Center for Integrative Genomics, Lausanne, 1015, 
Switzerland, 2CHUV, Swiss Laboratory for Doping Analyses, Epalinges, 
1066, Switzerland 
 
Peroxisome proliferator-activated receptors form a small family of three 
nuclear receptors (PPARα, PPARβ/δ and PPARγ), which act as lipid 
sensors to modulate gene expression. As most metabolic studies are 
conducted in male animals, understanding the sex specificity of the 
underlying molecular pathways has been neglected. For instance, PPARα 
has been considered as having low activity in female liver, because of the 
lack of peroxisome proliferation when females are exposed to peroxisome 
proliferators. 
 
This point of view is now challenged by the observation that there is a 
sexual dimorphism in PPARα post-translational modification, which plays 
an active role in gene repression. In female mice, PPARα has broad 
repressive actions on hepatic genes involved in steroid metabolism and 
immunity. Using the steroid oxysterol 7α-hydroxylase cytochrome P4507b1 
(Cyp7b1) gene as a model, we elucidated the molecular mechanism of this 
sex-specific PPARα-dependent repression. Initial sumoylation of the ligand-
binding domain of PPARα triggered the interaction of PPARα with GA-
binding protein alpha (GABPα) bound to the target Cyp7b1 promoter. DNA 
and histone methyltransferases were then recruited, and the adjacent Sp1-
binding site and histones were methylated. These events resulted in loss of 
Sp1-stimulated expression and thus downregulation of Cyp7b1. 
Physiologically, this repression conferred on female mice protection against 
experimentally estrogen-induced intrahepatic cholestasis.  
 
Coregulator recruitment participates in tissue-specific actions of nuclear 
receptors. To explore whether sexual dimorphism involves coregulators, we 
analyzed hepatic PPARα protein complexes in both sexes. We found three 
proteins that interact preferentially with PPARα in female liver. We 
identified the PPAR interaction motif of one of them and explored its 
coregulator abilities, which required NADP+, suggesting that PPARα trans-
repression is redox-sensitive. One of the processes, which are repressed in 
females, is isoprenoid synthesis. In support of this finding, co-treatment of 
hepatoma cells with 17β-estradiol and PPARα ligands diminished 
isoprenoid synthesis, which was associated with reduced cell proliferation. 
 
Collectively, our data identify PPARα as a key actor of hepatic sexual 
dimorphism. The ongoing characterization of this function aims to unveil 
why the female liver is more resistant to inflammation and cancer.  
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OXYSTEROLS ARE LIGANDS FOR THE ORPHAN NUCLEAR 
RECEPTOR RORγT, A KEY REGULATOR OF TH17 CELL 
DEVELOPMENT 
 
Katherine Rouleau1, Xiaoshan Min2, Zhulun Wang2, Anke Konrad3, John E 
Sims1, Antony Symons1  
 
1Amgen Inc., Inflammation, Seattle, WA, 98199, 2Amgen Inc., Molecular 
Structure, San Francisco, CA, 94080, 3Amgen GMBH, Research, 
Regensburg, 93053, Germany 
 
Th17 cells are CD4+ cells that express the pro-inflammatory cytokine IL-17 
and have been identified as a distinct T cell lineage involved in mediating 
inflammation and auto-inflammatory disorders. In human disease, IL-17 has 
been shown to be elevated in the synovial fluid of rheumatoid arthritis 
patients as well as in the gut mucosa of Crohn’s and ulcerative colitis 
patients.  
The RAR-related orphan receptor (RORγt) is a member of the nuclear 
receptor superfamily and has been identified as a key transcription factor 
required for the development of Th17 cells. Nuclear receptors require 
coactivator binding to activate transcription of their target genes. For many 
nuclear receptors small molecule ligands bind the ligand binding domain of 
the receptor and regulate association with the coactivators/corepressors. 
RORγt has been considered an orphan nuclear receptor as regulation by a 
small molecule has not been demonstrated.  
Utilizing a biochemical coactivator peptide binding assay we have 
identified a class of cholesterol derivatives with activity specific to RORγt 
versus RORα and PPARγ. In this assay these molecules perform as agonists 
and enhance RORγt -LBD protein binding to the coactivator peptide 
GRIP1. Further validation that these cholesterol derivatives are RORγt 
ligands was provided by mass spectrometry, a scintillation proximity assay 
and an X-ray crystal structure of the RORγt ligand binding domain.  
In contrast to the agonist activity of oxysterols in the RORγt biochemical 
assay, these molecules act as inhibitors in a RORγt -dependent reporter 
assay.  
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CIRCADIAN TRANSCRIPTIONAL REPRESSORS CRY1 AND CRY2 
MEDIATE TRANSREPRESSION BY THE GLUCOCORTICOID 
RECEPTOR 
 
Katja A Lamia1,2, Grant D Barish1, Ruth T Yu1, N Henriette Uhlenhaut1,3, 
Johan W Jonker1,4, Jamie Whyte1, Michael Downes1, Ronald M Evans1  
 
1The Salk Institute for Biological Studies, Gene Expression Laboratory, La 
Jolla, CA, 92037, 2The Scripps Research Institute, Chemical Physiology, La 
Jolla, CA, 92037, 3Max-Delbrueck-Centrum Fuer Molekulare Medizin, 
Genetics and Physiology, Berlin, 13125, Germany, 4 University Medical 
Center Groningen, Department of Pediatrics, Groningen, 9700 RB, 
Netherlands 
 
Nuclear hormone receptors (NRs) regulate physiology by modulating gene 
expression in response to lipophilic ligands, including hormones, vitamins, 
and dietary lipids. Ligand stimulation of NRs can influence the transcription 
of target genes either positively (transactivation) or negatively 
(transrepression). Transactivation is mediated by ligand-induced 
recruitment of co-activators or release of co-repressors while 
transrepression requires the NR C-terminal domain and unknown accessory 
factors. We demonstrate that the circadian transcriptional repressors 
cryptochromes 1 (Cry1) and 2 (Cry2) interact with several nuclear hormone 
receptors. Studying the interaction of Cry1 and Cry2 with the glucocorticoid 
receptor (GR) in detail, we found that Cry1 and Cry2 interact with the C-
terminus of the GR and are required for most transrepression observed in 
response to the synthetic GR ligand dexamethasone in mouse embryonic 
fibroblasts. In addition, dexamethasone-induced transactivation of many 
genes was increased in Cry-deficient fibroblasts suggesting that 
cryptochromes oppose transactivation in addition to contributing to 
transrepression. In mice, genetic loss of Cry1 and/or Cry2 resulted in 
glucose intolerance and constitutively high levels of circulating 
corticosterone, suggesting reduced glucocorticoid suppression of the 
hypothalamic-pituitary-adrenal (HPA) axis coupled with increased 
sensitivity to the hyperglycemic effects of glucocorticoid-mediated 
transactivation in the liver. Dexamethasone-induced transcription of pepck 
was strikingly increased in Cry-deficient livers, while recruitment of GR to 
the pepck promoter was unaffected by the absence of Cry1 and Cry2. 
Finally, Cry1-/-;Cry2-/- mice subjected to 8 weeks of chronic 
dexamethasone treatment exhibited incomplete suppression of circulating 
corticosterone and greater glucose intolerance compared with wildtype 
littermates subjected to the same chronic treatment, consistent with a 
positive shift in the transcriptional response to the synthetic glucocorticoid 
ligand. 
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PROMOTER ELEMENTS AND PROTEIN FUNCTION OF THE 
ATYPICAL COREPRESSOR TNIP1 INDICATE AN EXPRESSION 
FEEDBACK LOOP  
 
Igor Gurevich, Carmen Zhang, Priscilla Encarnacao, Vincent Ramirez, 
Brian Aneskievich  
 
University of Connecticut, Pharmaceutical Sciences, Storrs, CT, 06269 
 
Nuclear receptor (NR) regulation of transcription is dependent on auxiliary 
proteins known as coactivators and corepressors. We isolated TNFAIP3 
interacting protein 1 (TNIP1) from a human keratinocyte cDNA library and 
identified it as a corepressor of retinoic acid receptors (RARs). RARs 
control gene expression in both normal skin and non-skin tissues and are 
important pharmacologic targets in skin and hematopoietic cancers. TNIP1 
interacts with target NRs only in the presence of ligand but represses their 
activity making it unlike NCoR or SMRT and functionally more like 
RIP140 and LCoR. Prior to our demonstration of it as a corepressor of 
ligand-bound RAR, TNIP1 protein was reported i)to shuttle HIV nef and 
matrix proteins into the nuclei of infected cells and ii)to suppress 
cytoplasmic signaling leading to NF-kappaB activity. Recently, the human 
TNIP1 gene locus was reported as strongly associated with the 
inflammatory skin disease psoriasis through a genome-wide scan. TNIP1’s 
expression beyond skin cells and role in diverse pathways prompted us to 
investigate genomic elements controlling its expression. To this end, we 
isolated 6kb of the human TNIP1 promoter and subjected it to physical and 
functional analysis.  
Our study demonstrated the human TNIP1 promoter lacks a TATA box and 
is increasingly GC-rich approaching its variable transcription start sites. We 
identified Sp1 regulation of the proximal TNIP1 promoter. Intriguingly, we 
found potential NR binding sites of differing direct repeats within the distal 
sequence of the 6kb clone. Among these repeats, we demonstrated 
functional RAR binding sites through receptor up-regulation of the 
promoter in reporter constructs, receptor binding in mobility shift assays, 
receptor occupation of these sites in chromatin immuno-precipitation 
assays, and retinoid up-regulation of the endogenous gene. Through similar 
approaches, we found two NF-kappaB sites, one each within proximal and 
distal promoter regions. Positive control of the TNIP1 promoter by RAR 
and/or NF-kappaB sets the stage for a regulatory circuit by the very proteins 
whose functions are repressed by TNIP1. These results may place the 
regulatory elements of the TNIP1 promoter and the functions of its widely-
expressed protein in a negative feedback loop. The constitutive (Sp1) and 
inducible (RAR, NF-kappaB) expression of TNIP1 could contribute control 
to NR- and NF-kappaB-mediated gene expression networks in normal 
physiology of multiple cells and be subject to perturbation in psoriasis and 
other inflammatory diseases.  
Supported by grants from NIAMS and AFPE. 
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IMAGE-BASED ANALYSIS OF LIGAND-SPECIFIC COREGULATOR 
RECRUITMENT TO AN ESTROGEN RECEPTOR Α-OCCUPIED 
PROMOTER: AN APPLICATION FOR HIGH CONTENT SCREENING. 
 
Felicity J Ashcroft, Michael Bolt, Michael A Mancini  
 
Baylor College of Medicine, Molecular and Cell Biology, Houston, TX, 
77030 
 
Due to its important role in reproductive biology and regulation of diseases 
including breast cancer and osteoporosis, estrogen receptor α (ER) is the 
target of many therapeutic compounds including estrogen mimetics and 
selective ER modulators (SERMs). Considerable evidence also identifies 
ER as a probable target for some environmentally prevalent endocrine 
disrupting chemicals (EDCs) that pose serious risks to human health and 
ecosystems. There is therefore an ongoing need to improve technologies for 
the study of ligand-dependent modulation of ER, with a precedent to 
making these technologies accessible for use in both drug development and 
EDC testing.  
 
Structural and biochemical studies indicate that ligand-specific regulation of 
ER involves the induction of conformational changes in the receptor that 
modify its ability to bind to coregulator proteins and thus regulate 
transcription in a manner that is tissue specific.  
We have created and validated a microscopy-based approach to quantify 
coregulator recruitment to an ER-occupied promoter locus as part of a 
platform that is amenable to high content screening (HCS). This system 
exploits an engineered cell line harboring a microscopically-visible 
multicopy integration of an ER-regulated promoter (termed the PRL array). 
We have analyzed the dose-dependent recruitment of transcriptional 
coregulators RNA polymerase II (Pol II) and steroid receptor coactivator-3 
(SRC-3) to the PRL-array following treatment with a small panel of 
SERMs, at multiple timepoints. When compared to a 30 min treatment with 
17β-estradiol (E2), 4H-tamoxifen and Raloxifene both repressed the 
recruitment of Pol II and SRC3 to ER-occupied PRL-arrays. Conversely, 
treatment with the estrogen mimetic diethylstilbestrol induced similar levels 
of Pol II and SRC-3 recruitment to E2. Interestingly, the EDCs bisphenol-A 
and bisphenol-B both induce the recruitment of SRC-3, but not Pol II, to the 
ER-occupied PRL-array. Studies are ongoing to extend the panel of 
coregulators tested, with a particular focus on defining ligand-specific 
differences in coregulator recruitment that may be useful in predicting the 
tissue-specific physiological effects of SERMs and EDCs. 
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CONDITIONAL KNOCKDOWN OF P70S6 KINASE IN LIVER 
PROTECTS AGAINST HEPATIC STEATOSIS AND SYSTEMIC 
INSULIN RESISTANCE 
 
Eun Ju Bae1, Jianfeng Xu1, Jin-Long Chen2, Jerrold M Olefsky1  
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Obesity associated hepatic steatosis is manifested by selective insulin 
resistance where lipogenesis remains sensitive to insulin, whereas, the 
ability of insulin to suppress glucose production is impaired. P70 S6 kinase 
(S6K), the downstream substrate of mammalian target of rapamycin, has 
been highlighted as a molecular link between obesity and insulin resistance. 
To elucidate the physiological role of S6K in selective insulin resistance, 
we have created a mice model of liver specific knockdown of S6K by 
systemic delivery of adeno-associated virus carrying short hairpin small 
interference RNA for S6K and examined the effects of S6K deficiency on 
hepatic steatosis and systemic insulin resistance in C57Bl/6 mice. S6K 
knockdown in liver (L-S6K-KD) resulted in rapid lowering of blood 
glucose and fasting plasma insulin concentrations, without changes in food 
intake or body weight. This improvement was accompanied by enhanced 
glycogen content in liver. L-S6K-KD mice fed high fat diet showed 
improved glucose tolerance and insulin sensitivity compared to control. 
This insulin sensitization took place in liver, skeletal muscle, and adipose 
tissue as assessed by the hyperinsulinemic-euglycemic clamp technique. 
Additionally, L-S6K-KD mice showed amelioration of steatosis as 
demonstrated by triglyceride measurements and Oil Red O staining. This 
was associated with down-regulation of key lipogenic genes upon refeeding 
after a 15 hr fasting with a robust increase in insulin signal transduction in 
liver. Importantly, S6K deficiency mediated a significant increase in 
epididymal fat mass, under refeeding conditions, which is the opposite to 
the decrease in liver weight. In conclusion, our results demonstrate the 
importance of S6K as a modulator of the hepatic response to 
fasting/refeeding and for the development of hepatic steatosis and systemic 
insulin resistance in obese mice. 
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LOSS OF ER-REGULATED MICRORNAS IS FUNDAMENTAL TO 
HORMONE-INDEPENDENT BREAST CANCER CELLS. 
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Breast Cancer is a disease that affects thousands of women every year 
where death generally occurs due to metastasis and development of 
resistance to chemotherapeutic agents. A large subset of breast cancer is 
attributed to the dysregulation of estrogen receptor (ER) signaling. 
Postmenopausal women have decreased systemic estrogen, which 
presumably leads to a repressed ER signaling program. Treatment of 
postmenopausal breast cancer patients with aromatase inhibitors, which 
further decrease the level of estrogen by inhibiting its production from 
androgens, leads to an improved response when compared to anti-estrogen 
therapy. Previous studies have examined gene expression profiles in long-
term estrogen deprived (LTED) MCF7 cells, providing clues to how these 
cancers are regulated. We set out to further characterize these cells by 
examining microRNA (miRNA) expression in LTED cells. As a means to 
determine miRNAs that may be essential for the regulation of hormone-
independent ER-positive breast cancers, we profiled the expression of 738 
miRNAs in MCF7 breast cancer cell lines. We compared the miRNA 
expression levels of common MCF7 cells to a LTED derivative, MCF7:2A. 
Of the differentially expressed miRNAs, we discovered two different 
miRNA clusters that are directly regulated by ER in MCF7 cells. We 
observed induced ER binding near the primary-miRNAs (pri-miRNAs) that 
contain these clusters and that LTED cells have less overall basal ER 
interaction at these cis elements. This corresponds to a decreased expression 
of these pri-miRNAs in the LTED cells versus MCF7. Furthermore, 
treatment of MCF7s with fulvestrant, an anti-estrogen, reduces pri-miRNA 
expression. Predicted targets of these miRNAs include IGF1R and HER2, 
proteins known to be upregulated in LTED cells. We demonstrate 
modulation of the expression level of these proteins with the addition of 
miRNAs to LTED cells. Additionally, we show endogenous association of 
the mRNAs encoding HER2 and IGF1R with the Ago1 complex in MCF7 
cells and reduced association in the LTED cells. These data provide a 
mechanism by which growth receptors can be induced to express upon 
estrogen loss in breast cancer. Preliminary analysis of published datasets 
show a correlation between pri-miRNA expression and metastatic breast 
cancer where there is decreased miRNA expression in metastatic tumors. 
This study identifies both ER-regulated miRNAs and a potential 
postmenopausal breast cancer miRNA signature, which may lead to novel 
therapy of ER-positive breast cancers in postmenopausal women. 
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EFFECTS OF THE SELECTIVE GLUCOCORTICOID RECEPTOR 
MODULATOR COMPOUND A ON HSP70’S EXPRESSION AND 
FUNCTIONALITY IN THE COMBAT OF INFLAMMATION 
 
Ilse M Beck, Ruben Hoya Arias, Wim Vanden Berghe, Ali Adem Bahar, 
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Compound A (CpdA) possesses glucocorticoid receptor (GR)-dependent 
anti-inflammatory properties. Just like classic GR ligands, CpdA can 
repress NF-κB-mediated gene expression. However, the CpdA-activated 
GR is driven to a solely monomeric conformation incapable of mediating 
conventional glucocorticoid response element-regulated gene expression. 
As dimeric GR-driven transactivation is linked to most of the detrimental 
side effects of long-term glucocorticoid therapy, e.g. diabetes, osteoporosis, 
acquired glucocorticoid insensitivity, the selective GR modulator CpdA 
may thus exhibit a clear advantage over classic glucocorticoids. 
Here, we show that this selective GR modulator, similar to heat shock, can 
potently upregulate the transcription of heat shock genes Hsp70-1A and 
Hsp70-1B, the proteins of which are described to play a role in the heat 
shock-induced anti-inflammatory mechanism. These mRNA-based data 
were further confirmed via reporter gene analyses. Nevertheless, stimulation 
of Hsp70 by CpdA or heat shock most likely occurs via alternate 
mechanisms, as CpdA-instigated Hsp70 promoter activation is GR-
dependent and HSF1-independent, whereas heat shock-induced Hsp70 
expression occurs in a GR-independent and HSF1-dependent manner. 
Although CpdA can potently stimulate Hsp70 gene expression, Hsp70 
protein levels remain unaffected. Moreover, a pharmacological block of 
translation points out that CpdA does not need any de novo protein 
synthesis to exert its anti-inflammatory effects. Strikingly, the anti-
inflammatory mechanism of both heat shock and CpdA features reduced 
IκBα degradation and NF-κB p65 translocation. Finally, the presence of the 
Hsp70 as a chaperone appears to be pivotal for the CpdA-mediated 
inflammatory gene repression mechanism. 
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STRUCTURE ELUCIDATION OF ENDOGENOUS LIGANDS OF 
NUCLEAR HORMONE RECEPTORS AND OTHER SIGNALING 
MOLECULES THROUGH DIFFERENTIAL ANALYSIS BY 2D NMR 
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Endogenous small molecule ligands of many receptor proteins such as G-
protein couples receptors (GPCRs) and nuclear hormone receptors (NHRs) 
remain unknown due to loss of compound and/or biological activity during 
successive rounds of activity-guided fractionation of a metabolite extract. 
However, extensive fractionation aiming to isolate the active component is 
perceived as mandatory when trying to elucidate the structures of novel or 
unexpected ligands. Here we present an NMR-spectroscopy-based method - 
Differential Analysis by 2D NMR Spectroscopy (DANS) - that enables 
structure elucidation early in the fractionation process, based on spectra of 
chemically still very complex samples.  
By applying this method we were able to identify new structures of 
signaling molecules active in key pathways that regulate developmental 
progression of the model organism C. elegans. Developmental progression 
in C. elegans is regulated by two classes of signaling molecules: "Dauer 
pheromones" or "ascarosides" and steroid hormones called "dafachronic 
acids". Application of DANS facilitated access to the structures of novel 
ascarosides and dafachronic acids. Synthetic samples of these new 
endogenous signaling molecules could be used to investigate the signaling 
cascades they participate in in vivo. We show that the synthesized 
compounds constitute powerful tools when combined with genetics of genes 
that act upstream, downstream or in parallel to the receptor gene. This work 
highlights the potential of the DANS analytical method and its potential for 
structure elucidation of a wide variety of signaling molecules in metazoans.  
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Alternative activation of the immune system by Th2 cytokines is thought to 
exert anti-inflammatory activities, which are beneficial in reversing diseases 
associated with chronic inflammation. Therapeutics designed to skew the 
immune system to a Th2 profile are less than ideal because of their potential 
to aggravate autoimmunity and allergies. It remains unclear whether 
immunomodulatory molecules that display anti-inflammatory phenotypes 
can be used to treat metabolic syndrome and related inflammatory diseases. 
Here we show that HFD-induced obese mice treated with the immune 
modulatory glycan LNFPIII have improved insulin sensitivity, less lipid 
accumulation in the liver, and reduced inflammation systemically compared 
to their untreated controls. LNFPIII treatment improves insulin sensitivity 
in metabolically active tissues by activating insulin-signaling pathways. 
Furthermore, this signaling event appears to be initiated by macrophage 
derived cytokines. Taken together, our study suggests that 
immunomodulatory glycans may serve as a novel therapeutic approach to 
improve insulin sensitivity in metabolically active tissues and reverse the 
harmful effects of metabolic syndrome. 
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Transcriptional regulation of metabolic function is intimately dependent on 
the nuclear receptor family of transcriptional factors and in particular on the 
estrogen-related receptor ERR. Because ERRs function in a ligand-
independent way their transcriptional activity depends on the presence or 
absence of transcriptional coactivators such as the peroxisome-proliferator-
activated-receptor gamma coactivator 1α (PGC-1α), the master regulator of 
mitochondrial biogenesis and energy metabolism. ERR and PGC-1α are 
expressed at elevated levels in tissues subjected to high energy demand, 
such as the heart and brown adipose tissue, and they are co-induced in a 
tissue-specific fashion during development and in response to physiological 
stress.  
Structurally, most of our current knowledge on the molecular basis of the 
mechanism of action of nuclear receptors is based on the X-ray and NMR 
structures of the separated DNA and ligand binding domains. Furthermore, 
structural information on receptor/coactivator complexes is so far limited to 
peptides containing LXXLL motifs. Here we address the molecular 
mechanisms of coactivator recognition by ERR by using a structural 
approach combining analytical ultracentrifugation, small angle X-ray 
scattering (SAXS) and other biophysical and biochemical characterization 
tools. We show that a homodimeric ERRa complexed to its DNA response 
elements binds PGC-1α with a well defined stoichiometry. The SAXS data 
provide first molecular envelopes of the coactivator/receptor/DNA complex 
suggesting the possible localization of PGC-1α on the ERR homodimer 
bound to the DNA.  
 
The work was supported in part by the Association pour 
la Recherche sur le Cancer and by the European Commission SPINE2 
complexes (Contract No. LSHG-CT-2006-031220) under the Integrated 
Programme “Quality of Life and Management of Living Ressources". M.P. 
J.P. and D.I.S. were supported by the EU FP6 design study SAXIER, grant 
No. RIDS 011934.  
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There is a whole battery of in vitro tools to study the mechanism of action of 
nuclear receptor (NR) ligands. Receptor-reporter gene assays based on 
mammalian cells are often very sensitive, showing maximal responses to 
steroids in the pM range. In vivo, however, 1 nM 17β-estradiol, the circulating 
level in premenopausal women, is required to maximally activate the ERα. The 
sensitivity of many mammalian cell lines is most likely reflecting the selection 
of these tumour cell lines during competition of growth. It’s thus questionable 
whether these cell lines are the most suited models to study NR activity. Yeast 
based assays show comparable sensitivities towards natural hormones as normal 
healthy human cells and do not suffer from crosstalk of other NRs. Combined 
with models to mimic metabolism and bioavailability they offer great tools to 
specifically study NR activity.  
Here we used bovine liver slices to study both the metabolism and the effect of 
steroids on gene expression. Liver slices exposed to the AR inactive pro 
hormone DHEA revealed 1) an increase in androgenic activity as observed by 
the yeast bioassay, and 2) the formation of 7α-hydroxy-DHEA, 7-oxo-DHEA, 
5-androstene-3,17-diol, 17α-testosterone, 4-androstenedione (4-AD), and 17β-
testosterone as detected by LC-TOFMS analysis. The same liver slices were 
subjected to expression microarray analysis. DHEA exerted gene expression 
changes that were very similar to those induced by 17β-T. Taken together, this 
demonstrates that DHEA is bioactivated by liver slices, enabling detection of 
prohormones both by the yeast bioassay and by gene expression.  
A similar approach was used for 2-isopropylthioxanthone (ITX), a 
photoinitiator widely used in printing ink. Due to the absence of sufficient 
toxicological data, an adequate risk assessment for ITX was lacking. The yeast 
estrogen and androgen bioassays revealed ITX to exert both anti-estrogenic and 
anti-androgenic activity. The DR CALUX® bioassay demonstrated ITX to 
activate the Ah-receptor. The potencies of ITX detected by these bioassays were 
confirmed by expression microarray studies on rat liver cells exposed either in 
vitro or in vivo to ITX and using TCCD, Casodex and Flutamide as reference 
compounds.  
Presently we perform experiments using the Ussing chamber model to study the 
transport of ITX and it’s effect on metabolism and gene expression in rat 
intestine. These studies show that chemical-analytical, bioassay, organ slices, 
Ussing Chamber, and –omics-based analysis are complementary, offer the 
possibility to perform more adequate risk assessments and might eventually be 
able to replace animal testing.  
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GLUCOCORTICOIDS ENHANCE THE EXPRESSION AND 
FUNCTION OF THE NLRP3 INFLAMMASOME 
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Glucocorticoids have long been recognized as powerful anti-inflammatory 
compounds and are, in fact, is one of the most widely prescribed class of 
drugs in the world. Emerging evidence suggests that glucocorticoids may 
also have potent pro-inflammatory potential. In light of this, we sought to 
examine the effects of glucocorticoids on the NOD-like receptors (NLRs). 
The NLRs form the central component of a multiprotein complex known as 
the inflammasome and are essential for the activation and release of the pro-
inflammatory cytokines IL-1 beta and IL-18. NLRP3, one of the most-
widely studied NLRs, is activated in response to a wide variety of pathogen- 
and danger-associated molecular patterns, including LPS and ATP, 
respectively. Furthermore, germline and somatic mutations in NLRP3 are 
the underlying cause of a number of autoimmune diseases, such as Muckle-
Wells syndrome and Familial cold autoinflammatory syndrome. NLRP3 has 
a wide tissue distribution, but is highly expressed in macrophages and 
osteoblasts. As a model system, the monocytic cell line THP-1 was 
differentiated into macrophages by phorbol-ester treatment. Following 
differentiation, THP cells are able to process and secrete IL-1 beta in 
response to NLR agonists. Interestingly, we have found that the synthetic 
glucocorticoid, dexamethasone, led to a significant increase of NLRP3 
messenger RNA while not significantly changing other components (i.e., 
caspase-1 or IL-1 beta). Functionally, concomitant administration of 
dexamethasone significantly enhanced ATP-mediated release of mature IL-
1 beta in a dose- and time-dependent manner. This effect is specific for 
glucocoritcoids, as only cortisol but not aldosterone, estrogen or 
testosterone was able to enhance secretion of IL-1 beta following ATP 
stimulation. Furthermore, pretreatment with the glucocorticoid receptor 
antagonist Ru486, blocked the dexamethasone-dependent increase in IL-1 
beta release. Finally, in addition to IL-1 beta, dexamethasone also enhanced 
the release of the pro-inflammatory cytokine TNF-alpha following ATP 
stimulation. These results demonstrate a novel role for glucocorticoids in 
the initial inflammatory response by the innate immune system in response 
to insult. 
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Obesity is associated with low-grade inflammation that negatively impacts 
insulin sensitivity. We recently reported that high fat diet (HFD) leads to a 
sustained increase of IkB kinase ξ (IKKξ) mRNA, protein and activity in 
liver, adipocytes and adipocyte tissue macrophages. IKKξ knockout mice 
were surprisingly resistant to diet-induced weight gain, chronic 
inflammation in liver and white adipose tissue (WAT), hepatic steatosis and 
whole-body insulin resistance. Hyperinsulinemic-euglycemic clamp studies 
revealed a temporal change in insulin sensitivity in different tissues. IKKξ 
knockout produced improved suppression of hepatic glucose production 
after 2 months of HFD, while improved glucose uptake in muscle was not 
significant in knockout mice until 4 months of HFD.  
 
To ascertain the contribution of differences in weight gain to the improved 
metabolic profile of knockout mice, we performed metabolic studies on 
weight-matched animals after shorter (6-8 weeks) HFD, a point at which 
hyperglycemia and hyperinsulinemia have just developed. Interestingly, 
weight-matched IKKξ knockout mice exhibited increased whole body 
oxygen consumption and increased UCP-1 expression in WAT, independent 
of obesity. Both liver and serum triglycerides were significantly lower in 
the weight-matched KO mice. Diet-induced macrophage and T cell 
infiltration were markedly reduced in both WAT and liver, while the 
inflammatory cytokine expression was significantly lower only in livers of 
the KO mice. However, glucose and insulin levels were indistinguishable at 
this time point.  
 
To identify downstream targets of IKKξ, we performed beadchip analyses 
comparing gene expression profiles in liver and WAT of WT and weight-
matched KO mice. The majority of differences were observed in metabolic 
genes in both tissues, although inflammatory genes were also lowered in 
liver of knockout mice. These data suggest that upon its induction after 
HFD, IKKξ exerts profound direct effects in liver and adipose tissue to 
regulate energy expenditure and inflammation.  
 
 21 
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Nuclear receptors (NRs) regulate a wide range of physiological processes 
and their action occurring at the level of transcription has been found to 
involve dynamic regulation of chromatin structure. Histone methylation 
plays a fundamental role in regulating both chromatin structure and 
transcription. The histone demethylase LSD1 has been shown to act as both 
a transcriptional co-repressor with histone H3 di-K4 demethylase activity 
and a co-activator with H3 di-K9 demethylase activity. We hypothesize that 
histone modifying enzymes like LSD1 can be regulated by the proteins they 
interact with. Transcription factors such as NRs are likely candidates as 
regulators of histone modifying enzymes given their duel roles in 
transcription activation and repression. Here we show that multiple NR 
proteins are capable of inhibiting LSD1 H3 di-K4 HDM activity but do not 
alone convert LSD1 to a H3 di-K9 demethylase. We also propose possible 
mechanisms for LSD1 ability to contribute to both activation and repression 
of gene transcription. 
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ACTION IN THE PREGNANT UTERUS. 
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The appropriate timing of the onset of labor is critical to a successful 
pregnancy with devastating consequences with the occurrence of pre-term 
birth. Reduced uterine progesterone receptor (PR) function through 
administration of the PR antagonist RU-486 to pregnant mice or women 
induces the onset of pre-term labor at any gestational time point. Whereas 
administration of exogenous progesterone (P4) can decrease the risk of pre-
term birth in high-risk human pregnancies and delay the onset of labor in 
mice. However the mechanism and targets of P4 and PR action that mediate 
uterine quiescence are unknown. We have identified a direct target of PR 
action in the pregnant uterus, uterine caspase-3, that is directly linked to the 
contractile ability of the uterine myocyte. We hypothesize that non 
apoptotic uterine caspase-3 action maintains the uterine myocyte in a state 
of contractile dysfunction through proteolytic cleavage of components of 
the myocyte contractile architecture utilizing conserved caspase-3 cleavage 
sites. Although activation of caspase-3 is typically associated with the onset 
of apoptosis other studies have also identified caspase-3 as a negative 
regulator of myocyte contractility in cardiac, skeletal and smooth muscle 
without resulting in cell death. 
We have identified four putative P4 response elements (PRE’s) in the 
mouse and one in the human, 2Kb upstream from the pro-caspase 3’ start 
site of transcription. Utilizing a human myometrial cell line, we have 
identified by ChiP analysis a 7-fold increase in recruitment of the PR 
mediated by P4 which was ablated in the presence of RU-486. We have 
found that administration of P4 to pregnant mice delays the onset of labor 
through upregulation of uterine caspase-3 action resulting in elevated 
proteolytic cleavage of components of uterine contractile architecture such 
as smooth muscle α and γ actin. On the other hand administration of 150μg 
RU-486 on E13 to pregnant mice precipitates the onset of pre-term birth as 
a consequence of diminished uterine caspase-3 action and precocious 
reconstitution of the uterine contractile architecture permitting the onset of 
uterine contractions. Force transduction analysis utilizing pan caspase 
inhibitors confirm that inhibition of uterine caspase-3 activity results in 
increased contractile potential. Together these data define caspase-3 as the 
first protein found in the pregnant uterus that can be directly associated with 
the contractile potential of the uterus during pregnancy and to be a direct 
target of increased P4 and PR action. 
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DLK, a mixed-lineage kinase family member, is a regulator of 
development, cell differentiation, apoptosis and neuronal response to injury. 
Recent studies from our laboratory showed interestingly that DLK 
expression is up-regulated in 3T3-L1 cells induced to differentiate into 
adipocytes and that DLK depletion by RNA interference impairs the 
expression of genes known as master regulators of adipogenesis, including 
the peroxisome proliferator-activated receptor-γ (PPARγ). Because the 
PPARγ agonist rosiglitazone was found to increase the expression of 
endogenous DLK in 3T3-L1 cells, we hypothesized that PPARγ is required 
for the transcriptional activation of the DLK gene. To test this notion, we 
first examined the effects of pharmacological inhibition or shRNA-
mediated depletion of PPARγ in 3T3-L1 cells on DLK protein expression. 
Besides blocking adipocyte conversion of 3T3-L1 cells, inhibition of 
PPARγ completely abolished the accumulation of DLK seen upon exposure 
of cells to the differentiation cocktail. Moreover, mice treated orally with 
the PPARγ agonist rosiglitazone respond with increased DLK protein level 
in the mesenteric adipose tissue depot when compared to controls. In 
support for a role of PPARγ in activating DLK gene transcription, two 
potential PPARγ binding sites, located at -611 and -769 base pairs upstream 
of the transcription start site, were identified in the proximal promoter of the 
DLK gene using bioinformatic tools. Chromatin immunoprecipitation with 
antibodies against PPARγ revealed that these sites become occupied by 
PPARγ as differentiation proceeds. The sequence surrounding the potential 
PPARγ sites, but not a control sequence located 1 kb upstream, was also 
enriched for RNA polymerase II and retinoid X receptor (RXR), the 
essential heterodimer partner of PPARγ. In addition, we show that the 
binding of PPARγ, RNA polymerase II and RXR to the DLK proximal 
promoter correlates with the increase in DLK protein levels observed during 
3T3-L1 preadipocyte differentiation. Taken together, these results show that 
the DLK gene is a target for PPARγ-mediated transcriptional activation in 
differentiating 3T3-L1 adipocytes. Interestingly, this mechanism of 
regulation is not unique to adipocytes because similar results were obtained 
in Neuro-2a neuroblastoma cells undergoing differentiation. Since PPARγ 
plays a central role in both adipogenesis and neurogenesis, it is tempting to 
speculate that DLK, one of its target genes, represents a potential candidate 
in the etiology of obesity and/or neurodegenerative illnesses. 
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Glucocorticoids (GCs) can relieve the symptoms of various inflammatory 
and immune disorders through interferences with the activation and/or 
activity of pro-inflammatory transcription factors NF-κB and AP-1, a 
mechanism known as transrepression. However, as GCs can additionally 
control genes involved in sugar, lipid and protein metabolism, mostly via a 
mechanism known as transactivation, chronic usage in patients suffering 
from immune disorders results in a range of undesirable effects. A 
controlled restriction in the targeted signaling pathways affected by GR is 
therefore predicted to result in a higher specificity and selectivity towards 
immune modulation. We previously characterized the action mechanism of 
a dissociated non-steroidal GR modulator CpdA, which favors GR 
transrepression over transactivation mechanisms via stimulating monomeric 
GR formation. Here, we explored how selective modulation of GR affects 
the activation and activity of AP-1.  
 
Our results demonstrate that CpdA, unlike classic GCs, selectively blocks 
NF-κB- but not AP-1-driven gene expression. CpdA rather sustains AP-1-
driven gene expression, a result which could be mechanistically explained 
by the failure of CpdA to block upstream activated JNK kinase and 
concomitantly also phosphorylation of c-Jun. In concordance, CpdA 
sustained the expression of the activated AP-1 target gene c-jun, as well as 
the production of the c-Jun protein. Finally, ChIP analysis data clearly 
demonstrates that only DEX-activated GR, but not CpdA-activated GR, is 
recruited to AP-1-driven promoters. The molecular basis of this selectivity 
is currently being explored, but already fits with the assumption that a 
ligand-induced differential conformation of GR may expose different 
interaction surfaces and thus yield a different transcription factor interaction 
profile.  
 
KDB and IMB are postdoctoral fellows at the Research Foundation - 
Flanders (FWO-Vlaanderen).  
* KDB and IMB contributed equally 
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SPRET/Ei mice are extremely resistant to acute LPS-induced lethal 
inflammation when compared to C57BL/6. We found that in vivo 
SPRET/Ei mice exhibit strongly reduced expression levels of cytokines and 
chemokines. To investigate the role of the potent anti-inflammatory 
glucocorticoid receptor (GR) in the SPRET/Ei phenotype, mice were treated 
with the GR antagonist RU486 or bilateral adrenalectomy. Under such 
conditions, both C57BL/6 and SPRET/Ei mice were strongly sensitized to 
LPS and the differences in LPS response between SPRET/Ei and C57BL/6 
mice were completely gone. These results underscore the central role of GR 
in the LPS hyporesponsiveness of SPRET/Ei mice. Compared to C57BL/6, 
SPRET/Ei mice were found to express higher GR levels, which were 
reflected in increased GR transactivation. Using a backcross mapping 
strategy, we demonstrate that the high GR transcription levels are linked to 
the Nr3c1 (GR) locus on chromosome 18 itself. Unexpectedly, SPRET/Ei 
mice exhibit a basal overactivation of the hypothalamic-pituitary-adrenal 
axis, namely strongly increased corticosterone levels, ACTH levels and 
adrenocortical size. As a consequence of the excess of circulating 
glucocorticoids (GCs), levels of hepatic gluconeogenic enzymes are 
increased and insulin secretion from pancreatic β-cells is impaired, both of 
which result in hyperglycemia and glucose intolerance in SPRET/Ei mice. 
We conclude that SPRET/Ei mice are unique since they display an unusual 
combination of elevated GR expression and increased endogenous GC 
levels. Hence, these mice provide a new and powerful tool for the study of 
GR- and GC-mediated mechanisms, including immune repressive functions, 
neuroendocrine regulation, insulin secretion, and carbohydrate metabolism. 
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The widespread use of glucocorticoids (GC) as highly potent 
immunosuppressors is hampered by pleiotropic side effects on metabolism 
necessitating a better mechanistic understanding of the GC actions. 
Glucocorticoid receptor (GR), which conveys the biological activities of GCs, 
regulates transcription of a wide variety of genes by recruiting distinct 
multiprotein co-regulator complexes in a gene- a response element-specific 
manner. A p160 family member, TIF2/GRIP1 is one of the key cofactors 
facilitating both GR-mediated activation and repression by serving as a platform 
for the assembly of histone modifying and chromatin remodeling complexes. 
Interestingly, GRIP1 also serves as a coactivator for the key effectors of toll-
like receptor (TLR) and type I interferon (IFN) signaling, interferon regulatory 
factors (IRF)3 and 9, respectively, enhancing the transcription of innate immune 
response genes. GR activation triggers loss of GRIP1 from IRFs, which 
contributes to GC-induced immunosuppression. The exact mechanisms 
facilitating GRIP1 recruitment to specific genes and regulatory complexes, or 
those preferentially ‘turning on’ its coactivator or corepressor properties remain 
to be elucidated. 
Unexpectedly, we found that GRIP1 is phosphorylated in response to GC 
stimulation. Indeed, upon exposure of cultured cells to a synthetic GC, 
dexamethasone (Dex), GRIP1 protein undergoes a dramatic and transient 
electrophoretic mobility shift, which is abolished by the treatment of cell lysates 
with calf intestinal phosphatase. GC-induced GRIP1 phosphorylation was 
dependent on a physical interaction between GRIP1 and GR, as disruption of 
the GR “charge clamp” or GRIP1 NR box-3, required for the GR:GRIP1 
interface formation, abolished GRIP1 mobility shift. Likewise, treatment with 
partial GR antagonist RU486 which induces GR conformation incompatible 
with GRIP1 binding, eradicated the GRIP1 shift in a dose-dependent manner. 
These data indicate that GR likely brings a protein kinase into the complex to 
modulate the activity of its own cofactor via phosphorylation. Based on the 
results of a pilot screen for the GRIP1 kinases using a panel of inhibitors, we 
are testing several candidate kinases for their ability to phosphorylate GRIP1 in 
vitro. We have identified by mass spectrometry a series of endogenous 
phosphorylation sites (6 hormone-dependent and one constitutive) whose 
functional significance is presently being characterized. We propose that GR-
dependent GRIP1 phosphorylation influences transcription of GR target genes 
and may dictate the preferential use of GRIP1 by GR over other transcriptional 
regulatory complexes such as those triggered by the TLR or IFN signaling. 
 
This work was supported by the NIH NIAID and the Lupus Research Institute.  
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Expression of the nuclear receptor Nur77 (NR4A1) is induced in WAT in 
response to fasting conditions and β-adrenergic stimulation. We therefore 
performed microarray-based expression profiling of WAT from wildtype 
and Nur77-/- mice submitted to prolonged fasting. Results revealed Nur77-
dependent changes in expression profiles of 153 transcripts (P≤0.05). 
Mapping those transcripts onto functional associations and known 
biochemical pathways revealed connections to insulin signalling, and to 
lipid, fatty acid and glucose metabolism. Additionally, Nur77-dependent 
expression profiles were assayed in mature 3T3-L1 adipocytes with and 
without Tet-induced Nur77 overexpression, submitted to β-adrenergic 
stimulation. As several of the Nur77-regulated genes are known PPARγ2 
targets (ie. G0s2, Grp81, Fabp4, and Adiponectin) we further assayed the 
expression level of PPARγ2 in a bigger cohort of fasted mice and found a 
significant Nur77-dependent regulation of PPARγ2 (P=0,021, n=10). 
Furhermore, we show with chromatin immunoprecipitation and luciferase 
assays that the PPARγ2 promoter is a direct target of Nur77-dependent 
regulation. In conclusion, we present data implicating Nur77 as a regulator 
of PPARγ2 in WAT. 
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Prostate cancer incidence in the UK is approximately 35,000 cases per year 
and is the second most common cause of male cancer-specific death. 
Treatment of choice for locally advanced or metastatic disease is maximum 
androgen blockade. The majority of men that receive this therapy eventually 
relapse with castrate resistance prostate cancer (CRPC).Cell line studies 
implement ERK1/2 activition in the transition from hormone naïve prostate 
cancer (HNPC) to CRPC. Evidence suggests that ERK kinase activation 
induces phosphorylation of AR at Serine 81to stimulate prostate cancer cell 
growth and induce PSA expression.  
The aim of the current study was to investigate if the relationship between 
the AR and ERK1/2 is upheld in clinical prostate cancer specimens. A 
cohort of 55 patients with matched HNPC and CRPC tissue was established 
with full clinical follow-up. Immunohistochemistry was employed to assess 
expression of AR, AR81, ERK1/2 and phosphorylated ERK1/2 (pERK).  
All 55 patients in the cohort were diagnosed with HNPC and subsequently 
progressed to CRPC.In the transition for HNPC to CRPC 8% of patients 
exhibited an increase in AR81 expression and 20% exhibited an increase in 
ERK1/2 expression.PSA at diagnosis (p=0.034) and high pERK expression 
in HNPC (p=0.03) were associated with shorter time to biochemical relapse. 
A negative correlation between AR and ERK1/2 expression was observed 
in HNPC (R2=-0.383, p=0.004), but no association with AR81 and ERK1/2 
or pERK was observed in this stage of disease.  
Gleason sum (p=0.009), presence of metastasis at diagnosis (p=0.0002), 
presence of metastasis at relapse (p=0.003) and high ERK1/2 expression in 
CRPC (p=0.003) was associated with shorter disease specific survival. In 
CRPC no correlations were observed between AR, AR81 and ERK1/2 or 
pERK. AR81 expression did however positive correlated with proliferation 
index as assessed by Ki67 expression (R2=0.339, p=0.025). When 
expression of AR81 and ERK1/2 were combined, disease specific survival 
was significantly shorter when both were expressed compared expression of 
one or expression of neither (4.2 years vrs 5.4 year vrs 7.6 years 
respectively, p=0.0006).  
No correlations with AR81 and ERK1/2 or pERK were observed,high 
expression of AR81 and ERK1/2 combined had a synergistic effect of 
decreased disease specific survival. Interactions between both these proteins 
warrant further investigation. 
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Steroidogenic factor-1 (SF-1, NR5A1) is a nuclear receptor (NR) primarily 
involved in the development and homeostasis of the steroidogenic organs in 
the hypothalamic-pituitary-adrenal/gonadal axis. It governs the expression 
of enzymes responsible for converting cholesterol to steroid hormones, 
including the mitochondrial cholesterol transport protein StAR and 
members of the cytochrome P450 family of enzymes. The structure of the 
SF-1 ligand-binding domain revealed phospholipids in the ligand binding 
pocket and reports of synthetic ligands affecting SF-1 transcriptional 
activity have started to emerge. In vivo regulation of SF-1 is known to 
include posttranslational modifications where phosphorylation can activate 
and SUMOylation repress its transcriptional activity. SF-1 repression also 
occurs via interactions with a corepressor complex containing the NR 
DAX-1 and, as we have shown (Mol Cell Biol 29: 2230-42, 2009), the 
ubiquitin ligase RNF31, HDAC3 and SMRT. 
 
It was recently shown that SF-1 is over-expressed in childhood 
adrenocortical tumors and that SF-1 can increase proliferation of 
adrenocortical cells, expanding the role of SF-1 beyond steroidogenic 
regulation. In light of this, we decided to take a genome-wide approach to 
investigate the role of SF-1 in the adrenal cortex by using RNAi-mediated 
knockdown in the adrenocortical carcinoma cell line H295R followed by 
microarray analysis. We find that SF-1 is important for controlling 
pathways involved in both steroidogeneseis and cell proliferation. New 
possible targets of SF-1 regulation are identified and old ones confirmed. 
We also assess the effect of cAMP-treatment when cells are depleted of SF-
1, giving an indication of the role of SF-1 in basal versus induced 
steroidogenesis. We hope that our data will help advance the understanding 
of the multifaceted roles of this important receptor.  
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Type I aerobic muscle inherently maintains high oxidative and vascular 
capacity even without exercise. How this occurs could have important 
implications in treatment of vascular disease and ischemia when exercise 
may not be possible. Here we show that the orphan nuclear receptor ERRγ, 
a potent metabolic and mitochondrial regulator, is expressed at high levels 
in type I muscle but not in type II glycolytic muscle. However, transgenic 
expression of ERRγ in glycolytic type II muscles (ERRGO mice) or 
cultured cells, powerfully regulates VEGF expression, angiogenesis and 
vascular supply in absence of exercise. ERRGO mice show increased 
expression of genes promoting fat metabolism, mitochondrial respiration 
and type I fiber specification. In parallel, the type II muscle in ERRGO 
mice display an activated angiogenic program marked by myofibrillar 
induction and secretion of pro-angiogenic factors, frank neo-vascularization 
and a 100% increase in running endurance. Surprisingly, the induction of 
VEGF and type I muscle properties by ERRγ does not involve the 
transcriptional co-activator PGC1α or Hif1α which remain at basal levels. 
Instead, ERRγ “genetically activates” the energy sensor AMPK which is 
typically inactive in absence of exercise. Therefore, ERRγ and AMPK, 
known regulators of mitochondrial function and metabolism, together 
control a novel angiogenic pathway that anatomically synchronizes vascular 
arborization to oxidative metabolism revealing an exercise-independent 
mechanism for matching supply and demand. 
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The macrophage-mediated inflammatory response is a key etiologic 
component of obesity related tissue inflammation and insulin resistance. 
The transcriptional factor FoxO1 is a key regulator of cell metabolism, cell 
cycle and cell death. Its activity is tightly regulated by the phosphoinositide-
3-kinase-AKT (PI3K-Akt) pathway, which leads to phosphorylation, 
cytoplasmic retention and inactivation of FoxO1. Here, we show that 
FoxO1 promotes inflammation by enhancing Tlr4-mediated signaling in 
mature macrophages. By means of chromatin-immunoprecipitation 
combined with massively parallel sequencing (ChIP-Seq), we show that 
FoxO1 binds to multiple enhancer-like elements within the Tlr4 gene itself, 
as well as to sites in a number of Tlr4 signaling pathway genes. While 
FoxO1 potentiates Tlr4 signaling, activation of the latter induces AKT and 
subsequently inactivates FoxO1, establishing a self-limiting mechanism of 
inflammation. Given the central role of macrophage-Tlr4 in transducing 
extrinsic proinflammatory signals, the novel functions for FoxO1 in 
macrophages as a transcriptional regulator of the Tlr4 gene and its 
inflammatory pathway, highlights FoxO1 as a key molecular adaptor 
integrating inflammatory responses in the context of obesity and insulin 
resistance. 
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Posttranslational modifications (PTMs) present an important mechanism to 
regulate the activity of transcriptional coregulators. While de-modification 
may play an extremely important role in balancing the transcriptional 
output, no enzymes have been identified so far which can for example de-
ubiquitinate coregulator proteins. We have previously shown the 
acetyltransferase Tip60 to be essential for 3T3-L1 adipogenesis. 
Interestingly, Tip60 protein but not mRNA expression increased during 
differentiation, suggesting that Tip60 protein levels may be regulated by 
ubiquitination-deubiquitination. Here we show that the deubiquitinase 
USP7/HAUSP stabilizes Tip60 in adipogenesis. Using a probe which only 
binds to active deubiquitinases (DUBs), we found only 2 DUBs to be 
activated during 3T3-L1 adipogenesis, USP7/HAUSP and UCHL3. These 
two proteins also present the major DUB activities in mouse white and 
brown adipose tissue. In common with disruption of Tip60 function, 
siRNA-mediated reduction of USP7 protein impairs differentiation of 3T3-
L1 pre-adipocytes. The Tip60 and USP7 proteins are both located in the 
nucleus of differentiated 3T3-L1 cells, and the two proteins interact in these 
cells. Co-expression of USP7 with Tip60 leads to the stabilization of Tip60 
and increases its steady-state level, and Tip60 is deubiquitinated by USP7 
both in vivo and in vitro. Knockdown of USP7 in 3T3-L1 adipocytes leads 
to the down regulation of Tip60 protein level, underscoring the role of 
USP7 in the stabilization of Tip60 in adipocytes. Since both USP7 and 
Tip60 are important regulators of gene expression and chromatin structure 
and are both important in p53 pathway, this interaction could have more 
general implications in cell differentiation and metabolism. 
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Toll-like receptors (TLRs) recognise specific microbial motifs and respond 
by inducing pro-inflammatory genes that govern both innate and adaptive 
immune responses. Activation of TLRs initiates a signalling cascade which 
leads to the induction of transcription factors such as NF-κB and interferon-
regulatory factors (IRFs) which regulate gene expression. Dysregulation of 
these signalling pathways can lead to inflammatory diseases and so these 
pathways are tightly controlled by negative regulators of immune 
signalling. In 2000, Lin et al. indentified Cactin (Cactus interactor) as a 
novel interactor of Drosophila Cactus, a regulator of Drosophila Toll 
signalling. We have cloned the human ortholog of Cactin and show that it 
acts as a negative regulator of TLRs. Overexpression of hCactin suppresses 
TLR-induced activation of NF-κB and IRF transcription factors whereas 
knockdown of hCactin augments the induction of these responses. hCactin 
localises to the nucleus and this nuclear localisation is critical for 
manifesting its inhibitory effects on TLR signalling. Cactin does not interact 
with the human ortholog of Cactus (IκBα) but does interact with nuclear 
IκB-like and other proteins that are resident of the nucleus. These findings 
define Cactin as a novel negative regulator of TLR signalling that exhibits 
its regulatory effects in the nucleus. 
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The lung is one of the key client tissues for glucocorticoids in the clinic, 
however, a detailed understanding of the target genes that are controlled by 
the glucocorticoid receptor (GR) in various lung cell types, nor their 
physiologic impact, does not exist. These knowledge gaps are barriers to 
both the development and evaluation of novel therapies for lung disease that 
modulate GR signaling. To address this issue, we used expression profiling, 
high throughput qPCR, and gene ontology analysis to annotate the GR-
regulated transcriptome in cultured airway smooth muscle (ASM), a critical 
target cell type for asthma therapeutics. Several lines of investigation 
emerged from this initial discovery process. First, we performed detailed 
qPCR validation for a subset of 40 of the 487 genes identified with a high 
degree of confidence by microarray (adjusted p < .01) as regulated by GR 
after 4 hours of treatment with dexamethasone. We found that this gene 
subset exhibited a very high degree of concordance with respect to GR 
regulation in 6 independent primary human ASM lines derived from 
different donors. Second, we found that activation of GR signaling in ASM 
rapidly reduces mRNA levels of numerous genes in a manner consistent 
with GR regulating mRNA stability; again this observation was consistent 
across numerous ASM lines. Third, to establish the in vivo impact of non-
inflammatory GR-regulated genes in ASM, we analyzed airway 
contractility in mice lacking Klf15, a GR target gene that had no known 
function in the lung. We found reduced airway contraction in Klf15-/- mice 
induced to develop asthma through allergy sensitization followed by 
exposure to aerosolized allergen. Intriguingly, inflammation was 
indistinguishable between Klf15-/- and wild type mice, suggesting that 
Klf15 impacts airway contractility in a manner that does not depend on a 
reduction in the allergic response. Together, our results indicate that: 1) the 
GR response is surprisingly similar across primary cultured airway cell 
lines derived independently from different donors; and 2) non-inflammatory 
GR target genes in the lung potentially contribute to the therapeutic impact 
of GR activation and thus might be therapeutic targets in their own right. 
We propose that annotation of the GR transcriptome in primary cells or 
tissues followed by selected in vitro and in vivo target validation is a useful 
experimental paradigm to define mechanisms of therapeutic effect and new 
drug targets in clinically important GR client tissues. 
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Estrogen signaling plays important and diverse roles in many tissues, 
stimulating some tissues to grow while keeping other tissues quiescent. We are 
exposed to estrogenic compounds such as genistein (GEN), which is made in 
plants, and bisphenol A (BPA), which is synthesized industrially. To understand 
the molecular consequences of exposure to environmental estrogens in different 
cell types, we induced ECC-1, a human endometrial cancer line, and T-47D, a 
human breast cancer line, with BPA, GEN, and the endogenous estrogen 
estradiol (E2). We then performed ChIP-seq to measure estrogen receptor α 
(ERα) binding across the genome and RNA-seq to analyze gene expression 
changes. In both cell lines, we observed that 10 nM E2 induced ERα binding at 
~8,500 sites across the genome, while 100 nM GEN induced ~5,000 binding 
sites, and 100 nM BPA induced ~2,000 binding sites. Within a cell line, more 
than 95% of binding sites induced by GEN and BPA were also induced by E2. 
RNA-seq data showed that the number of genes that change upon induction 
with each ligand correlates with the number of ERα binding sites induced by 
each ligand. Our results indicate that GEN and BPA do in fact induce ERα 
binding in the genome, although they are weaker agonists of ERα than E2 in 
both cell lines. 
 
We also found that binding of ERα and mRNA changes induced by E2 
treatment were very different between ECC-1 and T-47D. While both cell lines 
exhibit 8,500 ERα binding sites, we found that only 17% overlap. We analyzed 
binding sites that were cell line-specific and discovered that T-47D-specific 
binding sites were enriched in binding sequences for FOXA1, a known ERα 
interacting transcription factor (Krum SA et al 2008; Carroll JS et al 2005). 
FOXA1 expression is 100-fold higher in T-47D and therefore served as a good 
candidate for explaining cell type-specific binding. We performed ChIP-seq of 
FOXA1 in both lines and discovered more than 30,000 binding sites in T-47D 
and only 2,500 binding sites in ECC-1, corresponding to mRNA levels of 
FOXA1. In T-47D there is strong overlap between FOXA1 and ERα binding 
sites (53% overlap), while in ECC-1 there is modest overlap (18% overlap). 
This co-occupancy suggests a role for FOXA1 in determining ERα binding sites 
in T-47D, but not in ECC-1. Overall, these results indicate that different ligands 
for ERα induce similar binding sites within a cell type, while differences in the 
interacting factors present in cell types can contribute to very different ERα 
binding regimes.  
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The steroid hormone estrogen (E2) and its intracellular receptors, the 
estrogen receptors α (ERα), are integral parts of many signal transduction 
processes that, if altered, result in diseases such as breast cancer. ERα is 
known to stimulate transcription of RNA polymerase II target genes by 
promoting local changes in hormone-responsive promoters embedded in 
chromatin. In particular, chromatin can be modified by the di- and tri-
methylation of histone H3 lysine 27 (H3K27) that has a repressive effect on 
gene regulation, but can be reversed by the recently identified demethylase, 
JMJD3, resulting in gene activation. Here we show that JMJD3 and the 
methylation status of H3K27 are essential in regulation of the ERα-
dependent apoptotic response via Bcl-2 in breast cancer cells. The 
activation of Bcl-2 transcription is dependent on the demethylation of 
H3K27 by the E2-dependent recruitment of ERα and JMJD3 in hormone-
dependent breast cancer cells. This pathway is modified in cells resistant to 
anti-estrogens (AE), cells that also constitutively express Bcl-2. We show 
that the promoter structure and transcription status of Bcl-2 is active in these 
AE-resistant cells due to a lack of H3K27 methylation. The decrease in 
H3K27 methylation occurs because overexpressed human epidermal growth 
factor receptor 2 (HER2), via the kinase AKT, phosphorylates, and thus 
inactivates the H3K27 methyltransferase EZH2. Inactivation of this 
pathway via an AKT inhibitor renders these cells sensitive to the estrogen-
sensitive regulation of Bcl-2 dependent on JMJD3. Our results describe a 
novel mechanism in which the epigenetic state of chromatin affects the 
ability of a cancerous cell to respond to therapy. 
 37 
RBCK1 REGULATES PROLIFERATION IN BREAST CANCER CELLS 
POTENTIALLY THROUGH CONTROL OF ERα GENE EXPRESSION 
 
Nina Gustafsson1, Chunyan Zhao1, Jan-Åke Gustafsson1,2, Karin Dahlman-
Wright1  
 
1Karolinska Institute, Department of Biosciences and Nutrition, Huddinge, 
14183, Sweden, 2University of Houston,Center for Nuclear Receptors and 
Cell Signaling, Department of Biology and Biochemistry, Houston, TX, 
77204-5056 
 
Estrogen receptor α (ERα) is a member of the nuclear receptor superfamily 
and plays a central role in mammary epithelial cell proliferation and growth 
of estrogen-dependent breast cancer. ERα expression and activity is 
controlled by estrogen hormones. Upon binding to estrogens, ERα 
stimulates the expression of genes encoding cell cycle regulatory proteins 
thereby promoting cellular proliferation. While a major research focus has 
been directed towards understanding how ERα regulates the expression of 
its target genes, relatively little is known about the regulation of the ERα 
gene itself.  
Our recent findings identify a role for the E3 ubiquitin ligase RBCK1 in 
ERα-positive breast cancer cells in supporting cell cycle progression, 
potentially by driving transcription of ERα. siRNA silencing of RBCK1 led 
to reduced levels of ERα mRNA and protein levels, reduced ERα target 
gene expression and reduced estrogen-stimulated entry into the S phase. 
Chromatin immunoprecipitation (ChIP) revealed that RBCK1 is recruited to 
the ERα promoter, supporting that transcriptional regulation is one 
mechanism by which RBCK1 affects ERα mRNA and protein levels. In 
support of the RBCK1 dependent reduction of ERα mRNA levels in breast 
cancer cell lines, analysis of breast tumor tissues identified a positive 
correlation between levels of RBCK1 and ERα mRNA. Considering the 
critical role of ERα in proliferation of breast cancer, our findings aid in 
further understanding how to modulate the expression of the receptor, 
which may ultimately lead to new estrogen-based therapeutic strategies. In 
the poster, we will present our recent efforts trying to elucidate the 
functions of RBCK1 critical for its function as a regulator of ERα. 
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The Farnesoid X Receptor (FXR, NR1H4) has been shown to be involved 
in the control of bile acid, triglyceride, and cholesterol homeostasis 
suggesting that FXR agonists have a potential as new therapeutics in lipid-
related disorders. Here we present data obtained with the novel potent FXR 
agonist Px20350 in order to elucidate possible molecular mechanisms for 
FXR mediated cholesterol lowering in rodent animal models. 
C57Bl6 mice were kept on a 60% kcal high fat/0,5% cholesterol diet 
(HFCD) and dosed with 10 and 30mpk/d Px20350 for 6 weeks. Px20350 
Treatment resulted in a remarkable lowering of both plasma and liver 
cholesterol and triglyceride levels. Plasma lipoprotein profiling 
demonstrated a striking reduction of VLDL, LDL and HDL in FXR agonist 
treated mice. Several genes involved in triglyceride and cholesterol 
metabolism and transport were significantly down- or upregulated by 
Px20350. The gene expression data suggested that the export pathways for 
cholesterol and phospholipids from the plasma (periphery) via the liver into 
the intestinal lumen were massively increased upon activation of FXR. 
Furthermore, radiolipid uptake studies in SD rats and C57 mice indicated a 
reduced uptake of cholesterol and triglycerides by the intestine. The strong 
reduction of plasma and liver lipids (cholesterol and triglycerides) upon 
administration of Px20350 is mirrored by a significant reduction of liver fat 
accumulation which occurs in the control animals under HFCD.  
If translatable to humans, the concerted regulation in liver and intestine as 
well as the magnitude of the lipid lowering effects exerted by FXR agonists 
open a great therapeutic potential in diseases ranging from atherosclerosis 
up to Metabolic Syndrome and NAFLD/NASH. 
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Anti-malaria drug chloroquine has been used as an anti-inflammatory agent 
for treating systemic lupus erythematosus and rheumatoid arthritis, without 
clear mechanism of action. Here we report that chloroquine potently inhibits 
the expression of proinflammatory cytokines partially through 
transrepression of glucocorticoid receptor (GR). Instead of direct binding to 
GR, chloroquine synergistically activates glucocorticoid signaling via 
inhibition of lysosomal functions. In mouse collagen induced arthritis 
model, chloroquine synergizes the therapeutic effects of glucocorticoid. 
Lysosomal inhibition by bafilomycin A1, an inhibitor of V-type ATPase, or 
by knockdown of transcription factor EB (TFEB), a master activator of 
lysosomal biogenesis, mimics the effects of chloroquine. These results 
reveal an unexpected regulation of glucocorticoid signaling by lysosomes 
and provide a mechanistic basis for treating inflammation and autoimmune 
diseases by combination of glucocorticoids and lysosomal inhibitors.  
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PKC signaling to NFAT/AP-1 critically involves the recently identified 
orphan receptor NR2F6 which is predominantly expressed in the CD4+ T 
helper cell (Th)17 subset (Hermann-Kleiter et al., Immunity 2008). 
Mechanistically, PKC-mediated phosphorylation on Ser 83 within the 
DBD-domain of NR2F6 results in the release of NR2F6 from its DNA 
binding sites within the Il17a promoter, as revealed by EMSA and ChIP 
analysis. NR2F6 potently antagonizes the ability of Th17 CD4+ T cells to 
induce expression of key cytokines such as IL-17, IL-23, and IL-21.  
In Th17 cells differentiated and activated ex vivo, loss of Nr2f6 results in 
amplified NFAT DNA binding at the Il17a promoter and subsequently 
increased IL-17 transcription. Consistently, Nr2f6-deficient mice have 
hyper-reactive lymphocytes and develop late-onset immune-pathologies and 
are hypersusceptible to the Th17-dependent model of experimental 
autoimmune encephalomyelitis. Taken together, our study establishes 
NR2F6 as PKC substrate and critical transcriptional repressor of 
autoimmunity. 
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The antiestrogen tamoxifen is the major adjuvant therapy for estrogen 
receptor alpha (ERalpha)-positive breast cancers. Tamoxifen has 
successfully decreased the mortality rate of breast cancer patients in the past 
decades; however, a significant fraction of patients is refractory or acquires 
resistance to this treatment. Tamoxifen-bound ERalpha recruits 
transcriptional corepressors SMRT and N-CorR, thereby repressing 
ERalpha target genes and inhibiting cell cycle progression. We hypothesize 
that mis-regulation of the corepressors SMRT or N-CoR contributes to 
tamoxifen resistance. Indeed, several reports including ours suggest that low 
levels of the corepressors SMRT and N-CoR compromise tamoxifen-
mediated repression of ERalpha target genes and its ability to inhibit cell 
proliferation.  
 
Patients with ERalpha- and Her2/ErbB2-positive are resistant to tamoxifen 
therapy. Her2/ErbB2, a member of the ErbB transmembrane receptor 
tyrosine kinase and a potent mitogenic activator, promotes its activity 
through several downstream effectors. We have previously demonstrated 
that Her2/ErbB2 down-regulates steady-state levels of SMRT through 
Cdk2/Pin1-mediated degradation which relieves tamoxifen-mediated 
repression of ERalpha target genes, and thus renders tamoxifen resistance. 
In a search for E3 ligases that promote SMRT degradation, we found that 
the Her2/ErbB2 downstream E3 ligase, β-TrCP1 targets SMRT for 
degradation in a manner that is independent of Cdk2 or Pin1. SiRNA 
knockdown and overexpression experiments show that β-TrCP1, but not β-
TrCP2 specifically down-regulates SMRT protein accumulation. Protein-
protein interaction assays have been used to map the SMRT-β-TrCP1 
interaction domains. Based on these observations, we propose a model in 
which Her2/ErbB2 promotes tamoxifen resistance through Cdk2-Pin1- and 
β-TrCP1-mediated down-regulation of SMRT protein levels in ERalpha-
positive breast cancer patients.  
 
Our future goal is to apply the lessons learned from cell studies and test our 
hypothesis in xenograft nude mice. Our study will elucidate a novel 
regulation of SMRT protein homeostasis and provide a new strategy to 
develop therapeutic agents to breast cancer.  
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The androgen receptor (AR) is a transcription factor that works by binding 
androgens to turn genes on or off. The same AR that regulates normal 
growth and differentiation during male development also plays an integral 
role in the pathogenesis of prostate cancer. Thus, the cell context in which 
AR functions, is an important determinant of its actions and consequently, 
AR-driven prostate cancer. We hypothesize that AR function is controlled 
by cellular proteins that instruct AR to control gene expression, and that 
these proteins work differently in cancer cells compared to normal non-
growing cells. Thus, our objective is to identify cellular factors that control 
AR activity as potentially new therapeutic targets for prostate cancer.  
 
Using a high throughput genome-wide RNA interference (RNAi) screen 
with an AR-responsive reporter gene as the readout, we identified proteins 
that increase or decrease the activity of AR, thereby generating a 
comprehensive list of the factors capable of affecting AR actions. 
 
Of the ~14,000 factors screened by RNAi, we identified ~350 candidates, 
whose depletion from the cell either decreases or increases AR activity. Of 
those, ~40 selectively affected AR but not glucocorticoid receptor (GR) 
transcriptional activity. Reassuringly, we isolated factors previously shown 
to regulate AR function, thus validating the screen. Importantly, the screen 
yielded new factors that lower AR transcriptional activity including 
“drugable” targets such as protein kinases. For example, we found that 
depletion of the homeodomain interacting protein kinase 2 (HIPK2), a 
nuclear kinase that has been recently shown to participate in transcriptional 
events, attenuates AR but not GR activity, which could represent new 
therapeutic target in prostate cancer. In contrast, factors whose RNAi-
mediated destruction increases AR activity may represent new tumor 
suppressor genes.  
 
This is the first genome-wide unbiased screen for mediators of AR function. 
Knowing what proteins affect AR activity will help in the design of new 
therapies to treat prostate cancer, especially those refractory to current 
hormone ablation therapy. 
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The TRAP/Mediator, subcomplex of RNA polymerase II holoenzyme, acts as 
the end-point integrator of a variety of activators and conveys intracellular 
signals to the general transcription machinery. Among the subunits, 
MED1/TRAP220 is crucial for various biological events through its interaction 
with distinct activators such as nuclear receptors. In hematopoiesis, MED1 
plays a pivotal role in optimal VDR- and RAR-mediated myelomonopoiesis and 
GATA-1-induced erythropoiesis. In this study, we present evidence that MED1 
in stromal cells is involved in supporting hematopoietic stem and/or progenitor 
cells (HSPCs) through osteopontin (OPN) expression. When normal bone 
marrow (BM) cells were cocultured with mitomycin C-treated Med1-/- or 
Med1+/+ MEFs, growth of BM cells were significantly suppressed on Med1-/- 
MEFs compared with the control during the two-week period, but recovered 
when cocultured on Med1-/- MEFs into which MED1 was re-introduced (Rev-
Med1-/- MEFs). Further, the number of long-term culture-initiating cells (LTC-
ICs) was attenuated for BM cells cocultured on Med1-/- MEFs compared to the 
control, but recovered when cocultured on Rev-Med1-/- MEFs. A microarray 
analysis of mRNA comparing Med1+/+ and Med1-/- MEFs disclosed 
approximately 15 genes whose expressions were profoundly attenuated in 
Med1-/- MEFs. Among molecules encoded by these genes we focused on OPN 
because solely OPN was known to have BM niche function. The Opn mRNA 
was attenuated in Med1-/- but recovered in Rev-Med1-/- MEFs. Addition of 
recombinant OPN to Med1-/- MEFs restored the growth of cocultured BM cells 
and the number of LTC-ICs, both of which were attenuated by the addition of 
the anti-OPN antibody to both Med1+/+ MEFs and BM stromal cells, OP-9 and 
MS-5. Luciferase reporter assays disclosed that the basal level, as well as VDR- 
and Runx2-mediated synergistic activation, of Opn transcription was 
specifically attenuated in Med1-/- MEFs, and that the basal transcription and 
ligand-dependent activation were dependent on the N-terminal domain (amino 
acids 1 to 602) and NR-recognition motifs of MED1, respectively. ChIP assays 
disclosed recruitment of Mediator, VDR and Runx2 onto the Opn promoter. 
Taken together, these data suggest that MED1 in niche cells, through 
upregulating VDR- and Runx2-mediated transcription on the Opn promoter, 
plays an important role in HSPCs support. 
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Background- Glucocorticoids (Gcs) are the most potent anti-inflammatory 
agents known and are used to treat a number of chronic inflammatory diseases 
such as inflammatory bowel disease and rheumatoid arthritis (RA). However, 
their use is limited by side-effects. Therefore, better understanding how Gcs 
work is of central importance. Gcs are released in pulses from the adrenal gland 
giving rise to oscillations in blood plasma concentrations. The biological 
significance of such oscillations has not been explored.  
Hypothesis- Pulsatile vs continuous glucocorticoid delivery differentially 
influences target cell responses.  
Meth- A flow-through culture system was established to explore the role of Gc, 
(hydrocortisone (Hc)) oscillations in HeLa cells and primary T cells. Cells were 
subjected to either continuous (100ng/ml) or pulsatile (100ng/ml) Hc for 12 
hours in the flow-through system. A microarray was performed to identify 
genes differentially regulated by Hc delivered in pulses compared with 
continuous treatment in HeLa cells. The expression of 5 such genes (FKBP5, 
GILZ, GLUL, IL6ST and IL-8) were then analysed in response to pulsatile and 
continuous Hc treatment by qRT-PCR. Apoptosis was also measured by 
Annexin V assay. Data were compared using independent sample t test.  
Results- Hc increased the expression of endogenous FKBP5, GILZ, GLUL, 
IL6ST and repressed IL-8 expression in both continuous and pulsatile treatment. 
However, fold induction of FKBP5 and GILZ were lower with pulsatile Hc than 
when given continuously (p<0.02, p<0.007 respectively). No differences were 
observed in expression of GLUL, IL6ST and IL-8 between the two delivery 
modes.  
HeLa cells (n=3) showed a significantly greater degree of apoptosis in the 
pulsatile treatment group compared to the continuous group (p<0.001), although 
in primary T cells, no difference was seen.  
Bioinformatic analysis identified common binding sites for the transcription 
factor CCAAT Displacement Protein (CDP) in the differentially regulated target 
genes found in the microarray. The importance of CDP was explored in HeLas 
using a luciferase reporter gene under the control of MMTV promoter, known 
to be both GC responsive and contain CDP binding sites. A significantly higher 
MMTV-Luc activity was observed with continuous Hc compared to pulsatile 
(p< 0.001), confirming the in silico findings.  
Conclusion- We present data, on two cell types, supporting the biological 
relevance of altered Hc dynamics to target cell responses. These findings help 
us better understand the importance of the natural ultradian cortisol pulsatility 
and has implications for therapeutic glucocorticoid drug design and also for the 
administration of glucocorticoids therapeutically.  
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Background- Williams-Beuren syndrome (WBS) is caused by contiguous deletion 
of approximately 1.5Mb at Chr:7q11.23. It manifests as multi-system developmental 
disorder with various phenotypes including cardiovascular, cognitive and endocrine 
disorders such as hypothyroidism, hypercalcemia and osteoporosis. Importantly, 
diabetes mellitus and glucose intolerance have been reported in 75% of affected 
adult cases. The deleted region is thought to encode for 26-28 genes including 
WBSCR22. The function of WBSCR22 is currently unknown but sequence 
homology suggests it encodes a putative methyltransferase protein.  
Hypothesis- WBSCR22 is a novel glucocorticoid sensitivity gene which acts 
through the glucocorticoid receptor (GR) to alter GR functions.  
Methods- To investigate whether WBSCR22 alters glucocorticoid sensitivity, GR 
transactivation and transrepression assays were performed in HeLa cells, using a 
luciferase reporter gene under the control of glucocorticoid (Gc)-responsive tyrosine 
amino transferase-3 (TAT3-Luc) and NF-kB responsive element (NRE-Luc) in the 
absence or presence of dexamethasone (Dex). GR specificity of WBSCR22 was also 
explored using TAT3-Luc assays in nuclear hormone receptor deficient HEK cells 
through exogenous expression of GR, mineralocorticoid receptor (MR), 
progesterone receptor (PR) and androgen receptor (AR). Data were analysed in 
triplicates and compared using independent sample t tests.  
Results- GR activation by 10nM Dex significantly increased TAT3-Luciferase 
activity compared to the control (p<0.001) in HeLa cells. Overexpression of 
WBSCR22 significantly enhanced GR-mediated TAT-3 activation (p<0.002) in the 
presence of 10nM Dex. TNF-α (0.5ng/ml) maximally activated NF-kB luciferase 
reporter gene resulting in GR transrepression. This effect was impaired with higher 
TNF- α concentration (5ng/ml). Co-transfection of NRE-Luc and WBSCR22 
transfection however, was not seen to modulate GR-mediated repression of NF-kB 
activity.  
Dex, corticosterone, progesterone and dihydrotestosterone (DHT) elicited activation 
of TAT3 promoter in HEKs exogenously transfected with GR, MR, PR or AR. 
However, when WBSCR22 was added a robust induction of TAT3 promoter was 
observed which was unique to GR and not MR, AR or PR. This activation was 
found to be both ligand-independent (p=0.001) and ligand-dependant (p<0.001).  
Conclusion - WBSCR22 specifically increases transactivation by GR of TAT3 
promoter but does not affect GR-mediated transrepression. This will provide insight 
into the potential mechanism of action of WBSCR22 and characterise the function 
of WBSCR22 gene to determine its potential importance in Gc related pathologies. 
 46 
BDNF AND GLUCOCORTICOID RECEPTOR SIGNALING AND 
CROSSTALK 
 
Freddy D Jeanneteau1, Marcus Lambert2, Thomas A Neubert1, Francis S 
Lee3, Michael J Garabedian2, Moses V Chao1  
 
1NYU-Skirball Institute of Biomolecular Medicine, Molecular 
Neurobiology, New York, NY, 10016, 2NYU Langone school of Medicine, 
Microbiology, New York, NY, 10016, 3Weill Cornell Medical College, 
Psychiatry, New York, NY, 10065 
 
Two cardinal signaling systems, the corticosteroid and the neurotrophins, 
are involved in scaling stress responses. Glucocorticoid (GC) is a hormone 
secreted by the adrenal gland under the control of the brain to orchestrate 
the physiological response to threats and stress. Brain-derived neurotrophic 
factor (BDNF) is secreted upon neuronal activity to strengthen the neuronal 
circuits. Both systems are interrelated because prolonged secretion of GC 
by administration or chronic stress reduces BDNF synthesis and function in 
the brain. In contrast, short-lasting and moderate elevation of GC levels 
rapidly induces BDNF expression and signaling in the brain. To explain 
these effects, we hypothesize that BDNF and GC undergo crosstalk between 
their respective receptors. Using microarray assays of primary cortical 
neurons, we analyzed the genome-wide effects of treatments with 
dexamethasone (Dex), a synthetic GC in comparison with BDNF. Whereas 
Dex or BDNF treatments alone regulated independent sets of genes, co-
treatment with Dex and BDNF targeted and enhanced a separate set of 
genes. Among the regulated genes, the expression of the neuropeptide CRH 
(corticotrophin releasing hormone) was down-regulated by Dex, up-
regulated by BDNF, but hyper-repressed by the combination of ligands. The 
BDNF receptor (TrkB) antagonist, K252a, abolished the transcriptional 
effects of BDNF upon Dex signaling though its nuclear receptor. CRH is 
the major brain-derived trigger of GC release. We found CRH expression is 
down-regulated and basal GC plasma level is reduced in BDNF and TrkB 
knockout mice. Administration of Dex (0.1 mg/kg) strongly repressed GC 
plasma levels in wild-type mice, but only weakly in TrkB and BDNF 
knockout mice. These results indicate crosstalk exists between GC and 
BDNF signaling. Using mass spectrometry of neurons treated with BDNF, 
we found that the GC receptor (GR) was rapidly phosphorylated at specific 
sites within the N-terminal domain by BDNF. Mutation of these 
phosphorylation sites changed the transcriptional profile of the GR in 
cortical neurons. Therefore, BDNF signaling can modify and amplify GR 
transcriptional activity in the brain, which provides a mechanism to account 
for the differential effects of GC levels upon stress and behavior. 
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Alpha actinins (ACTNs) are known for their ability to modulate 
cytoskeletal organization and cell motility by crosslinking actin filaments. 
Overexpression of ACTN4 has been linked to breast cancer, but the 
underlying mechanisms remain largely unknown. We show here that 
ACTN4 harbors a functional LXXLL receptor interaction motif, interacts 
with nuclear receptors in vitro and in mammalian cells, and potently 
activates transcription mediated by nuclear receptors. While ACTN4 
potentiates estrogen receptor alpha (ERα)-mediated transcription in 
transient transfection reporter assays, knockdown of ACTN4 decreases it. In 
contrast, histone deacetylase 7 (HDAC7) inhibits estrogen receptor alpha 
(ERα)-mediated transcription. Moreover, the ACTN4 mutant lacking the 
CaM (calmodulin)-like domain that is required for its interaction with 
HDAC7 fails to activate transcription by ERα. Chromatin 
immunopreciptation (ChIP) assays demonstrate the association of ACTN4 
and HDAC7 with the ERα target promoter pS2 gene, indicating that 
ACTN4 and HDAC7 directly regulate the expression ERα target gene. 
Knockdown of ACTN4 by siRNA significantly decreases the expression of 
ERα target genes, pS2 and PR and cell proliferation of MCF-7 breast cancer 
cells with or without hormone, whereas knockdown of HDAC7 exhibits 
opposite effects. Interestingly, overexpression of wild-type ACTN4, but not 
the mutants defective in interacting with ERα or HDAC7, resulted in 
increases in pS2 and PR mRNA accumulation in a hormone-dependent 
manner. In summary, we have identified ACTN4 as a novel, atypical 
coactivator that regulates transcription networks to control cell growth. 
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Several studies have demonstrated solid evidence for the potential value of 
targeting epidermal growth factor receptor (EGFR) signaling to enhance the 
anti-tumor activity of radiation. However, therapeutic resistance has 
emerged as an important clinical issue. Here, we investigated whether 
strategies for targeting EGFR-associated downstream signaling would 
radiosensitize a panel of non-small cell lung cancer (NSCLC) cell lines. 
Inhibition of K-RAS using RNA interference attenuated downstream 
signaling and increased radiosensitivity of A549 and H460 cells, while 
inhibition of EGFR did not. A549 cells harboring a K-RAS mutation at 
codon V12 were radiosensitized by siRNA targeting this codon. H460 cells 
having mutation at codon V61 was radiosensitized by siRNA targeting of 
this mutation. K-RAS siRNA did not radiosensitize H1299 cells possessing 
wild-type K-RAS.  
Inhibition of the PI3K-AKT-mTOR pathway led to significant 
radiosensitization of the two cell lines, while selective inhibition of ERK 
signaling did not. Inhibitors targeting the PI3K-AKT-mTOR pathway also 
abrogated G2 arrest following irradiation and induced γH2AX foci 
formation.  A dual inhibitor of Class I PI3K and mTOR effectively 
increased radiosensitivity of A549 and H460 cells. Inhibition of PI3K-AKT 
signaling was associated with downregulation of DNA-PKs. While 
apoptosis was the primary mode of cell death when cells were pretreated 
with LY294002 or AKT inhibitor VIII, cells pretreated with rapamycin or 
PI-103 showed mixed modes of cell death, including apoptosis and 
autophagy. 
 
Our results suggest possible mechanisms for counteracting EGFR 
prosurvival signaling implicated in radioresistance and offer an alternative 
strategy for overcoming resistance to EGFR inhibitors used in combination 
with irradiation. (Work supported by BAERI #2007-2001193 
&NRF#1E00061from Korean Ministry of Education, Science & 
Technology)  
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The Aryl Hydrocarbon Receptor (AhR) is a ligand-activated transcription 
factor and a member of the bHLH/PAS (basic Helix-Loop-Helix/Per-Arnt-
Sim) family of proteins. The AhR is activated by a variety of synthetic and 
natural compounds, including halogenated aromatic hydrocarbons such as 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The activated AhR has been 
implicated in immune suppression, disruption of endocrine signaling and 
alteration of cell growth. Significant differences have been observed among 
various species in the ability of ligands to bind the AhR and induce 
biological responses. While the PAS domain of the AhR is known to be 
responsible for ligand binding, the structural basis for the inter-species 
differences remains poorly understood. To address this, we constructed 
homology models of the AhR PAS domain from several different species 
using available structural information from other closely related proteins. 
Using these models, many of the intra- and inter-species differences in 
TCDD binding were structurally characterized using Molecular Docking. 
Virtual ligand screening of chemical libraries using the mouse AhR ligand 
binding domain model resulted in the identification of novel putative 
ligands. We will present data involving characterization of the newly 
identified ligands and their AhR-dependent biological effects. 
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Adipose tissue development is a process which involves the concerted 
action of several transcription factors together with their coactivators and 
corepressors. The peroxisome proliferator activated receptor γ (PPARγ) is 
considered to be one of the master regulators of adipocyte differentiation. 
The presence of two functionally distinct types of adipose tissue, white and 
brown (WAT and BAT), requires an even more complex regulation of 
adipose tissue development. Here we present an in silico analysis based on 
existing mRNA expression profiles of brown and white adipose tissue 
samples, combined with the list of nuclear receptor coregulators given by 
the NURSA site. Strikingly, 68 coregulators displayed higher expression in 
WAT compared to BAT, while only 9 genes displayed a higher expression 
in BAT than in WAT. Furthermore, we performed a peptide microarray 
analysis to study the interaction between PPARγ and 155 peptides derived 
from LxxLL/LxxxIxxxL containing coregulators. Of the ligand dependent 
interacting peptides, the peptides derived from RIP140, NCOR1 and SMRT 
displayed differential expression between BAT and WAT. It may therefore 
be hypothesized that both NCOR1 and SMRT might be involved in 
determining the distinctive properties of WAT and BAT, for instance by 
repressing brown-specific PPARγ target genes in WAT, as already has been 
shown for the repression of UCP1 by RIP140 in WAT.  
To conclude, the in silico analysis resulted in a list of 77 NR coregulators, 
of which a large part has not been linked previously to PPARγ. Further 
interaction studies may reveal PPARγ coregulators which are involved in 
determining brown/white adipocyte identity.  
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Uncontrolled adipose accretion (obesity) caused by an increasingly 
predominant sedentary lifestyle represents a key risk factor for a plethora of 
life-threatening clinical complications including type 2 diabetes mellitus 
and thus accounts for seemingly measureless world health costs. Expansion 
of the adipose depots occurs through growth, enhanced proliferation and 
differentiation of fat cells (adipocytes) or their progenitors, respectively. In 
fact, much attention has been devoted to identification of factors that inhibit 
or promote adipocyte differentiation, modulation of which might be an 
interesting avenue to combat obesity. The aim of this study is to identify 
novel players in adipogenesis, in particular factors that regulate epigenetic 
events ensuring the dramatic changes in the transcriptional profile. We 
initially focused on a novel class of proteins containing JmjC-domains that 
were attributed histone demethylating activity and that have been recently 
implicated in cellular differentiation. To assess the involvement of possible 
histone demethylating enzymes, mRNA expression levels of the 27 JmjC-
domain containing genes were assessed over the course of adipogenic 
differentiation of 3T3-L1 cells. One transcript in particular, hairless, 
showed a very rapid upregulation early after initiation of differentiation and 
a sharp decrease after peaking, declining back to almost basal levels. 
Hairless is a known corepressor and interacts with nuclear receptors such as 
the thyroid hormone receptor, the vitamin D receptor and the retinoic acid 
receptor-related orphan receptors. Based on the phenotype of hairless 
mutant mice and humans, hairless has an important role in the skin. Our 
group has found that knockdown experiments in 3T3-L1 cells showed an 
absolute requirement of hairless for adipogenesis to occur. Important 
transcriptional events that ensure adipocyte differentiation to proceed are 
not taking place. Furthermore, forced expression of hairless in non-
commited mesodermal cell lines potentiates their capacity to become 
adipocytes. Most importantly, hairless knockout mice showed a severe 
metabolic phenotype and markedly reduced adipose tissue formation. A cell 
autonomous differentiation defect was identified in preadipocytes and 
fibroblasts isolated from these mice. Detailed future investigations of the 
molecular mechanism will elucidate how hairless is exerting its 
proadipogenic effects. Our data provide a novel potential mechanism 
required for adipogenesis, thus possibly offering new therapeutic avenues 
that may interfere with unfavourable energy homeostasis in diabetic 
patients. 
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Glucocorticoids are steroid hormones involved in diverse cell type-specific 
physiological processes, including glucose, lipid, and protein metabolism, 
and are powerful anti-inflammatory agent. Extensive exposure to 
glucocorticoids can cause muscle atrophy and insulin resistance. Although 
these side effects are well documented, mechanisms governing 
glucocorticoid-induced muscle atrophy and insulin resistance are largely 
unknown. Our goal is to identify glucocorticoid-regulated primary genes 
that are responsible for inducing muscle atrophy and insulin resistance. 
Using chromatin immunoprecipitation-high throughput DNA sequencing 
(ChIPseq), we have identified 2252 glucocorticoid receptor (GR) binding 
regions, corresponding to 1608 genes, in mouse C2C12 myotubes. 
Microarray confirms that 142 of these 1608 genes are regulated by 
glucocorticoids. Among these potential primary GR targets, FoxO3A and 
PIK3R1 are two genes with known connection to muscle atrophy and 
insulin signaling pathway, respectively. Reported by others, constitutively 
active FoxO3A alone can cause muscle atrophy. Here, we show that 
glucocorticoids induce FoxO3A transcript and active protein levels. The 
expression of luciferase reporter that harbors GR binding regions of 
FoxO3A is significantly induced by glucocorticoids. Intriguingly, mutating 
a single nucleotide in one of the GR binding regions, glucocorticoid-
dependent reporter gene expression is abolished entirely, confirming the 
validity of FoxO3A GRE. Moreover, glucocorticoid treatment increases the 
acetylation of histone H3 and H4 in the surroundings of FoxO3A GR 
binding regions. Furthermore, overexpressing PIK3R1, the regulatory 
subunit of PI3K, has been reported to decrease insulin sensitivity; however, 
its role in muscle atrophy has not been tested. Here, we show that PIK3R1 
overexpression in C2C12 myotubes leads to a 35% decrease in cell 
diameter, which strongly suggests its role in glucocorticoid-induced muscle 
atrophy. Overall, we have identified several genes, activated by GR 
concertedly, modulate protein metabolism. These results shall benefit future 
therapeutic development for better pharmaceutical interventions. 
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Glucocorticoid receptor (GR) is a ligand-dependent transcription factor that is 
activated by glucocorticoid hormones (GC). Despite its ubiquitous expression, 
GR shows a remarkable ability to regulate gene expression in a cell type 
specific manner. Such tissue specificity of GR action is likely mediated through 
signal-dependent post-translational modifications of the receptor, such as 
phosphorylation. The brain is a major GC site of action, yet the impact of GR 
phosphorylation in facilitating GC action in neurons remains largely 
uncharacterized. We now report that primary neurons stimulated with the Brain 
Derived Neurotrophic Factor (BDNF), the ligand for the TrkB tyrosine kinase 
receptor, induce phosphorylation of GR. Using (MALDI-TOF) mass 
spectrometry, we identified two previously uncharacterized sites, Serine 155 
(S155) and Serine 287 (S287) within the N-terminal transcriptional regulatory 
domain of rat GR that are phosphorylated upon BDNF treatment. Here, we 
address how BDNF signaling modulates GR function.  
 
To investigate BDNF and GR crosstalk, we used a microarray approach to 
determine the genes that are regulated by GC and BDNF in primary rat cortical 
neurons. BDNF and Dexamethasone (Dex) co-treatment regulated more than 
twice the amount of genes compared to any single treatment. Interestingly, 45% 
and 55% of those genes in the BDNF + Dex treated group were uniquely 
induced and repressed, respectively, only upon co-treatment, suggesting that a 
distinct genetic program is elicited by co-treatment. Furthermore, the magnitude 
of a subset of the Dex-induced (and repressed) genes was amplified upon 
treatment with BDNF, suggesting a BDNF-dependent modification of select GR 
responsive genes. The effect of BDNF signaling on the GC-dependent 
transcription was validated by RT-qPCR on a select group of genes. Moreover, 
the effect of BDNF on GR activity appears dependent upon GR phosphorylation 
at S155 and S287, since a serine to alanine double mutation (GR 
S155A/S287A) abolished much of the gene expression induced by wild type 
GR at endogenous target genes in primary neurons.  
 
Using GR phospho-specific antibodies, we are currently investigating the 
molecular mechanisms sensitive to BDNF signaling that are employed by GR to 
modify transcription. Although GC and BDNF are often viewed as antagonistic 
pathways in chronic stress and pathological conditions in the brain, we propose 
that BDNF signaling acts as an endogenous amplifier of GC response in 
neuronal cells through a GR phosphorylation-dependent mechanism. 
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The Liver X Receptor (LXR) is an important regulator of carbohydrate and 
lipid metabolism in humans and mice. We have recently shown that 
activation of LXR regulates cellular fuel utilization in adipocytes. In 
contrast, the role of LXR in human adipocyte lipolysis – the major function 
of human white adipocytes – has not been clear. In the present study, we 
stimulated in vitro differentiated human adipocytes with the LXR agonist 
GW3965 and observed an increase in basal and hormone-stimulated 
lipolysis. Microarray analysis of human adipocyte mRNA following LXR 
activation resulted in altered gene expression of several lipolysis-regulating 
proteins which was also confirmed by quantitative real-time PCR. In 
addition, we investigated the protein expression, phosphorylation and 
intracellular localization. Using chromatin immunoprecipitation we show 
that upon activation LXR is recruited to several promoters of lipolysis-
regulating genes. We propose that LXR is upregulating human adipocyte 
lipolysis via two distinct mechanisms. First by down-regulating the 
expression of the lipid droplet-coating proteins Perilipin and Cell death-
inducing DNA fragmentation factor, α subunit-like effector C (CIDEC) 
thereby increasing the access of lipases to stored triglycerides and 
enhancing basal lipolysis. Secondly, LXR activation downregulates 
phosphodiesterase 3B and upregulates adenylate cyclase 3 thereby 
increasing the intracellular levels of cAMP. By using siRNA treatment we 
also show that LXRα and LXRβ have different roles in regulation of human 
adipocyte lipolysis. In conclusion, we demonstrate a new role for LXR in 
human white adipocytes and provide a putative mode of action.  
This study was supported by the Swedish Research Council, NovoNordisk, 
Swedish Diabetes Association, EndoMet, Karolinska Institutet, the 
European Union [HEPADIP (LSHM-CT-2005-018734), ADAPT 
(HEALTH-F2-2008-201100], COST action BM 0602, Magn Bergvalls and 
Åke Wibergs foundations.  
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Numerous studies on estrogen signaling have undoubtedly led to the 
improvement in treatment for breast cancer and other endocrine related 
disorders. Since 1996, the discovery of the second estrogen receptor, ERβ, 
has brought about another dimension of complexity upon this picture of 
estrogen signaling. Its role in cell physiology remains a controversial topic. 
The challenges are mainly due to the lack of a reliable antibody for this 
particular protein and the differences in cellular contexts used to analyze 
ERβ functions. In the present study, we have successfully applied a phage 
display followed by an exon microarray to identify novel ERβ interacting 
proteins in a cell-free manner. Briefly, estradiol-bound ERβ was incubated 
on an ERE-coated plate; a phage library which expressed the breast cDNA 
was added; the peptides expressed on the phage surface allowed binding to 
the immobilized receptor; the cDNA from bound phage were extracted and 
subjected to exon microarray analysis. With p-values less than 0.05, we 
have identified 845 proteins at low-stringent threshold (FC > 1.01) and 372 
proteins at high-stringent threshold (FC > 2.00). 5 out of 7 novel ERβ 
interactors from our screen were confirmed using mammalian two hybrid 
assays. Currently, we are investigating a subset of the novel interactors 
which are involved in transcriptional regulation. Moving forward in this 
study, we wish to deliver a better understanding on the molecular functions 
of ERβ as part of the complex transcriptional machinery. Ultimately, this 
will give birth to new potential therapeutic targets for endocrine related 
diseases. 
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Vitamin A is essential for proper embryonic development. Both natural and 
synthetic retinoids are powerful regulators of cell growth and 
differentiation, and treatment of tissue cultures with these compounds 
enhances the differentiation of pluriopotent stem cells into specific cell 
lineages. Retinoic Acid (RA) induces cellular differentiation by activating 
the retinoid receptors which regulate gene transcription through binding to 
enhancers or promoters of the genes that they govern. RA can bind to both 
the Retinoic Acid Receptor (RAR) and the Retinoid X Receptor (RXR) and 
is believed to exert its effects through RAR/RXR heterodimers. It is 
currently unknown how much the RXR contributes to RA induced cellular 
differentiation. Preliminary results in our lab using pluripotent stem cells 
and an RAR selective ligand demonstrate that activation of RARs alone 
does not achieve the level of cellular differentiation that RA does. However, 
using a selective ligand to activate RXR alone achieves greater efficacy 
than RA. Our preliminary data using embryonic stem cells is promising and 
has confirmed that RXRs are the key regulators in stem cell differentiation. 
Our study will allow us to uncover novel pathways of RA signalling and to 
elucidate whether RXR is acting alone as a homodimer, or in conjunction 
with RAR as a heterodimer, as well as the target genes of the RXRs 
involved in cellular differentiation. By increasing our understanding of 
transcriptional regulation in the early stages of stem cell differentiation, we 
can learn how to direct lineage specification and to generate sufficient 
amount of tissues to use in the treatment of debilitating diseases.  
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Bone loss with aging results from attenuated and unbalanced bone turnover and 
is associated with a decreased number of bone-forming osteoblasts (OB), 
increased number of bone-resorbing osteoclasts (OC), and increased number of 
adipocytes (AD), in the bone marrow. These changes are associated with 
changes in marrow MSC lineage allocation and correlate with increased 
expression of PPARγ2, decreased expression of pro-OB Runx2 transcription 
factor, and increased expression of RANKL, a cytokine supporting 
osteoclastogenesis. Similarly to aging, PPARγ agonists TZDs cause bone loss, 
increase fat content in bone, and increase fracture risk in humans, specifically in 
postmenopausal women and elderly. In animals, TZDs induce bone loss by 
suppressing new bone formation and increasing bone resorption. Aging and 
estrogen deficiency sensitize bone to the TZD-induced loss by increasing bone 
resorption.  
PPARγ2 is a key regulator of bone cell development and activity. It directs 
MSC differentiation toward the AD and at the expense of OB lineage. Circadian 
protein Nocturnin, an accessory PPARγ protein, regulates MSC lineage 
allocation. PPARγ2 pro-AD activity is transcriptional in nature and involves 
binding to PPAR response elements (PPRE), whereas anti-OB activity is PPRE-
independent and involves suppression of Wnt, TGFβ/BMP and IGF-1 signaling 
followed by suppression of OB-specific transcriptional regulators. Pro-AD and 
anti-OB activities of PPARγ can be separated with selective ligands, reinforcing 
a notion of distinct regulatory pathways controlling these activities.  
PPARγ2 regulates the expression of a number of genes associated with the stem 
cell phenotype and formation of a micro-environment supporting 
hematopoiesis. It negatively regulates the expression of “stemness” genes, 
which include ABCG2, Egfr, CD44, Kitl, SDF-1, LIF and LIFR, and 
hematopoiesis-supporting genes. Thus, as a result of increased PPARγ 
expression with aging or activation with TZDs, MSCs lose their ”stemness” and 
are more prone to AD and less prone to OB differentiation.  
Bone fat (YAT) occupies a significant portion of bone marrow cavity. Its 
metabolic activity is unknown. YAT depot increases in its volume in response 
to estrogen deficiency and in metabolic diseases, such as obesity, diabetes, and 
anorexia nervosa. Gene expression profiling shows that YAT may display great 
plasticity in acquiring WAT-like or BAT-like phenotype in response to 
systemic changes in energy metabolism. This may be of local importance to 
bone, as well as to the systemic control of energy metabolism, e.g. in conditions 
of functional impairment of other fat depots. 
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Nuclear hormone receptors regulate diverse metabolic pathways. The 
orphan nuclear receptor LRH-1 is essential for bile acid biosynthesis in the 
liver and can induce glucocorticoid production in the intestine in response 
to inflammatory stress. Our previous results have shown that an unusual 
phosphatidylcholine species with two saturated 12 carbon fatty acid acyl 
side chains (dilauroyl phosphatidylcholine, DLPC) is an LRH-1 agonist 
ligand. Here we show that DLPC has remarkable antiinflammatory effects 
in two mouse models of chemically induced inflammatory bowel disease 
(IBD). In 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis, 
preventative DLPC treatment induces local glucocorticoid biosynthetic 
enzymes and antiinflammtory cytokines, and decreases proinflammatory 
cytokines in the colon. Moreover, in dextran sodium sulfate (DSS)-induced 
colitis, therapeutic DLPC treatment also induces local glucocorticoid 
biosynthetic enzymes and antiinflammatory cytokines, and decreases 
proinflammatory cytokines in the colon. These effects are lost in intestine 
specific Lrh-1 knockouts. Interestingly, DLPC treatment in DSS-induced 
colitis also induces Twist1 and 2, negative regulators of NF-kB complex in 
the colon. These findings identify an LRH-1 dependent phosphatidylcholine 
signaling pathway that regulates intestinal immunity in response to 
immunological challenges by triggering local corticosteroid production and 
negative regulators of NF-kB signaling pathway. 
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Gluconeogenesis makes a major contribution to hepatic glucose production, 
a process critical for survival in mammals. In this study, we identify the 
p160 family member, SRC-1 as a key coordinator of the hepatic 
gluconeogenic program in vivo. SRC-1 null mice displayed hypoglycemia 
secondary to a deficit in hepatic glucose production, as assessed by 
hyperinsulinemic-euglycemic clamp. Selective re-expression of SRC-1 in 
the liver restored blood glucose levels to a normal range. SRC-1 was found 
induced upon fasting to coordinate in a cell-autonomous manner, the gene 
expression of rate-limiting enzymes of the gluconeogenic pathway 
including pyruvate carboxylase (PC), fructose 1-6 bisphosphatase (FBP1) 
and phosphoenolpyruvate carboxykinase (PEPCK). At the molecular level, 
the main role of SRC-1 was to modulate the expression and the activity of 
C/EBPalpha through a feed-forward loop in which SRC-1 used C/EBPalpha 
to transactivate PC, a crucial gene for initiation of the gluconeogenic 
program. We propose that SRC-1, acts as a novel and critical mediator of 
glucose homeostasis in the liver by adjusting the transcriptional activity of 
key genes involved in the hepatic glucose production machinery. 
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One roadblock to research on and therapy of type-1 diabetes is the lack of a 
non-invasive method to image the imitation and unfolding of disease. We 
have developed a method, based on magnetic resonance imaging of 
magneto fluorescent particles (MRI-MNP) that permits in murine T1D 
models: detection of insulitis, an assessment of insulitis severity, prediction 
of conversion to overt diabetes, and early assessment of a drug’s efficacy in 
clearing islet inflammation. This technique has been exploited to identify a 
critical new pathway in T1D pathogenesis. Results from a just-completed 
small clinical trial argue for successful application of this technique to 
human T1D patients.  
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Until recently, structural studies of nuclear receptors have focused on their 
two individual core domains, the ligand-binding domain (LBD) and the 
DNA-binding domain (DBD), with the exception of the full retinoid X 
receptor (RXR) complex with the peroxisome proliferator-activated 
receptor (PPAR; Chandra et al., 2008). The presentation will address the 
architecture of the full nuclear receptor heterodimeric complex of the 
ligand-bound vitamin D receptor (VDR) and RXR bound to their DNA 
response element that comprises a direct repeat (DR3). The solution 
structure of the RXR/VDR/DNA complex has been determined by high-
resolution single particle cryo electron microscopy (cryo-EM) whilst 
overcoming technical challenges related to the small molecular weight of 
the object (100kDa, to our knowledge the smallest complex studied by 
cryo-EM up to now). The structure reveals an open conformation rather 
different from the crystallized PPAR/RXR complex. The RXR and VDR 
LBDs and DBDs adopt a parallel organization, with the LBDs 
perpendicular to the DNA and positioned at the DNA 5’-end of the response 
element (Orlov et al., submitted). The DBD and LBD parts are connected 
through well-resolved hinges, without additional contacts between DBDs 
and LBDs, suggesting that the hinges provide independent links to the 
DBDs and the DNA and thereby stabilize the complex in a precise 
conformation on its target DNA. The present structure has important 
implications in the general architecture of nuclear receptors and in addition 
provides first molecular insights into the orientation of transcriptional co-
regulators that are recruited to the area of transactivation helix H12. We will 
also present data on an entirely different complex bound to an inverted 
DNA repeat. 
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Obesity is associated with chronic low-grade inflammation that negatively 
impacts insulin sensitivity. This involves infiltration of M1 polarized 
proinflammatory macrophages into fat tissue, as well as inflammatory 
events in liver. High fat diet can increase NFκB activation in mice, which 
leads to a sustained elevation in level of IκB kinase ε (IKKε) in liver, 
adipocytes and adipose tissue macrophages. IKKε knockout mice are 
protected from high fat diet-induced obesity, chronic inflammation in liver 
and fat, hepatic steatosis and whole-body insulin resistance. These mice 
show increased energy expenditure and thermogenesis on high fat diet 
compared to wild type mice. They maintain insulin sensitivity in liver and 
fat, without activation of the proinflammatory JNK pathway associated with 
obesity. Gene expression analyses indicate that targeted deletion of IKKε 
increases expression of the uncoupling protein UCP-1, reduces expression 
of inflammatory cytokines, and changes expression of certain regulatory 
proteins and enzymes involved in glucose and lipid metabolism. Thus, 
IKKε may represent an attractive new therapeutic target for obesity, insulin 
resistance, diabetes and other complications associated with these disorders. 
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We have developed a novel high-throughput method for functional analysis 
of transcription by the Nuclear Receptor family. By combining the power of 
a validated cDNA expression library, covering the entire Nuclear Receptor 
Family, with pathway specific promoter-reporter libraries, we can 
specifically evaluate the transcriptional regulation of genetic pathways by 
any NR in a given context (i.e., in the presence or absence of ligand, in 
different cell lines etc.).  
A subgroup of the NRs, the Peroxisome proliferator-activated receptors 
(PPARs) are activated by fatty acids and are integrally involved in lipid and 
glucose metabolism. PPARγ is a master regulator of adipogenesis and a 
central player in the pathophysiology of Type 2 diabetes and obesity. 
PPARγ is also the molecular target for the widely prescribed 
thiazolidinedione (TZD)-class of insulin sensitizers. Despite their efficacy 
in glycemic control, TZDs are associated with various adverse side effects, 
including weight gain, edema, and liver and cardiovascular toxicity, which 
limits their clinical use. The molecular mechanisms by which TZDs mediate 
their insulin sensitizing effects are still poorly understood, but it is clear that 
adipose tissue plays a central role in their action.  
Using our functional screen for NR-mediated promoter regulation, we have 
identified novel targets of PPARγ which might provide insight into the 
mechanism by which TZDs and PPARγ mediate their insulin sensitizing 
effects. 
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We find that the G protein-coupled receptor 120 (GPR120) functions as a 
receptor/sensor for the omega-3 fatty acids, DHA and EPA. Stimulation of 
GPR120 with omega-3 FAs or a chemical agonist, causes inhibition of 
TNF-α and lipopolysaccharides (LPS)-induced inflammatory signaling 
responses in monocytic RAW 264.7 cells and in primary intraperitoneal 
macrophages. These effects proceed through a β-arrestin2/TAB1 dependent 
mechanism, which leads to inhibition of TAK1. All of these effects are 
abrogated by GPR120 knockdown. Since DHA-mediated GPR120 agonism 
induces anti-inflammatory effects in vitro, we fed high fat diets with or 
without omega-3 FA supplementation to wild type (WT) and GPR120 
knockout mice. The omega-3 FA treatment inhibited inflammation and 
enhanced insulin sensitivity in WT mice, but was without effect in GPR120 
knockout mice. In conclusion, GPR120 is a functional omega-3 FA 
receptor/sensor and mediates potent anti-inflammatory and insulin 
sensitizing effects.  
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Allostery in RXR heterodimers is poorly understood, including signal 
integration from ligands for both receptors, the silencing of RXR by VDR 
or TR, and ligand signaling via activation of the unliganded partner receptor 
(e.g. the phantom ligand effect). Here, we show that an electrostatic tether 
links the paired helices 11 of heterodimers and provides a conduit for 
transmission of allosteric information. A second region of the dimer 
interface mediates silencing of RXR by TR. 
 
Mutations of the electrostatic tethering amino acid RXRα E434 to other 
polar or charged amino acids effected signal integration with FXR, LXR, 
TR, or VDR, including differential loss or gain of function depending on 
the dimer partner and ligands. Treatment of RXR E434N/LXR with 9cisRA 
induced a substantial gain of function (150 fold activation) compared to 
wild-type heterodimer (10 fold activation). This effect was via the LXR 
coactivator-binding site, as shown by a second site suppressor mutant in the 
LXR AF2 surface, which fully blocked coactivator binding to LXR, and 
activation by 9cisRA. This suggests a model whereby ligand stabilization of 
helix 11 transmits allosteric information to the partner receptor helix 11, 
modulating helix 12 dynamics in the partner receptor.  
 
However, RXR 434 mutants were not able to restore responsiveness with 
TR or VDR, suggesting a different mechanism for silencing. We 
crystallized the RXRα/TRβ LBD heterodimer,showing RXR in an inactive 
conformation, despite the presence of coactivator peptide and RXR ligand. 
Buried in the center of the helix 11 dimer interface, RXR P423 is shifted by 
TR, causing a twist in the center of RXR helix 11. This twist is transmitted 
to helix 6, which lies across the top of the ligand binding pocket in the 
hydrophobic core of RXR. Finally, the twist in helix 6 W305 induces a 
clash with helix 3 L376 inducing dramatic shift of helix 3 that opens the 
ligand binding pocket, preventing both ligand and coactivator binding in 
this inactive conformation. These results were confirmed with H/D 
exchange mass spectrometry, showing reduced exchange in RXR helices 3 
and 11 in the presence of excess RXR ligand and coactivator peptide. This 
suggests that the active conformation of RXR in the presence of TR may be 
conformationally constrained. In conclusion, our work defines two distinct 
regions of the dimer interface that regulate integration of signals from both 
dimer partners versus the silencing of RXR by TR.  
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An increase in subclinical inflammation is frequently associated with 
obesity. Acute phase reactant proteins, such as C-reactive protein (CRP), α1 
acid-glycoprotein (α1 AG) and serum amyloid A (SAA) are clinically 
chronically elevated and are contributing factors towards metabolic 
dysfunction associated with the metabolic syndrome and are generally 
potently repressed by activation of PPARγ. We analyzed the plasma levels 
of three proteins that we have previously been identified as major secretory 
proteins from adipocytes We picked representatives of three groups of 
immune-related proteins: the classical acute phase reactant SAA3, α1 AG 
which is an acute phase reactant in the liver but which may have different 
functions in adipose tissue, and adipsin / complement factor D, a member of 
the alternative complement fixation cascade. Proinflammatory conditions, 
such as lipopolysaccharide and high fat diet lead to an increase in SAA3, 
have limited impact on α1 AG and decrease plasma adipsin levels. Similar 
trends are observed in the metabolically challenged ob/ob background, 
whereas mouse models that are protected against diet-induced challenges, 
such as adiponectin overexpressing mice, as well as PPARγ agonists display 
lower SAA3 levels and higher adipsin levels compared to controls. Fasting 
conditions are associated with a dramatic increase in SAA3 levels. These 
results further stablish the potent anti-inflammatory potential of PPARγ. 
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After hormone-activated steroid receptors bind to regulatory sites in their 
target genes, they recruit a large number of coregulators to modulate 
chromatin structure and regulate the recruitment and activation or 
repression of RNA polymerase II and its associated transcription factors. 
The intricate choreography of occupancy by these many coregulators on the 
target gene promoter has been thoroughly documented for a few target 
genes and suggests a complex and carefully coordinated series of 
functionally important interactions among many coregulators on the 
promoter. Furthermore, we and others have observed that individual 
coregulators are required for hormonal regulation of some but not all target 
genes that are regulated by a specific steroid hormone. In the context of 
these findings, the Stallcup lab is addressing several questions about the 
mechanistic and physiological roles of various coregulators in the hormone-
driven regulation of target gene expression: 1) We are using RNA 
interference coupled with chromatin immunoprecipitation on selected target 
gene promoters to dissect the functional relationships by which one 
coregulator controls promoter occupancy by other coregulators; this process 
should elucidate the mechanisms that lead to establishment of an active 
transcription complex or a repressed state on the promoter in response to 
hormone. 2) We are exploring the mechanisms responsible for promoter-
specific coregulator requirements. 3) We are defining subsets of hormone 
regulated target genes that require a specific coregulator and exploring the 
potential physiological implications of coregulator control of specific 
subsets of steroid hormone regulated target genes. 
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The androgen receptor (AR) is expressed in many human tissues, 
controlling diverse physiological processes, and is often involved in disease. 
There is a significant clinical need for drugs to treat AR-related diseases, 
but it has proven difficult to treat disease in one tissue without side-effects 
in others. For instance, systemic inhibition of AR prevents the growth of 
prostate cancer, but it also results in bone and muscle loss. We created a 
cell-based assay to monitor AR conformation change and successfully used 
the assay in screens to identify anti-androgens with novel, non-competitive 
mechanisms of action. Here, we have adapted this assay to identify cell-type 
specific AR agonists and antagonists, in an effort to create an in vitro screen 
for tissue selective AR modulators (SARMs). We expressed the AR 
conformation change reporter in cell lines derived from clinically relevant 
AR-expressing tissues, and screened a chemical library for compounds that 
matched desired clinical profiles. Importantly, we identified compounds 
that inhibit AR activity selectively in prostate cells, which may reduce the 
side-effects associate with systemic anti-androgen therapy. Concurrently, 
we are developing a rat model to assess the tissue selective activity of AR in 
response to potential SARMs. The model uses the transcription of AR-
regulated genes in multiple male and female tissues to develop a profile of 
AR activity in each tissue. We hope to validate this model using known 
SARMs and, in the near future, use it to test potential SARMs identified 
using the AR conformation change assay. 
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Adipogenesis is a tightly controlled process that involves an intricate 
network of transcription factors acting at different time points during 
differentiation. The peroxisome proliferator-activated receptor γ (PPARγ) is 
key player in this process; however, numerous other transcription factors, 
most notably members of the CCAAT/enhancer binding protein (C/EBP) 
family, have been shown to be critically involved. We have used DNase-seq 
to investigate genome-wide chromatin remodeling during adipogenesis. The 
temporal profile of DNase hypersensitive sites (DHS) representing open 
chromatin regions, can be clustered into four distinct clusters. Interestingly, 
during the first few hours following addition of adipogenic inducers there 
are dramatic changes in the occurrence of DHS. Some of these sites are 
unique to the early stages of adipocyte differentiation, whereas others 
persist in the mature adipocytes. Interestingly, we identify ~1000 
transcription factor hotspots where multiple transcription factors bind at 
overlapping sites few hours after stimulation with the adipogenic cocktail 
and we show that C/EBPβ is required for the establishment of many of these 
hotspots. Our data furthermore indicate that different pioneering factors 
may act early in adipogenesis at PPARγ target sites to open the chromatin 
structure and assist recruitment of PPARγ. 
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Drugs that target novel surfaces on the androgen receptor and/or novel AR 
regulatory mechanisms are promising alternatives for the treatment of hormone 
refractory prostate cancer (HRPC). The 52 kDa FK506 Binding Protein 
(FKBP52) has been shown to be an important positive regulator of AR in 
cellular and whole animal models and represents an attractive target for the 
treatment of prostate cancer. We have identified a surface region on the 
androgen receptor (AR) hormone binding domain that, when mutated, displays 
a greater dependence on FKBP52 for normal function. Interestingly, the BF3 
surface is also hypothesized to participate in the interaction of AR with the co-
activator β-catenin, and co-expression of FKBP52 and β-catenin act in synergy 
to up-regulate both hormone-dependent and hormone-independent AR function. 
In addition, we have developed a series of small molecules that effectively 
inhibit the FKBP52 regulation of AR function and the synergistic up-regulation 
of AR function by FKBP52 and β-catenin. Surface plasmon resonance studies 
have confirmed that these inhibitors disrupt the regulation of AR by FKBP52 
and β-catenin through interaction with the AR hormone binding domain. We 
have demonstrated that these novel compounds do not compete with hormone 
for binding the hormone binding pocket, nor do they compete with coactivator 
peptide for binding AF2. In addition, we have shown that these compounds 
inhibit AR function by preventing hormone-dependent dissociation of the 
Hsp90-FKBP52-AR complex which results in less hormone-bound receptor in 
the nucleus. Preliminary assays in early and late stage prostate cancer cells have 
demonstrated our novel compounds inhibit both prostate specific antigen 
expression and androgen-dependent proliferation. In summary, we have 
identified a putative FKBP52 interaction surface on the AR hormone binding 
domain and identified a series of small molecules that inhibit AR function by 
targeting that surface. This class of compounds, now termed NR alternate site 
modulators (NRAMs), would be useful in hormone-resistant prostate cancer, 
where coregulator overexpression and other mechanisms result in receptor 
activation in the absence of exogenous ligands. In addition, we have identified a 
novel functional interaction between FKBP52 and β-catenin, which has clear 
implications in prostate cancer progression to the hormone refractory state. 
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DNA acts as a sequence-specific allosteric ligand that influences 
glucocorticoid receptor (GR) structure and function (Meijsing, Pufall et al. 
(2009) Science 324:407). Among the suggestions of this finding are that 
certain GR binding sequences (GBSs) might direct cell-type specific 
activity of GR. To explore this, we performed ChIP-seq of GR in the 
presence of dexamethasone in three different cell lines: A549 lung 
carcinoma, U2OS osteosarcoma, and NALM-6 preB acute lymphoblastic 
leukemia. As expected, the position weight matrix-derived 15bp GR 
binding motif of inverted hexameric half-sites separated by three base pairs 
conformed to the canonical motif, and differed little between cell lines. 
However, individual GBSs exhibited remarkable sequence diversity, and 
were found rarely to be used repeatedly. Further, the presence of a canonical 
GBS within a GR binding region was highly cell type-dependent, ranging 
from 70% in U2OS to only 20% in NALM-6 cells, suggesting that GR 
might bind cell-specifically to non-canonical sequences. To examine 
directly the range of GR binding preferences, we used a microfluidic system 
to assay binding to a comprehensive library of random 8bp DNA sequences, 
which comprises all possible canonical GR half-sites among other 
sequences. These experiments demonstrated that although GR favors 
binding to a canonical site, it also has appreciable affinity for other 
sequences. To better understand how the structure of GR accommodates 
and responds to such diverse, but often subtle, changes in GBS, we took 
advantage of the sensitivity of nuclear magnetic resonance. Interestingly, 
even variations of non-contacted base pairs, including the spacer, appeared 
to influence the structure of the protein, indicating that DNA topology plays 
an important role in directing receptor structure. We conclude that GBSs 
comprise a very large set of distinct allosteric ligands, both canonical and 
non-canonical, and that the effects of DNA on conformation are not limited 
to directly contacted bases, suggesting that highly degenerate sequences can 
both bind and thereby influence the regulatory activity of GR. 
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Nuclear receptors (NRs) are major regulators of growth, inflammation, and 
metabolism. NR coactivators, such as the SRC-1/p160 family of molecules, 
amplify nuclear receptor induction of gene expression by coordinately 
implementing the downstream subreactions required for efficient NR-
dependent transcription, such as chromatin remodeling, initiation, 
elongation, alternative RNA splicing, and eventually, ubiquitinylation and 
turnover of the receptor-coactivator transcription complex itself. Thus, 
coactivators represent transcriptional ‘master genes’ that can play mediating 
roles in the development of many inherited and acquired hormone-related 
human pathologies.  
 
We will present evidence that SRC-family coactivators control multiple 
facets of growth and carbohydrate metabolism in mammals. SRC-3 controls 
primary breast tumor growth. SRC-1 is complementary to SRC-3 in 
oncogenesis; SRC-1 regulates, not primary tumor growth, but distant breast 
cancer metastasis. Finally, SRC-2 is a metabolic gate-keeper for glucose 
release from liver and its absence causes a Von Gierke’s Disease phenotype 
in mice. Recent work in mice in our lab has substantiated that SRC-2 also 
regulates fat absorption from the gut and storage to result in positive energy 
accretion/balance.  
 
The coactivator class of molecules is already providing important new 
insights to human diseases and promises to map future experimental 
blueprints for attacking ‘polygenic diseases’ and to generate novel ideas for 
proteomic therapeutic interventions. Studies are now underway in our 
laboratory to discover novel ligands that can directly bind to SRC-family 
coactivators and inhibit coactivator function by causing premature 
degradation of the molecules or inhibiting their functional interactions with 
NRs or other co-coactivators.  
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Peroxisome proliferator–activated receptor-γ (PPARγ) is the molecular 
target of the thiazolidinedione (TZDs) class of antidiabetic drugs that have 
many side effects. PPARγ is also activated by long chain unsaturated or 
oxidized/nitrated fatty acids, but its relationship with the medium chain 
fatty acids remains unclear despite that the medium chain triglyceride oils 
(MCT oils) have been used to control weight gain and glycemic index. We 
show that decanoic acid (DA), a major component MCT oils, is a direct 
ligand of PPARγ. DA binds and partially activates PPARγ without leading 
to adipogenesis. Crystal structure reveals that DA occupies a novel binding 
site. Treatments with DA and its triglyceride form improve glucose 
sensitivity and lipid profiles without weight gain in diabetic mice. Together, 
these results suggest that DA is a natural modulating ligand for PPARγ and 
the structure can aid in designing better and safer PPARγ-based drugs. 
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Thyroid hormone receptors α and β (TRα1 and TRβ1) function in the nucleus as 
transcription factors and direct the expression of specific genes in response to 
thyroid hormone. Both TRα1 and TRβ1 are shuttling proteins and their 
intracellular localization appears to be tightly regulated by a fine balance 
between nuclear import, nuclear retention, and nuclear export. We have carried 
out a detailed study on the signals involved in the nucleocytoplasmic shuttling 
of TRα1, by investigating the ability of separate domains of TR to target a 
heterologous protein either to the nucleus or cytoplasm. The four functional 
domains of TRα1 analyzed included the N-terminal transactivation domain 
which contains a novel nuclear localization sequence (NLS), the DNA-binding 
domain, the hinge domain which contains a classical bipartite NLS, and the 
ligand-binding domain (LBD). GFP-GST-GFP-tagged domain expression 
vectors were transiently transfected into HeLa cells. Fusion protein distribution 
patterns were visualized by live-cell fluorescence microscopy and scored for 
either a nuclear, cytoplasmic or whole cell distribution. Deletion studies 
indicated the presence of multiple nuclear export signals (NES’s) in the LBD of 
TRα1. Minimal regions that encode a transferable NES were cloned N-terminal 
to the hinge domain NLS to verify the nuclear export function. Three NES’s 
were identified in the LBD of TRα1, namely NESH3, NESH6 and NESH12. 
H3, H6 and H12 represent helices, 3, 6 and 12 respectively of TRα1. Classical 
NES’s interact with the export factor CRM1. Our studies show that NESH3, 
H6, and H12 follow a CRM1- independent nuclear export pathway. NESH12 is 
fully conserved in TRβ1. The region containing NESH12 is also involved in a 
ligand-dependent transactivation function, termed AF2. This AF2 functional 
domain is highly conserved among the nuclear receptor family members, thus 
highlighting the importance of NES function for this region. A detailed 
mutagenesis study revealed that multiple hydrophobic amino acids participate in 
the nuclear export function of NESH12. NES function was additive, as a second 
copy of NESH12 increased the nuclear export of the fusion protein. Specific 
mutations introduced in one or more copies of NESH12 resulted in a significant 
decrease in nuclear export activity. The three NES’s fall within the known hot 
spots of Resistance to Thyroid Hormone (RTH) mutations in TRβ1. One such 
mutation in NESH12, TRβ1 L454S showed moderately reduced nuclear export, 
compared to wild-type. This points to the possibility of reduced nuclear export 
as a contributing factor in RTH syndrome. The presence of multiple NLS’s and 
multiple NES’s and their conservation among the vertebrate species suggest that 
nucleocytoplasmic shuttling is crucial for the normal function of TR. 
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Prostate cancer is the second highest cause of male cancer related mortality. 
The main therapy for localised and metastatic disease is maximum 
androgen blockade.This approach has initial response rates of over 80% yet 
men relapse with castrate resistant prostate cancer (CRPC).Fluorescent in 
situ hybridisation was employed to asses AR amplification status and 
immunohistochemistry was employed to assess expression levels of AR, 
AR phosphorylated at serine residues 81, 94, 213,308, 650 and 791 in a 
cohort of 62 patients all with paired hormone naïve (HNPC) and CRPC 
tissue available for analysis.  
Amplification of the AR was observed in 1.5% HNPC, this increased 
significantly to 27% in CRPC (p<0.0001). Patients with AR amplification 
in CRPC had a significantly shorter time to death from relapse compared to 
patients without AR amplification (p=0.0002). AR and AR213 expression is 
significantly higher in AR amplified tumours compared to non amplified 
tumours (p=0.002 and p=0.025), and AR791 expression is significantly 
lower in AR amplified tumours compared to non amplified tumours 
(p=0.034).  
In CRPC high expression of AR and AR213 was associated of presence of 
metastases at relapse (p=0.018 and p=0.046, respectively) and with 
decreased time to death from relapse (p=0.038 and p=0.003). AR213 is also 
associated with a decreased disease specific survival (p=0.008). In contrast 
low expression of AR791 was associated with decreased time to death from 
relapse (p=0.04) and low expression of AR308 was associated with 
decreased disease specific survival (p=0.011) Use of paired tumours from 
each patient allowed changes in protein expression in the transition from 
hormone naive to castrate resistant disease to be assessed. Total AR, AR213 
and AR650 increased with the development of castrate disease (p<0.001, 
p<0.001 and p=0.003 respectively) and AR81 decreased with the 
development of castrate disease (p=0.001).  
In vitro results suggest that phosphorylation at AR213 sensitises the AR to 
low levels of androgens and stimulates prostate cancer growth at castrate 
levels. Therefore AR213 may serve as a diagnostic tool to predict patient 
outcome in response to maximum androgen blockade and inhibition of 
AR213 via the Akt pathway may be an effective therapeutic avenue to 
investigate for treatment of prostate cancer.  
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Unconventional prefoldin RPB5 Interactor (URI) was identified as a protein 
that binds the RPB5 subunit of polymerases and may function as a 
transcriptional repressor (Dorjsuren, et al., Mol. Cell Biol., 1998). URI mRNA 
is highly expressed in testis and our protein analysis indicates both cytoplasmic 
and nuclear localization in prostate cells. In addition to binding RPB5, URI was 
also shown to bind TFIIF and the DNA helicases TIP49 and TIP48 suggesting 
that URI is an important transcriptional regulator. URI also binds ART-27, an 
epithelial-specific AR cofactor that is decreased in prostate cancer and inhibits 
cell proliferation if over expressed in LNCaP prostate cells. Interestingly a gene 
profiling analysis of prostate cancer progression showed URI to be up-regulated 
in PIN (prostatic intraepithelial neoplasia) together with other Ets target genes 
(Tomlins et al., Science 2005), suggesting a possible role of URI in the initial 
stages of prostate cancer. We show that in prostate cells URI binds ART-27 and 
that the expression of one of the two proteins can affect the stability of the 
other, suggesting a tight relationship between URI and Art-27. Our data also 
suggest that URI as well as ART-27 is able to repress androgen receptor 
transcription. Knock down of URI decreases bicalutamide (casodex,CDX) 
inhibition of AR transcribed genes like PSA and FKBP5. Interestingly we show 
that in LNCaP cells, URI is phosphorylated in response to hormone (R1881) 
treatment and this occurs downstream of the mToR pathway. PMA, TNF-α and 
UV treatment of LNCaP cells also results in URI modification but these stimuli 
trigger URI phosphorylation downstream of p38 MAP kinase. These results 
suggest a role of URI in linking extracellular signaling to AR transcriptional 
regulation. Whole genome microarray analyzing of the impact of URI knock 
down on AR transcription showed that URI plays a role in the expression of 
genes aberrantly regulated in prostate cancer. Moreover mass spectrometry 
analysis of proteins interacting with URI in the nucleus of LNCaP cells showed 
that URI is part of several complexes involved in DNA transcription, chromatin 
modification, mitosis and DNA damage response. We also confirmed the 
binding of URI with the RPB5 subunit of RNA polymerase II as well as the 
binding to the general transcription factor IIF suggesting a possible role of URI 
in RNA polymerase II function. Moreover, LNCaP cells stably over-expressing 
URI protein form smaller colonies in a soft agar assay compared to control 
cells, suggesting that URI regulation is important for the establishment of the 
tumorigenic potential in prostate cancer cells. Collectively these data indicate 
that URI is able to represses AR-mediated gene transcription through the 
regulation of ART-27 co-repressor protein, RNA polymerase II transcription 
and possibly chromatin remodeling. 
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Familial partial lipodystrophy (FPLD) is considered to be a rare metabolic 
disorder however its clinical features may not be readily recognized. Early 
recognition is important because FPLD patients may require specific 
therapeutic approach. Here we screened medical records of patients with 
type 2 diabetes mellitus for extreme insulin resistance that was arbitrarily 
defined as the use of an insulin dosage ≥100U/day combined with a 
moderate to low BMI (≤ 27). From the 22 invited subjects, 12 patients were 
willing to participate. Five patients fulfilled the clinical features of 
lipodystrophy. One of these patients had previously been diagnosed as 
FPLD type 2, while another was known to have FPLD type 3. Three novel 
cases of lipodystrophy were identified in this population. One patient was a 
52 year old woman with type II DM and a history of SLE and chronic 
corticosteroid use that could explain lipodystrophy. In one of these patients 
a novel heterozygous mutation (Y151C) in PPARγ was identified, located 
within the zinc finger structure involved in DNA binding. In vitro analysis 
showed impaired DNA binding capacity in the Y151C mutant and hence 
reduced transcriptional activity compared to wild type PPARγ. Although 
FPLD appears to be rare, our data indicate that severe insulin resistance as 
defined by low BMI and high insulin usage should trigger clinicians to 
perform thorough clinical examination in search of lipodystrophy.  
 
#* authors contributed equally 
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Estrogens are critical regulators of many CNS functions including 
homeostasis, reproduction, learning, and memory. The actions of both 
endogenous and synthetic estrogens are mediated primarily by two high-
affinity estrogen receptors belonging to the nuclear receptor superfamily, 
ERβ and ERα. The latter, and most recently identified, has several splice 
variant isoforms present in the brain of both rat and human. Some of the 
human isoforms identified to date contain variable length deletions and 
substitutions in exons 7 and/or 8 (e.g. ERβ1, ERβ2, ERβ4, and ERβ5), 
resulting in a truncated receptor protein at the C-terminus. By contrast, the 
rat isoforms contain deletions in exons 3 or 4 (e.g. ERβ1Δ3 and ERβ1Δ4), 
and also amino acid insertions in the ligand binding domain (e.g. ERβ2). 
Previously, we showed in neuronal cells that rat ERβ1 increased 
transcriptional activity mediated by an estrogen response element (ERE), 
and at a complex promoter for the neuropeptide arginine vasopressin 
(AVP). By contrast, rat ERβ1 induced a constitutive decrease in 
transcriptional activity mediated at the activator protein-1 (AP-1) site. Rat 
and human ERβ are highly homologous, therefore in this study we used the 
human splice variants of ERβ in order to determine the relative importance 
of the E and F domains for conferring ligand-independent activity when 
mediated by an ERE or AP-1 site, and at the human AVP promoter. In stark 
contrast to the rat splice variants, our results showed little to no ligand-
independent activity of any human splice variant at a tandem ERE site, the 
exception being hERβ4, which was repressive. However, hERβ1 and 
hERβ4 both induced ligand-indpendent repression at an AP-1 site, similar to 
rat ERβ1. hERβ1 and hERβ4 also exhibit ligand-independent repression of 
the human AVP promoter, which was blocked with treatment of 3β-Diol, 
DHT, and ICI 182, 780. These data provide further understanding about the 
precise functions of each ERβ isoform in the brain, as well as highlight 
similarities and differences between the rat and human ERβ isoforms. 
Moreover, these data provide insight into the relative contributions of ERβ’s 
six functional domains on mediating transcription at various cis-regulatory 
promoter regions. 
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Estrogen receptor alpha (ERα)-positive breast cancers co-expressing 
pioneer factors FOXA1 and GATA-3, which are required for efficient ERα-
mediated gene expression, respond to anti-estrogen therapy. ERα:estradiol 
(E2) or ERα:E2-activated signaling molecules are believed to actively 
suppress growth factor signaling pathways in these cancers. Deregulation of 
this ERα function is suggested to cause aberrant activation of growth factor 
signaling and consequently anti-estrogen resistance. In this study, we 
investigated the ERα:E2 activated molecules that are likely to be involved 
in suppressing growth factor signaling. These studies identified TLE3, a 
transcription repressor, and LRIG-1, a negative regulator of growth factor 
receptors, as E2 inducible genes. Chromatin immunoprecipitation assays 
revealed binding of ERα and FOXA1 to the regulatory regions of TLE3 and 
LRIG-1. TLE3 is recruited to regulatory regions of target genes by FOXA1 
and represses transcription. LRIG-1 is a transmembrane protein that 
promotes degradation of several growth factor receptors including EGFR, 
ERBB2, ERBB3, and Met. It appears that ERBB3 is the primary target of 
TLE3 and LRIG-1 as E2 mediated repression of ERBB3 transcripts 
correlated with binding of FOXA1 and TLE to its regulatory region. In 
addition, E2-mediated increase in LRIG-1 protein correlated with lower 
levels of ERBB3 protein. ERBB3 regulatory regions lack binding sites for 
ERα raising the possibility that FOXA1-TLE3 mediate E2-dependent 
repression of this gene. Analysis of publicly available databases showed 
unfavorable recurrence-free and metastasis-free survival among anti-
estrogen treated patients with tumors that express lower levels of TLE3 or 
LRIG-1. These results suggest that ERα:E2 and FOXA1 expressing tumors 
with functional E2 signaling activity restrain growth factor activated 
signaling through TLE3 and LRIG-1. Functional studies are currently 
underway to determine the consequences of loss of expression of these two 
genes on growth factor receptor activation and anti-estrogen resistance. 
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Purpose. In addition to their well-documented ocular therapeutic effects, 
glucocorticoids (GCs) can cause sight-threatening side-effects including 
ocular hypertension and cataract. Although the molecular mechanisms of 
GC-induced ocular hypertension are not well-defined, GCs appear to 
increase aqueous humor outflow resistance and intra-ocular pressure via 
morphological and biochemical changes in trabecular meshwork (TM) cells. 
In the present study, we used Agilent microarray analysis to compare the 
effects of the synthetic GC DEX, the endogenous GC receptor (GR) agonist 
COR, and the endogenous mineralocorticoid receptor (MR) ligand ALD, on 
the complete transcriptome in two primary human TM cell lines. Methods. 
Transactivation of GR and MR were determined in HeLa and HEK 293T 
cells, respectively, by the GeneBLAzer beta-lactamase reporter gene assay 
(Invitrogen). For Agilent whole human genome microarray studies, TM 86 
and TM 93 cells were treated with 1 μM DEX, COR, or ALD for 24 hr. 
Differentially expressed genes were identified using the GeneSpring 
analysis package, and identification of specific signaling pathways and 
biologic functions was performed using Ingenuity Pathway Analysis (IPA) 
software. Results. The GR transactivation EC50 for DEX, COR, and ALD 
were 2.8, 71.7, and 669.8 nM, respectively. The MR transactivation EC50 
were 29.9, 1.6, and 0.41 nM for DEX, COR, and ALD, respectively. 
Microarray analysis revealed 402 and 289 genes commonly regulated by 
DEX, COR, and ALD in TM 86 and TM 93, respectively. These genes 
included RGC32, ITGA10, ANGPTL7, AOX1, FKBP5, ZBTB16, and 
MYOC. In addition, each agonist generated a unique set of genes in both 
TM cell lines. IPA analysis showed that in TM 86, ALD significantly 
regulated carbohydrate metabolism network, whereas DEX significantly 
modulated RNA-post-transcriptional modification network. In TM 93, COR 
significantly affected gene expression and cell cycle network, whereas DEX 
and COR both regulated DNA replication and repair network. Conclusion. 
The MR agonist, ALD, and the GR agonists, DEX and COR, commonly 
regulated a subset of genes including MYOC and FKBP5 in human TM86 
and TM93 cells. More importantly, each of the three agonists was capable 
of generating a unique transcriptional response and presumably a unique 
biologic effect in these cells. 
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The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription 
factor belonging to the PER-ARNT/-SIM (PAS) family of proteins. Past 
research on the AHR has focused mainly on its role as the primary mediator 
of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) toxicity, including potent 
immunosuppressive effects. However, a number of recent studies suggest a 
potential for the AHR as a therapeutic target for the treatment of 
autoimmune diseases and transplantation rejection by harnessing its 
immunomodulatory effects. Specifically, activation of the AHR by TCDD 
inhibits CD4+ T cell differentiation while increasing the frequency of CD4+ 
CD25+ (Foxp3+/-) T regulatory cells (Tregs). These AHR-dependent Tregs 
promote immune suppression and ongoing tolerance of self-antigens. In 
support of a therapeutic potential for the AHR in the treatment of disease, 
treatment of the non-obese diabetic (NOD) mice model with TCDD 
suppresses the onset of autoimmune Type 1 diabetes, correlating with an 
increased population of CD4+/CD25+/Foxp3+ T regulatory cells. However, 
clinical use of TCDD is unlikely due to its history as an environmental 
toxicant. Therefore, delineation of signaling events downstream of AHR 
activation in T cells leading to induction of Tregs and identification of other 
ligands that promote AHR-dependent Tregs is crucial for advancing the 
potential therapeutic use of AhR ligands. Here, we present our progress in 
identification of such alternative ligands, several of which exhibit promise 
for AHR-mediated immunosuppression. 
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Estrogen receptor β (ERβ) is strongly expressed in cells of the immune 
system. In addition, several studies have suggested an anti-proliferative role 
of ERβ in normal tissues and in some cancer cells. This prompted us to 
analyze the effects of estradiol (E2) and a selective ERβ agonist on 
lymphoma growth in culture and in vivo. Using immunofluorescence, we 
found significant nuclear expression of ERβ in murine and human Burkitt´s 
lymphoma cell lines. While estradiol (E2) had only minor effects on cell 
growth, a selective ERβ agonist (provided by Karo Bio AB) showed a 
strong and significant antiproliferative effect of the murine T cell 
lymphoma cells and the human Burkitt lymphoma cell lines in culture. To 
evaluate whether natural estrogen levels may have an effect on lymphoma 
growth in vivo, male and female C57Bl/6J mice were challenged with the 
murine T cell lymphoma cells. Male mice developed significantly larger 
tumors as compared to female mice. Ovarioectomy increased tumor growth 
to the rate seen in males. To investigate whether lymphoma growth may be 
reduced by estrogen treatment in vivo, ovariectomized mice challenged with 
the murine lymphoma cells were treated with E2 or the selective ERβ 
agonist. The selective ERβ agonist strongly inhibited T-cell lymphoma 
growth, while E2 had a weaker inhibitory effect. The reduced tumor size 
seen following selective ERβ agonist treatment was mainly due to reduced 
proliferation but also involved increased apoptosis. Our results demonstrate 
an ERβ ligand-dependent antiproliferative effect of lymphoma cells 
expressing endogenous ERβ and that lymphoma cell growth in vivo can 
efficiently be inhibited via ERβ. This study suggests that ERβ agonists may 
complement currently existing therapies of lymphomas providing an 
inhibitory effect via ERβ on tumor cell growth. 
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FKBP51 (FK506-binding protein 51) is a sensitive biomarker of 
corticosteroid and androgen responsiveness in lung and prostate, 
respectively. We have elucidated the molecular mechanisms underlying the 
induction of FKBP51 by glucocorticoid receptor (GR) and androgen 
receptor (AR) in A549 lung and VCaP prostate cancer cells, respectively. 
Quantitative chromatin immunoprecipitation scans and enhancer activity 
analyses indicate that activation of the FKBP51 locus by glucocorticoids 
and androgens in vivo is triggered by the loading of their receptors to 
regions at ~34 kb 5’ and ~87 kb 3’ from the transcription start site (TSS), 
both acting as the major enhancers for the AR in VCaP cells but merely the 
latter one for the GR in A549 cells. Steroid exposure decreased the histone 
density at several regions of the gene, which was paralleled with the 
occupancy of SWI/SNF chromatin remodeling complexes within the locus. 
The proximal promoter region of the gene along with the major intronic 
steroid-regulated enhancer had elevated levels of H3 acetylation and H3K4 
tri-methylation, whereas H3K36 tri-methylation more generally marked the 
gene body and reflected the occupancy of RNA polymerase II. The 
occurrence of these active chromatin marks within the FKBP51 locus 
already prior to steroid exposure suggests that it was poised for transcription 
in these cells. Interestingly, our ChIP scans further showed that the FKBP51 
region encompassing the steroid-regulated enhancers is bordered by CTCF- 
and cohesin-binding (RAD21) sites in both cell lines. We propose a model 
in which the CTCF-cohesin complexes stabilize the chromatin loops 
mediating the long-range interactions between the steroid receptors and the 
transcription machinery. 
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The role of estrogen and estrogen receptors in the onset of human labor is not 
clearly defined and may be involved in preterm birth. It has been postulated that 
increased ER action at term may inhibit uterine PR transactivation. These 
events would lead to a functional withdrawal of PR action and thus the onset of 
labor. We hypothesize that alternate ER transcripts in the pregnant uterus may 
play a critical role in governing PR responsiveness at term. There is mounting 
evidence that potential alternative ER proteins encoded by mRNA splice 
variants such as the hERα46 variant may play a role in the mediation of 
estrogen responsiveness.  
Utilizing multiple ER antibodies we identified by western blot analysis two 
,hERα46 and hERα51, major ER isoforms in the myocyte of human pregnant 
myometrial tissues, explant cultures and in our telomerase immortalized 
myometrial cell line (hTERT). The full length ERα66 was confined to the 
cytoplasmic fraction in all human uterine samples examined. To confirm the 
presence of the hER46/51α variant transcripts, we undertook RTPCR and RPA 
analysis of hTERT cell lines as well as myometrial tissues isolated from 
pregnant human uterus. The RTPCR and RPA analysis identified two alternate 
ERα transcript which when translated would give rise to a 46kDa and a 51kDa 
(Δ 7 isoform) ERα proteins. 5’ RACE data also identified that the uterine 
ER46α utilized a novel promoter in intron 1 as its proximal promoter. We also 
determined that estrogen responsiveness of hERα46 in primary human 
myometrial explant cultures differ significantly between myometrium isolated 
from non-laboring pre-term (n=4) and term patients (n=4). Increased levels of 
nuclear hERα46 result upon exposure to estrogen in term patients whereas in 
pre-term myometrium the 46kDa isoform level remains unresponsive to 
estrogen. To examine if there were parallels in the mouse model system we did 
westerns for ERα in the mouse during pregnancy and found a truncated form of 
the protein in the uterus that was both in the cytoplasm as well as the nucleus 
but disappeared as ERα66 became the dominant form in the nucleus at term. 
In conclusion we have identified in the uterine myocyte, novel ERα proteins and 
transcripts that utilize both novel and known promoters. We have identified in 
human myometrial tissues ERα46 is preferentially isolated in the nuclear 
fraction, hERα51 is found both in the nucleus and cytoplasm whereas the 
classical ERα66 is restricted to cytoplasmic fraction. Furthermore we 
hypothesize that the truncated forms of the estrogen receptor may as term 
approaches and estrogen levels rise, function as a major uterine component of 
estrogen action and play a role in PR functional withdrawal. 
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Our previous studies indicated that ASXL1 functions as either coactivator 
or repressor of RAR in a cell-specific manner. In this study, we investigated 
the roles of ASXL family in the regulation of other nuclear receptor PPAR. 
GST pull-down assays showed that both ASXL1 and ASXL2, a paralog of 
ASXL1, interact with PPARα and PPARγ in vitro. The endogenous 
interaction between ASXLs and PPARγ were confirmed by 
immunoprecipitation (IP) assays. Transcription assays under over-
expression or knockdown conditions of ASXLs indicated that ASXL1 
down-regulated rosiglitazone-induced PPARγ activity, whereas ASXL2 
greatly increased PPARγ activity. Similarly, ASXL1 completely repressed, 
but ASXL2 increased the adipogenesis as determined by Oil Red O staining 
using 3T3-L1 cells that stably express ASXLs. Intriguingly, ASXL1 mutant 
defective in heterochromatin protein 1 (HP1) binding increased the 
adipogenesis as much as ASXL2, indicating that HP1 binding is required 
for the ASXL1 repression. The adipocyte differentiation gradually reduced 
the expression of ASXL1 without affecting ASXL2 level. The knockdowns 
of ASXL1 and ASXL2 showed opposite effect on adipogenesis. Chromatin 
IP assays showed that HP1α and methylated H3K9 occupied the promoter 
of PPARγ target gene aP2 together with ASXL1 in 3T3-L1 cells. In 
contrast, ASXL2 occupied aP2 promoter together with acetylated H3K9, 
MLL1, and methylated H3K4. These occupancies were consistently 
changed during adipogenesis. Finally, microarray analysis demonstrated 
that ASXL1 repressed, but ASXL2 increased the expression of adipogenic 
genes, which are mostly targets of PPARγ. These results implicate that 
ASXL family provides diversity in the regulation of adipogenesis via 
differential modulation of PPARγ activity. 
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Mammalian nuclear receptors are key regulators of mitochondrial 
biogenesis and energy expenditure and are therefore popular targets for 
promoting cardiovascular health, metabolic fitness, and overall wellbeing. 
In C.elegans, the most likely candidate for a similarly acting nuclear 
receptor regulating mitochondrial function is NHR-49. Like its mammalian 
counterparts, we show that the C.elegans NHR-49 targets similar metabolic 
pathways to modulate mitochondrial physiology in nematodes. NHR-49 
orchestrates the regulation of multiple lipid metabolism pathways by 
partnering with distinct binding receptors to modulate a specific suite of 
genes. By knocking out the individual binding partner we can tease out the 
target genes contributing to the different nhr-49-/- phenotypes. One such 
nhr-49-/- phenotype is a significant alteration in intestinal mitochondrial 
density and morphology. The impaired expression of genes in the 
sphingolipid breakdown and fatty acid desaturase pathways is most likely 
responsible for this phenotype. Additionally we demonstrated that one of 
the sphingolipid breakdown genes, acid ceramidase, partially contributes to 
the aberrant nhr-49-/- mitochondrial phenotype. Our work shows the 
involvement of very specific genes in the nuclear receptor mediated control 
of mitochondrial density and shape, paving the way for a better 
understanding of the transcriptional regulation of mitochondrial biogenesis 
and function.  
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Warfarin, an antagonist of vitamin K, is the oral coumarin anticoagulant 
widely used to control and prevent thromboembolic disorders. Warfarin is 
clinically available as a racemic mixture of R- and S-warfarin; S-enantiomer 
has 3-5 times greater anticoagulation potency than its optical congener. 
Recently, Vitamin K2 function has been proposed via Pregnane X receptor 
(PXR) in osteocytes. In the liver, PXR acts as a xenobiotic sensor that 
controls expression of many genes involved in drug/xenobiotic metabolism 
and clearance.  
The aim of the paper was to examine whether enantiomers of warfarin 
stereoselectively interact with PXR receptor to up-regulate main 
drug/xenobiotic-metabolizing enzymes of cytochrome P450 superfamily.  
Interactions of warfarin enantiomers were tested in transient transfection 
gene reporter assays, TR-FRET ligand binding assay and up-regulation of 
PXR-target genes mRNAs has been studied employing semi-quantitative 
RT-PCR in primary human hepatocytes.  
We found that both enantiomers interact with PXR. R-warfarin significantly 
induced CYP3A4 mRNA in cultures of primary human hepatocytes or in 
LS174T intestinal cells. S-warfarin is less potent inducer of PXR-target 
genes in the liver and activates PXR only in supraphysiological 
concentrations. We show that R-warfarin can significantly up-regulate 
major drug-metabolizing enzymes in the liver and thus may cause drug-
drug interactions with co-administered drugs.  
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The glucocorticoid receptor (GR) regulates numerous genes governing 
physiological processes including inflammation, metabolism, and 
development that may be influenced by the circadian clock, which itself can 
be entrained by GR. The molecular mechanism of this entrainment by GR 
has not been well described. Among the circadian genes whose cycling is 
affected by GR are the Period genes PER1, PER2 and PER3. Previous work 
in our lab showed that GR-mediated induction of mouse Per2 mediates 
glucose homeostasis in a mouse model (1), whereas GR-mediated 
repression of mouse Per3 is required for the adipogenic cell fate decision 
(2), thus linking GR regulation of metabolism to two clock genes. To 
investigate the mechanism of clock entrainment, as well as gain further 
insight into gene-specific regulation by GR, we have begun to examine the 
transcriptional dynamics of human PER1. PER1 encodes a clock protein 
essential for maintenance of the transcriptional feedback loop that 
constitutes the basis of the circadian program. We found that PER1 is the 
circadian gene induced most rapidly and with the greatest magnitude upon 
addition of the GR agonist dexamethasone, and we identified two GR 
binding regions located near alternative transcriptional start sites. We are 
currently interrogating how these GR binding regions temporally operate to 
affect transcription from these alternative start sites, how they participate in 
entraining circadian rhythm, and whether GR regulation of PER1 plays a 
direct role in metabolic regulation. 
 
1. So AY, Bernal TU, Pillsbury ML, Yamamoto KR, Feldman BJ. (2009) 
Glucocorticoid regulation of the circadian clock modulates glucose 
homeostasis. Proc Natl Acad Sci. 106(41):17582-7.  
 
2. Costa MJ, So AY, Kaasik K, Krueger K, Pillsbury ML, Fu YH, Ptacek 
LJ, Yamamoto KR, Feldman BJ. Circadian rhythm gene Period 3 is an 
inhibitor of the adipocyte cell fate. (Submitted 2010)  
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The ligand-activated nuclear receptors Liver X Receptors (LXRs) regulate 
cholesterol metabolism and immune inflammatory responses in 
macrophages. Moreover, activation of LXRs in macrophages inhibits the 
development of atherosclerosis. Enhanced levels of the hydrolytic enzyme 
arginase 1 (Arg1) in alternatively activated macrophages are associated with 
a low-atherosclerotic response in rabbits and Arg1 expression is markedly 
decreased in foam cells within the lesion. In humans, Arg1 SNP rs2781666 
is associated with an increase in myocardial infarction. Altogether, these 
data suggest an atheroprotective role for this enzyme.  
Arg1 expression in macrophages is largely regulated by cytokines, such as 
IL-4, that elicit anti-inflammatory responses. Our studies show that 
T0901317-activated LXRα not only induces the expression of arginase 1, 
but also synergistically enhances its IL-4-induced mRNA and protein 
expression in both the RAW 264.7 macrophage cell line and primary bone 
marrow-derived macrophages. In addition, a -4.8kb Arg1 promoter 
fragment is responsive to T0901317 in the presence of LXRα indicating that 
the regulation of Arg1 mediated by this nuclear receptor occurs at the 
transcriptional level. Our ChIP experiments, however, demonstrate that 
LXRα is not recruited to the Arg1 promoter in LXR ligand-treated cells. 
Instead, LXR appears to regulate Arg 1 expression via the increased 
recruitment of PU.1, an Ets transcription factor family member, to the Arg1 
promoter upon LXR ligand treatment. This work provides a new molecular 
mechanism by which LXR agonists regulate the expression of an IL-4 
modulated anti-inflammatory gene with potential implications on 
atherosclerosis progression. 
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The peroxisome proliferator activator receptor-γ coactivator 1α (PGC-1α) is 
a transcriptional coactivator that regulates lipid catabolism, mitochondrial 
number and function. Increasing evidence suggests that either reduced 
levels or compromised activity of PGC-1α can be associated with the 
development of insulin resistance (IR) and type 2 diabetes (T2D). Also, 
mitochondrial dysfunction and increased mitochondrial oxidative stress has 
been proposed to play an important role in IR and T2D. Additionally, 
accumulation of muscular free fatty acids (FFAs) has been implicated in IR. 
The type of FFAs, saturated or unsaturated, is critical in the development of 
IR, as the degree of saturation correlates with IR. Here, we compare the 
effects of the saturated FFA, palmitate, the unsaturated FFA, oleate, and a 
mixture of each on the production of mitochondrial reactive oxygen species 
(mtROS), mitochondrial function, expression of PGC-1α and mitochondrial 
transcription factor (TFAM), and insulin signaling pathway in rat L6 
skeletal muscle cells. Only palmitate caused a significant increase of 
mtROS production, which correlated with concomitant mitochondrial 
dysfunction and inhibition of insulin signaling. Oleate alone did not cause 
mtROS generation and its addition prevented palmitate-induced 
mitochondrial dysfunction and inhibition of insulin signaling. PGC-1α 
protein level and promoter activity were decreased after palmitate treatment, 
while addition of oleate increased both PGC-1α protein level and promoter 
activity. Also, expression of TFAM was significantly diminished after 
palmitate, but not oleate, treatment. Addition of the ROS scavenger N-
acetylcystein (NAC) to palmitate restored both the expression and promoter 
activity of PGC-1α as well as TFAM expression, suggesting that palmitate-
induced oxidative stress contributed to the downregulation of these 
transcription factors. Based on these results we propose that ROS-induced 
downregulation of TFAM and PGC-1α expression may further contribute to 
palmitate-induced mitochondrial dysfunction and oxidative stress by 
decreasing mitochondrial biogenesis and thus establishing a vicious cycle of 
events in which palmitate-induced oxidative stress causes mitochondrial 
dysfunction, which causes a concomitant increase in ROS production. In 
this regard, the present study enhances the understanding of the mechanisms 
involved in IR. Identification of the pathways that regulate mitochondrial 
function and mtROS production can provide new potential therapeutic 
strategies for preventing of IR and other factors contributing to the 
development of T2D.  
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As part of the human circadian cycle, cortisol acts via the glucocorticoid 
receptor (GR) to regulate gene expression. We previously discovered that 
expression of Period 1 (PER1), a key circadian regulator, is induced by 10-
fold lower doses of the cortisol mimic Dexamethasone (DEX) than other 
GR target genes. To find additional low-dose responsive genes, we used 
RNA-seq to measure gene expression in A549 lung epithelial cells treated 
with low doses of DEX. Remarkably, we found that, in A549 cells, PER1 
responds to lower doses of DEX than all other genes. To understand the 
mechanism of the response, we used ChIP-seq to measure genomic GR 
occupancy at high and low doses of DEX. Of the thousands of loci bound 
by GR at high DEX, only 1% are bound at a low dose concomitant with 
PER1 induction. We found GR occupying two sites near the PER1 
transcription start site (TSS). One site, located upstream of the TSS, is 
bound by GR at low and high DEX, while the other site, located 
intronically, is only bound at high DEX. We found that the DNA sequence 
upstream of the PER1 TSS, including the endogenous promoter and the 
low-dose GR site, is sufficient to drive expression in response to low doses 
of both DEX and cortisol. From this larger sequence, we isolated a 250 bp 
enhancer surrounding the GR binding site that is sufficient for low dose 
expression. To test if the GR binding sequence (GBS) creates the low-dose 
response, we swapped the PER1 low-dose GBS with a typically responding 
GBS. Interestingly, we observed no change in hormone sensitivity, 
indicating that the context of the GBS, and not the GBS itself, is responsible 
for hypersensitivity of PER1 to corticosteroids. Within the low-dose PER1 
enhancer, we found consensus DNA binding sites for many factors, 
including nuclear factor 1 (NF-1). A 2 bp mutation of one NF-1 site 
converted the low-dose enhancer to one with a typical response. However, 
introducing the NF-1 site into a typically responding enhancer was 
insufficient for low-dose response. Removal of other sequences in the 
hypersensitive enhancer also reduced dose-sensitivity, indicating that a 
complex interaction of cofactors is responsible for the sensitivity of PER1 
expression to corticosteroids. These results show that a network of 
regulatory elements flanking an otherwise normal GR binding site increases 
sensitivity of PER1 to low levels of corticosteroids, potentially triggering 
production of PER1 before other genes in the circadian cycle. 
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The transcriptional co-repressor SMRT utilizes two major receptor 
interacting domains (RID1 and RID2) to mediate nuclear receptor (NR) 
signaling through epigenetic modification. The physiological relevance of 
such interaction remains poorly defined. We report here a mouse model 
with RID1 knockin mutations, termed SMRTmRID1, which preserves SMRT 
interaction with RID2 associated NRs, including peroxisome proliferator-
activated receptors (PPARs). These mice exhibit reduced mitochondrial 
function, inhibited anti-oxidant gene expression and increased susceptibility 
to oxidative damage, leading to premature aging and related metabolic 
diseases. At the molecular level, SMRTmRID1 suppresses PPAR activity, and 
the defect of SMRTmRID1 cells in oxidative stress sensitivity is partially 
rescued by PPAR activation. In concert, we identify polymorphisms in the 
human SMRT gene associated with type 2 diabetes and adiponectin levels. 
These data uncover a role of SMRT RID2 in mitochondrial oxidative 
metabolism, which may serve as a drug target to improve health span. 
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Cancer cachexia involves profound metabolic imbalance leading to weight 
loss, muscle wasting and fat depletion. Despite the fact that cachexia is the 
direct cause of death in 20-30% of all cancer patients, little is known about 
the underlying mechanism. Multiple biological pathways may contribute to 
this catabolic process, including nuclear receptor signaling and pro-
inflammatory cytokines, however the etiology of tissue wasting 
accompanied by increased metabolic rate observed in cancer patients is not 
known. Brown adipose tissue (BAT) plays a key role in thermogenesis & 
energy balance and could be responsible for physiological perturbations 
such as hypermetabolism. Therefore, we investigated the impact of the 
cachectic Colon 26 (C26) adenocarcinoma on BAT in mice. 
EM and light microscopy of BAT showed profound delipidation & reduced 
size of brown adipocytes in cachectic C26 tumour-bearing mice, together 
with higher density of mitochondria. Circadian expression profiling of 
nuclear receptors and other molecular regulators of lipid accumulation & 
utilisation and their corresponding target genes showed dramatic activation 
of BAT. Alterations in the diurnal rhythmic expression pattern of PGC1, 
PPARδ, PPARγ, C/EBPα and target genes CPT1α, PBE, FAS, DGAT2, 
ELOV3, LPL and PERILIPIN, indicate dysregulated circadian control of 
lipid metabolism accompanied by increased mitochondrial and peroxisomal 
β-oxidation in BAT of cachectic mice. In addition, increased Deiodinase 2, 
Adenylate cyclase 3 and UCP1 mRNA and protein show the BAT 
thermogenic pathway is switched on. These changes persist when cachectic 
mice are acclimatized to 28oC, confirming the inappropriate activation of 
BAT despite thermoneutrality. While the cachectic mice do reduce food 
intake, pair-feeding experiments demonstrate that the changes in BAT could 
not be attributed to restricted nutrients. A potential link between these 
alterations in nuclear receptors during the development of cachexia and 
tumour-derived cytokines such as IL-6 is the observed increase in 
suppressor of cytokine signaling 3 (SOCS3) and phosphorylation of STAT3 
in BAT. 
CONCLUSION Chronic stimulation of IL-6 signaling in BAT of cachectic 
mice due to systemic release of cytokines by tumours alters nuclear receptor 
expression & energy homeostasis, potentially contributing to the catabolic 
state. Activation of BAT, despite dramatically reduced food intake, 
represents a maladaptive response to nutrient deprivation in cancer 
cachexia. 
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The HER2 gene, coding for the EGFR family receptor HER2, is amplified 
in 25-30% of breast cancers. Herceptin, a humanized monoclonal antibody 
that inhibits the tumorigenic effects of HER2 is currently used for targeted 
therapy strategy of HER2 positive breast cancer, particularly as an adjuvant 
treatment strategy in combination with chemotherapy. Although initial 
response to Herceptin is good, the majority of patients that originally 
respond will develop resistance within a year. We have observed that in the 
HER2-positive SkBr-3 breast cancer cell line, which carries a co-
amplification of the HER2 and retinoic acid receptor alpha (RARA) genes, 
RA and Herceptin inhibit proliferation in a synergistic way. This synergy 
was not observed in the HER2 amplified cell line BT-474, which does not 
carry the co-amplification of RARA. In addition, the observed modulation 
by RA in SkBr-3 cells of genes that have been proposed to be implicated in 
Herceptin resistance suggests that RA could help prevent the development 
of resistance to Herceptin. Since about 40-50% of HER2-positive tumor 
samples show a co-amplification of the HER2 and RARA genes, we 
propose that this subgroup of HER2 positive tumors could benefit from 
association of retinoids with Herceptin treatment. 
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Thyroid hormone, the endocrine hormone secreted by the thyroid gland 
regulates crucial functions of growth, development, metabolism and 
homeostasis. The cellular actions of T3 are mediated by cognate thyroid 
hormone receptors (α and β) which are members of nuclear receptor 
superfamily. T3 binding to these receptors stimulates the recruitment of 
coactivator proteins to the thyroid hormone receptor proteins and 
consequent activation of downstream gene expression. Classically T3 target 
genes have been known to belong to groups like metabolic enzymes, 
transcription factors, ion channels among others. Mounting evidence 
indicates that T3 also causes upstream activation of certain kinase pathways 
in specific cell types including PI3Kinase and mTOR pathways. We have 
identified that T3 induces the transcriptional induction of a specific kinase 
called the serum and glucocorticoid regulated kinase 1 (SGK1). This protein 
belongs to AGC family of protein kinases and is activated downstream of 
PI3-kinase/Akt pathway. SGK1 has significant roles in cell survival, ion 
transport, salt homeostasis and integration of number of transcriptional 
inputs. In HepG2 cells, thyroid hormone induces the expression of 
SGK1mRNA and protein. At least partially, this transcriptional induction of 
SGK1 gene is mediated by a secondary gene product- early growth response 
1 (EGR1). Thyroid hormone causes rapid induction of EGR-1 mRNA in 
HepG2 cells. In these cells, siRNA mediated knockdown of EGR1 led to 
significant reduction in the transcriptional induction of SGK1 by T3. 
Furthermore, EGR-1 response elements were identified in the proximal 
SGK1 gene promoter. Collectively our data validates SGK1 as a novel T3 
target gene in HepG2 cells and identifies EGR1 as specific mechanistic 
pathway of SGK1 induction by T3. Given the ubiquitous nature of SGK1 
expression, our findings suggest a prominent role for SGK1 in thyroid 
hormone function. 
 96 
DUAL FUNCTION OF FOXA1 IN REGULATION OF ANDROGEN 
RECEPTOR BINDING TO CHROMATIN. 
 
Biswajyoti Sahu1, Marko Laakso2, Sampsa Hautaniemi1,2, Olli A Jänne1  
 
1University of Helsinki, Institute of Biomedicine, Helsinki, 00014, Finland, 
2University of Helsinki, Genome-Scale Biology Program, Helsinki, 00014, 
Finland 
 
Androgen receptor (AR) regulates distinct transcriptional program in a cell- 
and tissue-specific fashion and is of prime importance in both androgen-
dependent and castration-resistant prostate cancer [1]. Our genome-wide 
analysis of AR-binding sites (ARBs) in LNCaP-1F5 prostate cancer cells by 
ChIP-seq revealed FoxA1-binding sites as the most over-represented cis-
elements adjacent to ARBs. FoxA1 acts as a pioneer factor for ERα binding 
to chromatin and facilitates estrogen-dependent transcription [2,3]. 
However, FoxA1 is also known to recruit Groucho/TLE/Grg corepressor 
complexes to generate compact chromatin [4]. To understand the 
relationship between ARBs and FoxA1 occupancy, we used ChIP-seq to 
map FoxA1-binding sites on LNCaP-1F5 cell chromatin. Most of the ARBs 
(72%) overlapped with FoxA1-binding sites, lending credence to the role of 
FoxA1 as pioneer factor in androgen signaling. Interestingly, depletion of 
cells from FoxA1 by siRNA resulted in a dramatic increase (>2-fold) in the 
number of ARBs. The overlap of the ARBs in FoxA1-depleted cells to 
those in parental cells was only ~50%. These results imply that there are 
three classes of ARBs in LNCaP-1F5 cells: (i) the sites that need FoxA1 for 
binding to chromatin, (ii) the sites that are independent of FoxA1, and (iii) 
the sites the accessibility of which is masked by FoxA1 and that appear 
upon FoxA1 depletion. Therefore, FoxA1 appears to act both as a pioneer 
factor that facilitates AR binding and as a repressor that generates compact 
chromatin structure inaccessible to AR binding. Our expression profiling 
data support this conclusion, in that FoxA1 depletion both modulated the 
magnitude of responsiveness of a number of genes (e.g., KLK3, FKBP5, 
TMPRSS2, and SGK1) and permitted expression of a new set of genes upon 
androgen exposure. Androgen regulation of these latter genes was 
commensurate with the appearance of new ARBs in their regulatory regions 
in FoxA1-depleted cells. Collectively, the present work has revealed 
important new insights into the role of FoxA1 in androgen signaling and 
AR function. 
 
[1] Wang et al., Cell 138: 245, 2009; [2] Carroll et al., Cell 122: 33, 2005; 
[3] Lupien et al., Cell 132: 958, 2008; [4] Sekiya and Zaret, Mol Cell 28: 
291, 2007. 
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Study: Glucocorticoids (GCs) are used to treat pregnant women at risk for 
preterm delivery; however, exposure of fetuses to GCs may trigger adverse 
neurological side effects mediated in part by reduced neural progenitor cell 
(NPC) proliferation. While many established cell cycle regulators impact 
NPC proliferation, other signaling molecules, such as the gap junction 
protein connexin 43 (Cx43), appear to also influence proliferation although 
its precise role and mechanism of regulation remain unresolved. Gap 
junction function is influenced by GCs in some cells, but hormone effects 
on this form of intercellular communication in NPCs and resulting 
functional consequences have not been examined. 
Methods: NPCs from embryonic (E14) mouse cortices were subject to a 
2min-1h exposure to the glucocorticoid receptor (GR) agonist 
dexamethasone (DEX), and/or the GR antagonist RU486 and the reversible 
gap junction inhibitor 1-heptanol. Cell lysates were subject to Western blot 
to measure Cx43 and ERK1/2 expression and phosphorylation. Gap 
junction intercellular communication (GJIC) was assayed by live cell 
Fluorescence Recovery after Photobleaching (FRAP). Cell proliferation was 
measured by assessing S phase (i.e. BrdU incorporation) and cell cycle (i.e. 
Ki67 expression) progression. 
Results: Treatment of NPCs with Dex for 1h led to both significantly 
increased Cx43 phosphorylation at Ser279/282, an ERK target site, and 
decreased GJIC. All DEX effects were blocked by continuous co-
administration of RU486. ERK1/2 activation (as measured by Western blot 
analysis of ERK1/2 phosphorylation) was transient and first detected within 
2min of DEX treatment. A 1 hr delay in the addition of RU486 following 
DEX exposure led to a significant reduction in cell proliferation by 24h, as 
did 1h 1-heptanol treatment. Pre-treatment with the transcription inhibitor 
Actinomycin D did not reverse the decrease in GJIC following 1H DEX 
treatment. Co-treatment with the ERK inhibitor PD98059 reversed the DEX 
induced increase in Cx43 phosphorylation and the loss in GJIC. 
Conclusion: These findings indicate unique, rapid, non-genomic and 
MAPK-ERK1/2 dependent effects of GCs on regulation of GJIC and 
subsequent proliferation in NPCs. Strikingly, a 1h delay in the addition of 
RU486 following DEX did not reverse the DEX effects on cell 
proliferation, suggesting that rapid actions of GR are responsible for DEX-
dependent inhibition of NPC proliferation.  
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Studies over the last decade indicate that estrogen protects pre-menopausal 
women against cardiovascular disease, at least in part, by binding to and 
activating the estrogen receptors (ERs), ERα and ERβ. However the idea of 
using estrogen to protect against cardiovascular disease (or, indeed, the use 
of estrogen as part of hormone therapy to treat adverse menopausal 
symptoms) is greatly complicated by the fact that estrogen treatment has 
different effects in different tissues. In particular, estrogen treatment 
increases the risks of venous thrombosis and of cancer in the uterus and 
breast. The effects of estrogen are largely mediated by the transcriptional 
regulatory response that occurs when estrogen-bound ERs are recruited to 
specific chromatin locations. Importantly, recent studies have shown that 
the gene regulatory effects of the active, natural form of estrogen (17β 
estradiol, E2) differ greatly between human MCF7 and U20S cell lines, as 
do the chromatin binding sites for ERα. These results suggest that tissue-
specific responses to estrogen are mediated by tissue-specific distributions 
of ER, and highlight the importance of performing mechanistic studies in 
vascular tissues for understanding the vasoprotective effects of estrogen. 
 
Studies from our research group have shown that the genomewide gene 
regulatory response of mouse aortic tissue to E2 changes dramatically with 
time of hormone treatment (2, 4 or 8 hrs). To begin to understand the 
mechanisms for this response, we recently mapped the genomewide 
chromatin locations of ERα in mouse aorta after 45 minute E2 treatment, 
using ChIP-seq. Our results indicate that ERα binding within 50kb of 
transcription start sites is strongly associated with transcriptional 
upregulation, but not with downregulation. Furthermore, the fraction of 
upregulated genes with nearby ERα binding peaks is higher at early time 
points than at 8 hrs, consistent with the model that early regulated gene 
products contribute to the long term response to E2. Comparing our results 
to those from a recent study in mouse liver tissue, we find very little overlap 
between regulated genes and ERα binding sites in aorta versus liver, 
consistent with the hypothesis that the response of aortic tissues to E2 is 
largely determined by an aorta-specific distribution of ER. The results of 
these studies are helping to refine new mechanistic models for vascular-
specific gene regulatory responses to estrogen. 
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Although best known for its female reproductive functions, oxytocin (OT) 
also participates in regulation of the stress response in both males and 
females. It is expressed in hypothalamic neurons that participate in the 
stress response and is regulated by the predominant circulating sex steroid. 
The mechanisms of OT regulation by testosterone, in particular, are poorly 
understood. Recently it has been found that 3β-diol, a testosterone 
metabolite, binds estrogen receptor beta (ERβ). Thus, circulating 
testosterone may regulate OT expression by its conversion to 3β-diol, which 
then binds to ERβ. In the present study a hypothalamic cell line is being 
used to compare the effects of E2 and 3β-diol on occupancy of the OT 
promoter by ERα/β and co-regulators. The type and degree of histone 
modifications elicited are being monitored, as well. ChIP analysis has been 
targeted to a region of the OT gene promoter that contains a composite 
estrogen response element (ERE). At 30 mins, E2 failed to alter the 
occupancy of OT both by ERα or ERβ. It also failed to alter the degree of 
H3 or 4 pan-Acetylation. At 60 mins, however, E2 down regulated all these 
parameters: ERα & β by 40% and pan-AcH3 and 4 by 60%. In contrast to 
E2, at 30 minutes 3β-diol increased ERβ occupancy 3 fold and the level of 
pan-acetylated H4 (pan-AcH4) 4 fold. There was no effect on ERα 
occupancy or the degree of pan-AcH3. At 60 mins, however, 3β-diol 
decreased ERα and β occupancy to the same levels as E2 had, but had no 
significant effect on the pan-acetylation of either histone. Thus, the two 
ligands lead to different patterns of occupancy by ERα and β receptors and 
to different levels of H3 and 4 pan-acetylation. The 3β-diol effect 
corroborates the hypothesis that testosterone regulates OT expression via 
this metabolite. Furthermore, they suggest that this stress-related gene is 
regulated by ERα and β both in females and males and does so via different 
kinetics. Funded by NS039951 (RJH; RMU co-investigator) 
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Inflammation plays a critical role in the body’s ability to maintain and 
protect itself from invading pathogens. However, chronic onslaught and 
over-activity can both change the signaling pathways and mark the genes 
that respond to inflammatory signaling. Chronic inflammation is a well-
characterized contributor to diseases such as diabetes, atherosclerosis and 
arthritis and there have been numerous studies linking chronic inflammation 
and infection with prostate cancer. IL-1β is a pro-inflammatory cytokine 
that activates the JNK and p38 stress kinase pathways as well as NF-κB. 
Infiltrating inflammatory cells, such as macrophages and monocytes, 
release inflammatory cytokines and are found in malignant tissues, such as 
prostate cancer. Additionally, primary prostate epithelial cells have been 
shown to secrete IL-1β at the picogram per milliliter level.  
 
IL-1β affects the androgen receptor in two rather disparate ways. First, it 
modulates AR directly through phosphorylation at S650, which impacts AR 
mediated transcription at specific genes. Additionally 40% of prostate 
cancer samples investigated showed robust S650 staining in the nucleus 
indicating phosphorylation at S650 may play a role in a distinct subset of 
cancers. Second, activation of NF-κB suppresses transcription of AR 
through binding of MybB and p65 at the AR promoter. This decreases the 
levels of AR in LNCaP cells over multiple passages slowing their growth. 
Over time, however, AR levels are reestablished. Initially IL-1β signaling is 
protective, in the sense that it completely blocks anchorage independent 
growth, a hallmark of cellular transformation. Cells that have been 
acclimatized to IL-1β, however, are able to grow in anchorage independent 
conditions regardless of further IL-1β treatment. This suggests chronic 
inflammation and acute inflammation have very distinct effects on prostate 
cancer cells. We have established a model system to investigate these 
differential effects on growth and cell signaling by culturing LNCaP cells 
long-term in IL-1β.  
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Vitamin D receptor (VDR) is a nuclear receptor that mediates most known 
functions of 1,25-Dihydroxyvitamin D (1,25(OH)2D3), the hormonal form 
of vitamin D. VDR and 1,25(OH)2D3 are involved in calcium homeostasis, 
electrolyte and blood pressure regulation, immune response, and anti-
inflammation activity. The target genes of the VDR signal pathway include 
the enzyme Cyp24 and antimicrobial peptides beta-defensin and 
cathelicidin. Not surprisingly, VDR plays an essential role in 
gastrointestinal inflammation. Polymorphisms in VDR gene are associated 
with susceptibility to inflammatory bowel disease (IBD). Moreover, VDR 
deficient mice are more susceptible to bacterial infection. However, the 
majority of studies of vitamin D, VDR, and inflammation are focused on 
immunoregulation, with little emphasis on assessing the effects of VDR in 
intestinal epithelial cells. It is unknown how intestinal VDR signaling 
responds to commensal and pathogenic bacterial stimulation. This current 
study investigated the effects and mechanism of pathogenic enteric bacteria 
on VDR expression. We hypothesize that VDR expression determines how 
intestinal epithelial cells respond to pathogenic bacterial triggers. We found 
that mice lacking VDR had high amount of serum inflammatory cytokines 
and worse outcomes following Salmonella-induced infection. Moreover, we 
found that enteric bacterial colonization directly regulated VDR expression, 
distribution, and activity in intestinal cells. Furthermore, we defined the 
molecular mechanism of VDR negatively regulating the intestinal NF-
kappaB activity in the pathogenic bacteria stimulated cells. We showed that 
VDR negatively regulated bacterial-stimulated intestinal epithelial NF-
kappaB activity. Our studies provide new insight into the anti-inflammatory 
mechanism of VDR in inhibiting intestinal infection. Endogenous enteric 
bacteria play a crucial role in the pathogenesis of IBD. Our studies will 
establish a new target—VDR signaling for treatment of inflammatory bowel 
disease. 
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The differentiation of interleukin 17 (IL-17)-producing T helper cells (Th17 
cells) are important to the pathogenesis of autoimmune inflammation. 
Retinoic acid receptor-related orphan receptor gammat (RORγt) is a master 
regulator for Th17 cell differentiation. However, molecular mechanism of 
RORγt-dependent transcriptional control remains unclear. Here, we 
established large scaled culture system and a purification system of RORγt 
associating proteins from T cell 68-41 hybridoma cells. Associated proteins 
were purified with endogenous anti-RORγt antibody column and separated 
by SDS-PAGE, then identified by MALDI-TOF/MS. Besides known 
nuclear receptor-related co-regulators, novel transcriptional co-regulators of 
RORγt are identified. We found that these proteins act as transcriptional co-
activators for RORγt by using luciferase reporter assay. Interestingly, some 
proteins functioned as transcriptional co-regulators for Smad, NFAT, and 
AP1. Identified proteins regulated endogenous mRNA expression levels of 
IL17 induced by T cell receptor activation, TGFβ, and IL6 in 68-41 cells 
and primary helper T cells. Furthermore, overexpression of identified 
proteins changed the recruitment pattern of histone H3K4me2 on IL17 
promoter region. 
Thus, in this study we demonstrated the existence of transcriptional co-
regulators supporting RORγt function in helper T cells. 
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Estrogen receptor (ER) is important in the development and progression of 
breast cancer. Using ChIP-sequencing, we mapped the genomic landscape 
of ERα binding sites (ERBS) in the breast cancer cell line, MCF-7. To 
understand what factors can influence the transcriptional activity of ERα, 
we performed cofactor motif analysis on the ERα binding sites identified by 
ChIP-sequencing. Our analysis revealed the binding sequences of AP2 
family of transcription factors were highly enriched in the ERBS. The AP2 
family of transcription factors is known to orchestrate a variety of cellular 
processes, including cell growth, cell adhesion and tissue differentiation. 
AP2γ, a member of the AP2 family, has been shown to be over-expressed in 
breast tumors, however little is known on how it regulates transcription in 
breast cancer. Here, we showed that AP2γ is recruited to the distal ERBS of 
the estrogen regulated gene, rearranged during transfection (RET), in a 
ligand-independent manner. Using a combination of siRNA, ChIP and 
Chromosome conformation capture (3C) assays, we showed that AP2γ is 
essential for the recruitment of ERα and FoxA1, and the long-range 
chromatin interaction at the RET gene. Moreover, down-regulation of AP2γ 
resulted in reduced RET transcription. Taken together, our data suggests 
that multiple transcription factors (e.g. AP2γ and FoxA1) are pre-loaded at 
ERBS establishing functional complexes of cofactors that are required for 
the coordinated regulation of ERα activity. 
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Cancer cachexia is a catabolic condition characterized by progressive 
weight loss, fat depletion & muscle wasting. The impact of cachexia is 
severe, occurring in 20-80% of cancer patients depending on the tumour 
type and the direct cause of death in ~30% of all cancer sufferers. Although 
the mechanism of cachexia is unknown, there is a strong evidence for the 
involvement of increased systemic levels of tumor-derived cytokines (eg 
IL-6). Our focus has been primarily on the liver and hepatic metabolic 
pathways fundamental for the control of total body homeostasis. Given the 
integral role of nuclear receptors in regulating metabolic patways linked 
with circadian rhythm, we characterized the diurnal expression pattern of 
nuclear receptors & genes they regulate in the livers of cachectic colon 26 
(C26) tumour-bearing mice. Expression profiling was carried by cDNA 
microarray and MS-based iTRAQ proteomics. Six-timepoint analysis by 
RT-qPCR of the core circadian clock genes - BMAL1, CLOCK, CRY1 and 
PER2 as well as the nuclear receptors REVERBα and RORα showed 
significant changes to their normal rhythmic diurnal patterns, particularly at 
2am and 2pm. Analysis of liver samples by cDNA microarrays identified 
numerous genes which displayed a rhythmic pattern in normal mice (ie 
peaking at 2am or 2pm) many of which lost the normal circadian expression 
pattern in cachectic C26 livers. PPARα/δ/γ as well as ERRα all displayed 
markedly reduced expression, along with their target genes in fatty acid β-
oxidation (PBE, HADHA & B), fatty acid uptake (LPL), lipogenesis (FAS, 
SCD1) and glucose/pyruvate metabolism (PEPCK, PDK4). Expression 
profiling demonstrated decreased expression of many other genes& proteins 
in key energy generation pathways which is counter-intuitive to the 
expected role of the liver in settings of food restriction/weight-loss - ie to 
adaptively switch on fatty-acid use, ketone body production & 
gluconeogenesis. Evidence for links between such widespread disruptions 
to hepatic metabolic pathways & elevated tumour-derived IL-6 include 
activated STAT3 & increased SOCS3 mRNA and hepatic acute-phase 
proteins. Therefore distal tumours drive chronic stimulation of cytokine-
signaling in the liver altering the action of nuclear receptors and hence 
disrupting metabolic pathways responsible for maintaining energy 
homeostasis. The net outcome of impaired processing & supply of nutrients 
to muscle, fat & other organs would contribute to the devastating effects of 
cachexia. 
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Loss-of-function mutations in PPARG gene are implicated in human 
hypertension and PPARgamma agonists decrease blood pressure both in 
animal models and human patients. How PPARgamma affects blood 
pressure and vascular reactivity is still unclear in vivo. To study the role of 
PPARgamma in the pathogenesis of hypertension and vascular diseases, we 
generated mice with extremely low PPARgamma expression. Interestingly, 
we found that PPARgamma deficiency induced an increase in systolic 
blood pressure without significant change in diastolic blood pressure, 
ultimately causing a significant increase in pulse pressure. Loss of aortic 
elasticity, generally termed aortic stiffness, is thought to be one of the most 
important factors contributing to the increased pulse pressure. Thus, we 
hypothesized that PPARgamma deficiency impairs aortic elasticity, 
resulting in the increase in pulse pressure. Aortic pulse wave velocity 
(PWV) was significantly increased in PPARgamma hypomorphic mice, 
suggesting that aortas of PPARgamma hypomorphic mice were stiffer than 
those of wild-type mice. Expression of elastin in aortas was significantly 
decreased, and negatively correlated with aortic PWV in PPARgamma 
hypomorphic mice. This was accompanied by increased expressions in gene 
and protein of MMP-9 in aortas of PPARgamma hypomorphic mice. 
Together, our results suggest that PPARgamma deficiency impairs elasticity 
in aorta and underscore the importance of PPARgamma in the regulation of 
blood pressure and vascular reactivity. 
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Foxl2 is a forkhead transcription factor essential for proper reproductive 
function in females. Human patients carrying mutations in the FOXL2 gene 
display Blepharophimosis/ Ptosis/Epicanthus inversus Syndrome (BPES), 
an autosomal dominant disease associated with eyelid defects and 
premature ovarian failure in females. Likewise, mice homozygous mutant 
for Foxl2 display craniofacial malformations and female infertility. To 
elucidate the molecular mechanisms underlying the impaired 
folliculogenesis of Foxl2 knockout mice, we have deleted the Foxl2 gene 
postnatally using the Cre-loxP system. Surprisingly, several male-specific 
genes reported to be essential for testis development are upregulated in 
Foxl2 mutant ovaries. In males, the transcription factor SRY, encoded by 
the Y chromosome, is normally responsible for triggering the indifferent 
gonads to develop as testes rather than ovaries. Inducible deletion of Foxl2 
in adult ovarian follicles leads to immediate upregulation of testis-specific 
genes including the critical SRY target gene Sox9. The cell fate switch of 
ovarian granulosa into testicular Sertoli cells is accompanied by 
transdifferentation of theca cell lineages into Leydig-like cells with ectopic 
expression of the testosterone-synthesizing enzyme 17ßHSD3 and elevated 
serum testosterone levels comparable to male animals. A similar phenotype 
of postnatal sex reversal has been observed in ovaries of Estrogen Receptor 
(ER) alpha beta double mutant mice. Using various approaches such as 
immunoprecipitation, luciferase assays and transgenic mouse lines, we 
show that Foxl2 interacts with ER both physically and genetically to repress 
expression of Sox9 from a gonadal-specific cis regulatory element. Our 
results show that maintenance of the ovarian phenotype is an active process 
throughout life. They might also have important medical implications for 
the understanding and treatment of some disorders of sexual development in 
children and premature menopause in women. 
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The effects of the biologically most active form of vitamin D, 1α,25-
dihydroxyvitamin D3 (1α,25(OH)2D3) are mediated through the vitamin D 
receptor (VDR), which is a member of a superfamily of ligand-inducible 
nuclear receptors that control expression of their primary target genes in 
response to binding of steroidal or other lipophilic compounds. VDR binds 
as a heterodimer with retinoid X receptor (RXR) to specific segments of 
DNA, the vitamin D response elements (VDREs). In order to locate genome 
wide the VDREs we used an in silico screening method, which was based 
on systematic EMSA assays of VDR binding to a large panel of DR3 type 
VDREs. The in silico screening data was challenged using FAIRE and ChIP 
-seq using antibodies against VDR and RXR in the presence and absence of 
1α,25(OH)2D3. Finally, we used microarrays to determine the genes that 
were affected by the 1α,25(OH)2D3 treatment. 
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Cytotoxic T cells (CTL) are important mediators of the adaptive immunity 
organizing the defence against virus-infected or tumour cells. Moreover, during 
transplantation, CTL can contribute to pathological conditions, such as acute 
organ rejection. Therefore, CTL inhibition is a desired therapeutic approach.  
Taking into consideration that PPARγ has been established to attenuate CD4+ T 
cell activation, we elucidated whether PPARγ can alter CTL activity as well. 
Thus, we established a non-radioactive allogenic in vitro cytotoxicity assay. Our 
experimental set up included P815 (haplotype H-2d) cells as target cells and 
CTL derived from spleens of C57BL/6 mice (haplotype H-2b) as effector cells. 
To initially activate effector cells, CTL were co-incubated with γ-irradiated 
splenocytes derived from Balb/c mice (haplotype H-2d) for 10 days. Following 
this first step, effector cells were co-incubated with P815 target cells, 
beforehand stained with CellTrackerOrange to follow cell demise. CTL-
dependent target cell lysis was analyzed after 1 and 24 h by flow cytometry. 
Although 1 h after CTL addition no target cell destruction was detectable, the 
amount of living CellTrackerOrange positive target cells was decreased to 
approximately 50% after 24 h. The optimal target vs. effector cell ratio was 
1:10. Raising the ratio to 1:50 did not enhance CTL-dependent cytotoxicity, 
whereas decreasing it to 1:5 or lower, significantly increased the number of 
surviving target cells. Incubating CTL for 1 h with 1 µM of the PPARγ-specific 
agonist rosiglitazone diminished target cell lysis to 25%. To verify a PPARγ-
dependent effect, CTL were derived from T-cell specific conditional PPARγ 
knockout (LckCre+/-PPARγfl/fl) mice. As to our expectation, CTL not expressing 
a functional PPARγ the addition of 1 µM rosiglitazone did not alter CTL-
dependent cytototoxicity. To characterize the molecular mechanism how 
PPARγ inhibits cytotoxicity, we analyzed the expression of genes established in 
mediating CTL-dependent cytotoxicity (FasL, perforin and granzyme B) by 
quantitative PCR in wild type and conditional PPARγ knockout mice. We found 
that FasL and granzyme B expression are increased in response to allogenic 
target cell addition, whereas perforin expression was not induced. In PPARγ 
wild type CTL the induction of FasL and granzyme B expression was 
attenuated in response to rosiglitazone treatment. In agreement to the 
observation in the cytotoxicity assay, rosiglitazone did not alter FasL and 
granzyme B expression in CTL not expressing a functional PPARγ. From these 
data we conclude that PPARγ mediated inhibition of FasL and granzyme B 
expression contributes to attenuate CTL-dependent cytotoxicity. Our data 
suggest that PPARγ-dependent inhibition of CTL cytotoxicity might be a new 
therapeutic approach to reduce transplant rejection. 
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While the molecular mechanisms by which the progesterone receptor (PR) 
regulates breast tumor growth and metastasis have not been fully elucidated, 
recent studies highlight the fact that PR has a complex role in breast cancer 
progression that may be dependent on ligand dose. For example, data from 
the Women’s Health Initiative trial suggest that low-dose progestins used in 
combination with estrogen are associated with an increased risk of invasive 
breast cancer compared to estrogen alone. On the other hand, high-dose 
progestin therapy has been used as an effective front-line and second-line 
treatment for advanced, metastatic breast cancer. To investigate this 
paradox, we undertook studies to identify aspects of PR biology that 
respond differently to treatment with low or high doses of progestins. 
Interestingly, we found that treatment of T47D breast cancer cells with low-
dose progestins generates a significantly more robust induction of a subset 
of PR target genes, including the cell cycle regulators cyclin D1 and E2F1, 
than treatment with high-dose progestins. Furthermore, we show that 
varying doses of progestins have differential effects on the receptor itself, 
including the subcellular localization, phosphorylation and subsequent 
turnover of PR. At the level of transcriptional regulation, our ChIP analyses 
have led us to hypothesize that the strength of PR activation of target gene 
expression may hinge upon the ratio of phospho-PR versus unmodified PR 
that is recruited to enhancer elements. This dose-dependent effect may 
result in the formation of different PR transcriptional complexes and 
explain the diverse downstream biologies that are regulated by varying 
levels of progestins throughout the female reproductive cycle and in 
diseases such as breast cancer. Given the wide range of medical therapies 
that utilize progestins, our findings may have important clinical 
implications. 
 110 
RAC3 IS A NOVEL PRO-MIGRATORY COACTIVATOR OF ERα 
WITH LINKS TO BREAST CANCER PROGRESSION 
 
Matthew P Walker, Maomao Zhang, Thien P Le, Muriel Laine, Geoffrey L 
Greene  
 
University of Chicago, Ben May Department of Cancer Research, Chicago, 
IL, 60637 
 
ERα is a ligand-dependent nuclear receptor that is important in breast 
cancer genesis, behavior and response to hormone-based therapies. T7 
phage display screening coupled with human genome-wide exon arrays was 
used to identify RAC3 as a putative ERα coregulator. RAC3 is a rho family 
small GTPase that is overexpressed in breast cancer, but its role in the cell 
is best characterized in the cytoplasm and membrane, and associated with 
cytoskeletal rearrangement. Here we show a novel role for nuclear RAC3 as 
an ERα transcriptional activator with implications for metastatic disease. 
Through in vitro and cellular work, RAC3 was shown to exist in a GTP-
bound state and act as a ligand specific ERα coactivator of E2 induced 
transcription. Overexpression of RAC3 induced pro-growth and pro-
migratory genes that resulted in increased migration in breast cancer cells. 
Chemical inhibition and genetic knockdown of RAC3 antagonized E2 
induced cell proliferation, cell migration, and ERα mediated gene 
expression, indicating that RAC3 is necessary for full activity of ERα. In 
agreement with the molecular data, RAC3 overexpression in ERα positive 
breast cancer correlated with a significant decrease in recurrence and a 
significant increase in the odds ratio of metastasis. In conclusion, RAC3 is 
novel coactivator that promotes cell migration and has clinical implications 
for ERα positive breast cancer metastasis. RAC3 may be a useful drug 
target for ERα+ breast tumors that fail antiestrogen or aromatase therapy. 
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The UBE2C oncogene is overexpressed in many types of solid tumors 
including the lethal castration-resistant prostate cancer (CRPC) that is 
highly heterogeneous in androgen receptor (AR) expression. While we have 
identified two CRPC-specific AR-bound enhancers that drive UBE2C 
overexpression in AR positive CRPC, little is known about the regulation of 
UBE2C in AR negative CRPC. Here we used a locus-centric chromosome 
conformation capture approach to identify three AR negative CRPC-
specific enhancers. We further show that selective phosphorylation of 
coactivator Mediator 1 (MED1) in AR negative CRPC is required for these 
enhancers to interact with the UBE2C promoter through chromatin looping, 
leading to AR negative CRPC growth. Our results not only suggest that 
development of specific therapies for CRPC should take account of 
targeting MED1 phosphorylation, but also define a novel role for the 
Mediator complex in forming or sustaining active chromatin structure via 
MED1 phosphorylation. 
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Ezetimibe is the inhibitor of cholesterol absorption and used in treating 
hyperlipidemia. It has been reported that ezetimibe not only decreases 
serum total cholesterol, but also reduces serum triglyceride and improves 
hepatic steatosis and insulin resistance in mice and human. However, that 
mechanism is not fully understood. Here we report the mechanism for that. 
We used KK-Ay mice, which is the animal model of the diabetes and 
obesity, fed a high fat diet with or without ezetimibe. In ezetimibe-treated 
mice, serum and hepatic lipids, serum glucose and insulin were decreased 
and the hepatic steatosis was ameliorated. OGTT and IPITT indicated 
improved glucose tolerance and insulin sensitivity. Administration of 
ezetimibe decreased liver X receptor (LXR) activity and lipogenic gene 
expressions in liver. Simultaneously, reactive oxygen species (ROS) and 
inflammatory cytokines were diminished. Consistent with that, in liver, 
JNK phosphorylation and IRS serine phosphorylation were decreased.  
These observations suggest that ezetimibe causes the reduce of LXR 
activity, followed by hepatic lipogenic gene expressions, and thereby 
decreases ROS production, and so reduces JNK phosphorylation and then 
improves insulin resistance.  
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Mediator recently has emerged as a central player in the direct transduction 
of signals from transcription factors to the general transcriptional 
machinery. MED1 (a.k.a. TRAP220/DRIP205/MED220) subunit of this 
complex has been shown to directly interact and mediate the transcription of 
nuclear receptors, in a ligand-dependent fashion, through its two classical 
LxxLL motifs. However, despite the strong in vitro evidence, there 
currently is little information regarding in vivo functions of the LxxLL 
motifs either in MED1 or in other coactivators. Towards this end, we have 
generated MED1 LxxLL motif-mutant knockin mice. Interestingly, these 
mice are both viable and fertile, and do not exhibit any apparent gross 
abnormalities. However, they do exhibit severe defects in pubertal 
mammary gland development. Consistent with this phenotype, as well as 
loss of the strong ligand-dependent estrogen receptor (ER)α-Mediator 
interaction, expression of a number of known ERα-regulated genes was 
down-regulated in MED1-mutant mammary epithelial cells and could no 
longer respond to estrogen stimulation. Interestingly, our experiments 
showed that estrogen-stimulated mammary duct growth but not uterine 
development was greatly diminished in of MED1-mutant mice. 
Furthermore, we found that MED1 is differentially expressed in different 
types of mammary epithelial cells and that its LxxLL motifs play a role in 
mammary luminal epithelial cell differentiation and progenitor/stem cell 
determination. These results, together with our most recent finding that 
muscle specific deletion of MED1 enhances insulin sensitivity, glucose 
tolerance and resistance to high fat diet-induced obesity, establish key 
tissue- and nuclear receptor- specific roles for MED1 in vivo. 
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Significant progress has been made in defining the molecular mechanism(s) 
by which cells distinguish between AR agonists and antagonists and how 
some receptor modulators can manifest their actions in a cell-selective 
manner. The most important of these are (1) differences in the relative 
expression level of receptor subtypes or isoforms, (2) the impact which the 
bound ligand has on the structure of its cognate receptor, and (3) the 
complement of coactivators and corepressors in a target cell which can 
interact with the activated receptor. These advances in our understanding of 
the molecular pharmacology of nuclear receptors have provided insights 
into the processes underlying drug resistance to antihormonal therapies and 
have provided direction to efforts aimed at the development of improved 
cancer therapeutics. We have developed and applied a cofactor 
interaction/AR conformation-based screen to define important mechanistic 
distinctions between existing antiandrogens and to direct the discovery of 
new classes of antagonists that function by unique mechanisms and which 
exhibit favorable activities in cellular models of hormone refractory prostate 
cancer. These findings highlight the primacy of receptor conformation in 
determining the pharmacological activities of bound ligands and provide 
direction for the pharmaceutical exploitation of this receptor in prostate 
cancer and other androgenopathies.  
 
In addition to focusing on AR itself we have also embarked on efforts 
aimed at identifying druggable targets downstream of AR that may yield 
useful therapeutics. Among the targets identified in this manner was a 
functionally active splice variant of the serine/threonine kinase 
Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ). 
Importantly, this variant was highly expressed in both the prostate and in 
prostate cancers. Inhibition of the CaMKKβ activity using pharmacological 
inhibitors or siRNA-mediated knockdown blocks androgen-mediated 
migration and invasion. Conversely, overexpression of the CaMKKβ 
variant alone led to increased migration. Given the key roles of CaMKKβ in 
the biology of prostate cancer cells, we propose that this enzyme is a 
potential therapeutic target in prostate cancer. 
 
Taken together the results of these studies highlight the utility of applying 
advances in our understanding of the molecular pharmacology of a well-
validated target (AR) to identify useful prostate cancer therapeutics.  
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Androgen receptor (AR) splice variants lacking the ligand binding domain 
(ARVs), originally isolated from prostate cancer cell lines derived from a 
single patient, are detected in normal and malignant human prostate tissue 
with the highest levels observed in late stage, castration-resistant prostate 
cancer. The most studied variant (called AR-V7 or AR3) activates AR 
reporter genes in the absence of ligand and could therefore play a role in 
castration resistance. To explore the range of potential ARVs, we screened 
additional human and murine prostate cancer models using conventional 
and next generation sequencing technologies and discovered several new, 
structurally diverse AR isoforms. Some, like AR-V7/AR3, display gain-of-
function whereas others have dominant interfering activity. We also find 
that ARV expression is coupled to full-length AR (AR-FL) mRNA 
production, both of which increase acutely in response to androgen 
withdrawal and are suppressed by testosterone. As expected, constitutively 
active, ligand-independent ARVs such as AR-V7/AR3 are sufficient to 
confer anchorage-independent (in vitro) and castration-resistant (in vivo) 
growth. Surprisingly, this growth is blocked by ligand binding domain 
targeted antiandrogens such as MDV3100 or by selective siRNA silencing 
of AR-FL, indicating that the growth promoting effects of ARVs are 
mediated through AR-FL. These data suggest that the increase in ARV 
expression in castrate-resistant prostate cancer is an acute response to 
castration rather than clonal expansion of castration or antiandrogen-
resistant cells expressing gain-of-function ARVs and furthermore provide a 
strategy to overcome ARV function in the clinic. 
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Estrogen receptor (ER)-negative breast cancers account for 25-30% of all 
cases and derive little or no benefit from current endocrine therapies. We 
have investigated the potential of targeting the androgen receptor (AR) in 
ER- breast cancers. AR is expressed in 60-70% of human breast tumors, 
independent of the ER status. Interestingly while androgens inhibit the 
growth of ER+/AR+ breast cancer cells, they stimulate the growth of those 
that are ER-/AR+. The mechanism, however, by which androgens and AR 
function to regulate breast cancer growth remains largely unknown. 
Analysis of gene expression profiles from human breast tumors revealed 
enriched expression of AR and androgen-regulated genes in the ER- breast 
tumors that over-express HER2. Through the analysis of the AR cistrome 
and androgen-regulated gene expression profiles in ER-/HER2+ breast 
cancer cells we find that AR mediates ligand-dependent activation of 
Wnt/β-catenin and HER2 signaling pathways through direct transcriptional 
up-regulation of WNT7B and HER3. Specific targeting of AR, Wnt/β-
catenin or HER2 impairs androgen-stimulated tumor cell growth. Thus, 
these findings suggest a potential role for therapies that target AR in ER-
/HER2+ breast cancers. 
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Epigenetic pathways are often aberrant in cancer cells, altering 
transcriptional control. Examples include the overexpression or 
mistargeting of DNA methyltransferases leading to silencing of tumor 
suppressor gene promoters, mutations in histone acetyltransferases resulting 
in their inactivation, or the abnormal recruitment of histone deacetylases to 
promoter regions by oncogenic fusion proteins, consequently inhibiting the 
expression of differentiation genes. Some of these aberrant epigenetic 
events can be reversed by modulating the action of epigenetic enzymes with 
chemical inhibitors, yet few inhibitors are available. The recent 
identification and characterization of an increasing number of histone 
modifying enzymes involved in epigenetic events makes it more imperative 
to develop chemical tools to modulate their biological activity. We have 
developed a unique cell-based system to screen for small molecule 
modulators of epigenetic pathways. This system has allowed us to identify 
candidate compounds that have the ability to re-activate the expression of a 
silenced reporter gene. Here, we present the activity of one of our candidate 
compounds against the growth of various human lung cancer cell lines and 
normal bronchial epithelial cells. IC50 measurements show the specificity of 
this drug for cancer vs. normal cells is superior to that of known epigenetic 
modulators such as trichostatin A and depsipeptide. The compound exhibits 
excellent potency with IC50 values as low as 2 nM. The anticancer potential 
of this drug is also seen in its ability to inhibit anchorage independent 
growth in soft agar colony formation assays and to decrease the rate of 
tumor growth in vivo in mouse xenograft models. Preliminary evidence 
suggests that in cancer cells this small molecule causes changes in the 
epigenetic landscape of a subset of genes and alters their expression, 
without affecting the expression of these genes in normal cells. In addition, 
this compound is able to modulate nuclear receptor activity in some 
biological systems, a phenotype which we are currently characterizing.  
 
Funded by NCI (K22CA118717 and R01CA125269-01 to EM).  
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Posttranslational modifications of histones such as methylation, acetylation, 
and phoshorylation regulate chromatin structure and gene expression. 
Demethylation at distinct lysine residues in histone H3 by lysine-specific 
demethylase 1 (LSD1) causes either gene repression or activation. As a 
component of co-repressor complexes, LSD1 contributes to target gene 
repression by removing mono- and dimethyl marks from lysine 4 of histone 
H3 (H3K4). In contrast, during androgen receptor (AR)-activated gene 
expression LSD1 removes mono- and dimethyl marks from lysine 9 of 
histone H3 (H3K9). Yet, the mechanisms that control this dual specificity of 
demethylation are unknown. Here, we show that phosphorylation of histone 
H3 at threonine 6 (H3T6) by protein kinase C beta I (PKCβI) is the key 
event that prevents LSD1 from demethylating H3K4 during AR-dependent 
gene activation. In vitro, histone H3 peptides methylated at lysine 4 and 
phosphorylated at threonine 6 are no longer LSD1 substrates. In vivo, 
PKCβI co-localises with AR and LSD1 on target gene promoters and 
phosphorylates H3T6 upon androgen-induced gene expression. RNAi-
mediated knockdown of PKCβI abrogates H3T6 phosphorylation, enhances 
demethylation at H3K4, and inhibits AR-dependent transcription. 
Activation of PKCβI requires androgen-dependent recruitment of the 
gatekeeper kinase protein kinase C (PKC)-related kinase 1 (PRK1). 
Importantly, elevated levels of PKCβI and phosphorylated H3T6 (H3T6ph) 
positively correlate with high Gleason scores of prostate carcinomas, and 
inhibition of PKCβI blocks AR-induced tumour cell proliferation in vitro 
and cancer progression of tumour xenografts in vivo. Together, our data 
establish that androgen-dependent kinase signalling leads to the writing of 
the novel chromatin mark H3T6ph, which in consequence prevents removal 
of active methyl marks from H3K4 during AR-stimulated gene expression. 
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Advanced prostate cancer is treated with anti-androgens, but in most cases, 
the disease will progress to a more aggressive state called castration 
resistant prostate cancer (CRPC). CRPC is commonly associated with 
increased androgen receptor (AR) gene expression. MDV3100, the second-
generation anti-androgen drug recently developed by our lab, retains 
antagonist activity in two CRPC models where the current clinically used 
first-generation AR antagonist bicalutamide (Casodex) has agonist activity. 
However, the underlying mechanism is not fully understood. 
 
Here we used an established CRPC cell line LNCaP/AR (LNCaP prostate 
cancer cells engineered to express higher levels of AR that mimic the 
clinical scenario) and performed chromatin immunoprecipitation coupled 
with massively parallel sequencing (ChIP-Seq) to map the AR binding sites 
in response to R1881 (AR agonist) alone or with a combined treatment with 
bicalutamide or MDV3100. Out of a total of 42,000 high confidence AR 
binding sites identified in response to R1881 alone, 32,000 sites are still 
bound by AR in the presence of bicalutamide, and only 2,000 bound by AR 
in the presence of MDV3100. Thus, bicalutamide only partially reduces AR 
DNA binding, while MDV3100 globally blocks AR DNA binding. This 
result provides a mechanistic explanation of superior antagonism of 
MDV3100 versus bicalutamide in CRPCs.  
 
By conducting the expression profiling under similar conditions as the 
ChIP-Seq experiment, we found 309 AR regulated genes (ARGs) with a 
fold change of two or greater in response to R1881, and most of them 
contain AR binding sites within 50kb of the TSS. MDV3100 has more 
profound effect on regulating ARGs compared to bicalutamide.  
 
Overall, this is the first time that the effect of anti-androgens on AR binding 
has been studied at a genome-wide level.  
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Steroid hormone receptors play preeminent roles in the development and 
progression of breast tumors. In particular, estrogen receptor α (ERα) 
represents an important prognostic and therapeutic factor in breast cancer. 
Estrogen-related receptors (ERRα, β and γ) are orphan members of the 
superfamily of nuclear receptors that share both structural and functional 
features with the ER, and consequently, may also play a role in the etiology 
of the disease. In this talk, we will first present a comprehensive view of the 
functional interaction between ERα and ERRα in breast cancer cells at a 
genome-wide level with a more precise attention to the events governing the 
expression of genes contained within the ERBB2 amplicon. Second, we will 
show that regulation of ERRγ expression in breast cancer cells by a specific 
miRNA (miR-378) encoded within the PGC-1β gene leads to a reduction in 
tricarboxylic acid cycle gene expression and oxygen consumption as well as 
an increase in lactate production and in cell proliferation, indicating that the 
miR-378/PGC-1β/ERRγ pathway is involved in the orchestration of the 
Warburg effect in breast cancer cells. Finally, we will demonstrate an 
unsuspected role for stromal RARβ in promoting mammary gland 
tumorigenesis suggesting that retinoid-based approaches for the prevention 
and treatment of solid tumours should be carefully re-evaluated. 
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During the last decade the AMP-activated protein kinase (AMPK) has 
emerged as a master regulator of cellular metabolism in many tissues. In 
skeletal muscle, where much of the work in this area originated, AMPK is 
potently activated by exercise and AMPK is considered an important 
regulator of multiple cellular functions. However, emerging data from our 
laboratory and other groups suggest that AMPK is not essential for many 
metabolic responses in skeletal muscle. In this talk, studies using knockout 
and transgenic approaches will be presented that suggest that AMPK may 
only play a limited role in glucose uptake and fatty acid oxidation in 
muscle, and some of the adaptations to chronic exercise training. If AMPK 
is not essential for many of the metabolic responses to exercise, then what 
are the critical signals? Studies from muscle-specific LKB1 knockout mice 
provide important clues. In fact, LKB1, the major upstream kinase for 
AMPK in skeletal muscle, has been shown to be necessary for both the 
acute effects of muscle contraction on glucose uptake and fatty acid 
oxidation, as well as some of the adaptations to chronic endurance training. 
Therefore, other LKB1 substrates, known as AMPK-related kinases, may be 
central to the effects of exercise on muscle metabolic processes. In 
particular, studies on sucrose non-fermenting AMPK-related kinase 
(SNARK), an AMPK-related kinase that has previously been shown to be 
regulated by multiple cellular stresses in kidney and several tumor cell 
lines, will be discussed. 
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Glucocorticoids play important roles in the regulation of distinct aspects of 
adipocytes biology. Excess glucocorticoids in adipocytes are associated 
with various metabolic disorders, including central obesity, insulin 
resistance and dyslipidemia. Glucocorticoids convey their signals through 
glucocorticoid receptor (GR), which can occupy genomic glucocorticoid 
response elements (GREs) to modulate the transcription of its primary 
target genes. To understand the mechanisms underlying the glucocorticoid 
effects on adipocytes, we used chromatin immunoprecipitation sequencing 
to isolate genome-wide GR binding regions (GBRs) in 3T3-L1 adipocytes. 
We found that many GBRs were located in, or close to genes involved in 
triglyceride (TG) synthesis, lipolysis, lipid transport and storage. Gene 
expression analysis and reporter assays confirmed that 14 of these genes are 
regulated by glucocorticoids and they contain functional GREs. Thus, they 
are potential GR primary targets (Scd-1, 2, Gpat3, 4, Agpat2, Lpin1, Lipe, 
Mgll, Angptl4, Cd36, Lrp-1, Vldlr, Slc27a2, S3-12). Although TG levels 
were not significantly increased by glucocorticoid treatment, stable isotope 
labeling technique revealed that 4-day glucocorticoid treatment induced the 
rate of TG synthesis and lipolysis, at the same time, in inguinal fat. This 
observation was in agreement with our finding that glucocorticoids activate 
genes involved in both TG biosynthetic and lipolytic pathways. Notably, we 
found that 9 of these 12 genes were induced in transgenic mice over-
expressing corticotropin-releasing hormone, which have elevated plasma 
glucocorticoid levels. These results suggested that a similar mechanism was 
used to regulate TG homeostasis during chronic glucocorticoid treatment. 
To further test whether these potential GR primary target genes indeed 
mediate glucocorticoid-regulated lipid homeostasis in vivo, knockout mice 
lacking specific potential GR primary target gene were used. Mice lacking 
Angptl4 gene have impaired glucocorticoid-induced lipolysis in inguinal 
fat. This is likely due to an impaired glucocorticoid-induced PKA signaling. 
Moreover, these mice are protected from glucocorticoid-induced 
hyperlipidemia and fatty liver. In summary, our studies identified a 
glucocorticoid-controlled gene network involving in the regulation of TG 
homeostasis in adipocytes. The dissection of the mechanisms governing this 
network should provide important insights into the therapeutic approaches 
against metabolic diseases. 
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Peroxisome proliferator-activated receptor gamma (PPARγ) is a class II 
nuclear receptor that plays a central role in adipose tissue differentiation and 
regulates lipid metabolism and insulin sensitivity in multiple tissues. 
PPARγ activation by thiazolidinediones is widely employed in clinical 
practice to improve insulin sensitivity. Human loss-of-function mutations in 
PPARγ cause familial partial lipodystrophy (FPLD), a rare disorder 
characterized by redistribution of adipose tissue and severe early-onset 
diabetes. Detailed study of several such PPARγ mutations has improved our 
understanding of the role of PPARγ in the pathophysiology of diabetes. A 
recently identified PPARγ mutant, E157D, causes FPLD in a large 
Canadian family. Glutamate 157, located in the P-box region of the DNA 
binding domain of PPARγ, interacts with the major groove of the DNA 
molecule and has been shown to be important for PPAR response element 
(PPRE) selectivity. Although the Glu>Asp mutation would not be predicted 
to disrupt the local conformation of the protein, it clearly causes a severe 
phenotype with dominant inheritance. We hypothesized that E157D PPARγ 
has altered binding site selectivity and regulates a different set of target 
genes than the wild-type receptor. We assessed E157D PPARγ activity on a 
small set of well-characterized PPREs. When ectopically expressed in 
NIH3T3 fibroblasts, the mutant receptor was generally defective at driving 
gene expression from heterologous transcription reporters as well as 
endogenous PPREs. The severity of this transcriptional defect was not 
uniform across all PPREs, ranging from full induction to two hundred-fold 
lower activity compared to the wild-type receptor. Surprisingly, the E157D 
mutation did not affect PPARγ binding affinity for PPREs in an 
electrophoretic mobility shift assay. Contrary to our original hypothesis, this 
PPARγ mutant binds DNA as well as the wild-type receptor, but fails to 
fully activate gene transcription. We conclude that the E157D mutation 
disrupts a post-DNA binding regulatory step in the transcription activation 
cascade and that the degree of this disruption is affected by the DNA 
sequence to which the receptor is bound. Our findings suggest a previously 
unrecognized, complex and finely tuned interaction between the nuclear 
receptor DNA binding domain and other members of the transcriptional 
machinery.  
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Accumulating evidence has established a clear role for the Steroid Receptor 
Coactivators (SRCs) in the regulation of systems metabolism. To gain a 
more global understanding of how the SRCs dynamically influence the 
metabolic landscape, we performed comprehensive metabolomics analysis 
upon ablation of each coactivator. These data revealed a multitude of tissue- 
and energy state-dependent functions for each of the three coactivators. Of 
particular interest, loss of SRC-3 leads to a marked increase in long and 
very-long chain acyl-carnitines, specifically in muscle. We have correlated 
the loss of SRC-3 with the muscle-specific loss of expression of the 
essential carnitine/acyl-carnitine translocase (CACT). Phenotypically, SRC-
3-/- mice resemble humans with a deficiency in this transporter, highlighting 
the physiological importance of SRC-3 in muscle. Ablation of SRC-3 in 
mice phenocopies the major hallmarks of human CACT deficiency 
including: elevated long/very-long chain acyl-carnitines, hypoglycemia, 
muscle weakness, hypoketonemia, cardiac arrhythmia, and 
hyperammonemia. Collectively, these studies provide the first evidence for 
a muscle-specific function of SRC-3 and perhaps identify SRC-3 as a new 
therapeutic target for the treatment of muscle-related and metabolic 
disorders. 
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Nuclear receptors transduce environmental and metabolic signals into 
alterations in gene expression by recruiting coregulators that alter chromatin 
structure. Rev-erbα (NR1D1) is expressed in a circadian manner and 
constitutes a negative limb of the circadian clock, primarily by repressing 
the expression of Bmal1. The repressive function of Rev-erbα is mediated 
by a corepressor complex that is anchored by Nuclear Receptor Corepressor 
(NCoR) and contains the epigenetic modification enzyme, histone 
deacetylase 3 (HDAC3). The enzyme activity of HDAC3 requires binding 
to NCoR via a SANT-motif-containing Deacetylase Activating Domain 
(DAD). Mice harboring an NCoR DAD mutation that prevents HDAC3 
binding have dysregulated circadian rhythms and alterations in metabolism 
that demonstrate the importance of epigenomic regulation, and in particular 
the NCoR-HDAC3 interaction, in normal metabolic and circadian 
physiology. The activity of Rev-erbα is controlled by binding of heme 
ligand, by lithium-modulated degradation, and by a dramatic circadian 
expression pattern. Genome-wide analysis of Rev-erbα and HDAC3 
binding in metabolic tissues reveals cistromes that include a large number 
of metabolic genes, and strongly suggest a key role of the Rev-erbα-NCoR-
HDAC3 axis in the normal circadian physiology of metabolism. The 
nuclear receptor PPARγ is the target of antidiabetic thiazolidinedione 
(TZD) drugs, and a transcriptional regulator of lipid metabolism. PPARγ is 
also required for adipogenesis. On a genome-wide scale, identification of 
PPARγ cistromes in adipocytes as well as macrophages has revealed tissue-
specific transcription factors and epigenomic marks that selectively target 
PPARγ to pathway-related DNA binding sites. The epigenomic regulation 
and functions of Rev-erbα and PPARγ highlight the key role of nuclear 
receptors in the integrated physiology of circadian rhythm and metabolism. 
 126 
HOMEOSTATIC LEVELS OF SRC-2 AND SRC-3 PROMOTE EARLY 
HUMAN ADIPOGENESIS  
 
Sean M Hartig1, Bin He1, Benjamin M Buehrer2, Michael A Mancini1  
 
1Baylor College of Medicine, Molecular and Cellular Biology, Houston, 
TX, 77030, 2Zen-Bio, Inc., Research and Development, Research Triangle 
Park, NC, 27709 
 
The related coactivators SRC-2 and SRC-3 interact with PPARγ to 
coordinate and amplify a transcriptional circuit that promotes adipogenesis. 
To identify potential coactivator interplay and redundancy during human 
adipogenesis, we utilized high content analysis at the single cell level to 
quantify new links between PPARγ, SRC-2, SRC-3 and lipogenesis in 
human subcutaneous adipocytes. As expected during the first 96 h of 
differentiation, there were robust and concomitant increases in PPARγ 
protein levels and lipid content within the bulk population. When examined 
on a cell-to-cell basis, marked cell-to-cell heterogeneity exists, with PPARγ 
and lipid levels varying up to a 1000-fold, which were further subdivided 
into PPARγhi/Lipidhi, PPARγhi/Lipidlo, PPARγlo/Lipidhi, PPARγlo/Lipidlo 
states to understand population kinetics during differentiation. In contrast, 
protein levels of SRC-2 and SRC-3 exhibited significantly less cell-to-cell 
variability. By a complementary FRET imaging approach, SRC-2 and SRC-
3 interact with PPARγ without significant increases upon treatment with 
differentiation cocktail. Collectively, we hypothesized that permissive 
levels of SRC-2 and SRC-3 were necessary for adipogenesis. To probe 
these coactivator thresholds, we down-regulated SRC-2 and SRC-3 while, 
simultaneously, quantifying PPARγ. Knockdowns of SRC-2 and SRC-3, 
individually or jointly, equally inhibited lipid accumulation by preventing 
lipogenic gene engagement, without affecting PPARγ protein levels. 
Supporting a dominant pro-adipogenic role for SRC-2 and SRC-3, 
knockdown of the other homologous p160, SRC-1, did not affect human 
adipogenesis. SRC-2 and SRC-3 knockdown increased the proportion of 
cells in a PPARγhi/Lipidlo state while synergistically increasing phospho-
PPARγ−S114, found to reduce PPARγ transcriptional activity and block 
adipogenesis. Together, these studies demonstrate that SRC-2 and SRC-3 
concomitantly promote human adipocyte differentiation, by attenuating 
phospho-PPARγ−S114, and modulating PPARγ cellular heterogeneity. 
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We seek to apply comprehensive metabolic analysis tools (sometimes called 
“metabolomics”) for understanding of mechanisms underlying chronic 
human diseases such as diabetes, obesity, and cardiovascular disease. 
Current approaches include metabolic profiling of important groups of 
metabolic intermediates by both “targeted” and “unbiased” mass 
spectrometry (in collaboration with Drs. James Bain, Robert Stevens, Olga 
Ilkayeva, Brett Wenner, Michael Muehlbauer, Mark Butler, and David 
Millington at Duke). These tools have been used to investigate the 
metabolic mechanisms underlying development of peripheral insulin 
resistance in animals and humans. For example, we have recently identified 
perturbations of branched chain amino acid (BCAA) catabolism in multiple 
cohorts of insulin resistant humans compared to normally insulin sensitive 
controls and have translated these findings to rodent models to demonstrate 
a contribution of BCAA to development of insulin resistance that is 
independent of body weight. We have also collaborated with Dr. Bert 
O'Malley and colleagues to investigate the metabolic impact of the 
transcriptional co-regulators SRC-1, SRC-2, and SRC-3. In this study, 
metabolic profiling allowed us to pinpoint the tissues and specific metabolic 
pathways impacted upon knock-out of each of the SRC family members. 
Finally, in collaboration with Dr. Alan Attie at the University of Wisconsin, 
we have integrated transcriptomic and metabolomic analysis to identify new 
pathways that control hepatic gluconeogenesis and PEPCK expression. 
These examples will serve to illustrate the potential of comprehensive 
metabolic profiling methods for providing insights into nuclear receptor 
biology and metabolic disease mechanisms. 
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Emerging evidence suggests that sustained inflammatory responses 
involving microglia and astrocytes contribute to the pathogenesis of 
neurodegenerative diseases that include Alhzheimer’s disease, Parkinson’s 
disease and Multiple Sclerosis. Microglia are the major resident immune 
cells in the brain, where they constantly survey the microenvironment and 
produce factors that influence surrounding glia and neurons. Astrocytes 
play key roles in neuronal support and tissue homeostasis within the CNS 
and also respond to infection and injury, with recent studies suggesting that 
communication between microglia and astrocytes can function to greatly 
amplify inflammation. Microglia and astrocytes switch from deactivated to 
activated phenotypes upon pathogen invasion or tissue damage and thereby 
promote an inflammatory response that serves to engage the immune 
system and initiate tissue repair processes. In most cases, these responses 
are self-limited, resolving once infection has been eradicated and tissue 
damage repaired. However, persistence of an inflammatory stimulus and/or 
failure in normal resolution mechanisms results in chronic inflammation 
that can contribute to neurotoxicity. Recent studies suggest that nuclear 
receptors and their ligands regulate pathogenic mechanisms that underlie 
neurodegeneration, including neurotoxic inflammation. Our studies have 
recently focused on defining signal-dependent transcriptional repression 
pathways that are utilized by Nurr1 and estrogen receptor beta to negatively 
regulate inflammatory gene expression in microglia and astrocytes. We 
propose that these pathways contribute to maintenance of normal tissue 
homeostasis within the central nervous system and become dysregulated in 
the context of neurodegenerative disease. 
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The nuclear receptor PPARγ has been shown to regulate glucose and lipid 
metabolism, and inflammation. Activation of PPARγ by ligand treatment 
leads to an improvement of atherosclerosis in multiple animal and human 
studies. This is mediated partially by macrophage PPARγ as it increases 
cholesterol efflux from the macrophage. However, as endothelium is 
involved in the development of atherosclerosis, we hypothesized that 
endothelial PPARγ plays a role in atherogenesis as well. To study this, we 
first replace the bone marrow of Tie2-cre driven PPARγ f/f mice in the LDL 
receptor null background and their littermate controls with PPARγ wildtype 
GFP+ bone marrow. This generates an endothelial specific knockout of 
PPARγ. After feeding them atherogenic diet for various periods of time, 
these mice were harvested for atherosclerotic lesion analyses. While 
endothelial PPARγ knockout mice and littermates have comparable blood 
pressure, fasting glucose, and weights, lesion analyses showed endothelial 
PPARγ knockout mice have 51% and 29% more lesion at the aortic sinus 
after 8 and 16 weeks of atherogenic diet, respectively (p<0.05). These 
results demonstrate that endothelial PPARγ plays an athero-protective role. 
To examine whether endothelial PPARγ is involved in early stages of 
atherosclerotic lesion development, we scored GFP+ macrophage 
infiltration into the lesser curvature of the aorta and found endothelial 
PPARγ knockout mice have 75% more macrophage infiltration and 
increased serum levels of soluble ICAM-1 and E-selectin after 2 weeks of 
atherogenic diet. To understand the function of endothelial PPARγ, we 
performed microarray analyses using primary endothelial cells isolated 
from mice before and two weeks after the initiation of atherogenic diet and 
found that the endothelial cells lacking PPARγ on chow diet exhibit a gene 
expression profile similar to wildtype endothelial cells after two weeks of 
atherogenic diet, suggesting that PPARγ knockout endothelial cells are 
already activated. Among the genes upregulated is the cytokine fractalkine, 
which is involved in both chemo-attraction and adhesion of leukocytes to 
the endothelium. In vitro studies confirm the increased ability for the 
PPARγ knockout endothelial cells to adhere to leukocytes comparing to 
wildtype cells and while this is not suppressed by rosiglitazone, it can be 
blocked by fractalkine neutralizing antibodies. In conclusion, deficiency of 
endothelial PPARγ leads to endothelial activation, increasing expression of 
adhesion molecules and cytokines, and consequently more severe 
atherosclerosis. 
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Chronic, low grade, inflammatory responses in metabolically active sites 
such as adipose tissue is a hallmark of chronic metabolic disease, especially 
obesity. This heightened metabolically triggered chronic inflammation or 
“metaflammation/paraflammation” is a critical link between obesity and 
other associated pathologies, such as insulin resistance, type 2 diabetes, 
hepatosteosis, cardiovascular disease and other pathologies. In metabolic 
context, inflammatory cascades involve both metabolic cells such as 
adipocytes and hepatocytes as well as immune effectors such as 
macrophages, mast cells and T cells. The collective activity of the 
inflammatory networks intersects with insulin receptor signaling at several 
levels to block insulin action and disrupt glucose and lipid metabolism. Our 
earlier work has identified the activation of inflammatory kinases such as c-
Jun N-terminal kinase (JNK) as a critical event seen in all forms of insulin 
resistance. Our studies, in search for intrinsic pathways leading to JNK 
activation and metabolic dysfunction, led to the discovery of endoplasmic 
reticulum (ER) dysfunction as a critical mechanism underlying metabolic 
disease, especially obesity and diabetes. Recently, we identified protein 
kinase R (PKR) as a potential intersection point between nutrients, 
organelle dysfunction and metabolic control. Using these systems, we are 
now pursuing the precise mechanisms by which nutrient sensing and 
metabolism intersect with immune response and organelle stress and 
identify the molecular targets of specific nutrients in their ability to engage 
components of the innate immune response. Here, I will present the latest 
developments and translational opportunities emerging from these platforms 
that are applicable to human metabolic diseases. 
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Dysregulated cytokine signaling is a key contributor to autoimmunity and 
inflammation; in particular, Type I Interferon (IFNα/β) has been causally 
linked to systemic lupus. Most autoimmune diseases are principally 
managed with glucocorticoids (GCs) which block proinflammatory 
cytokine gene expression. With respect to IFN, we have previously shown 
that activated glucocorticoid receptor (GR) controls the activity of 
interferon regulatory factor (IRF)3, a critical regulator of IFNα4/β gene 
transcription (Reily et al, EMBO J 2006). Interestingly, unlike their 
production, cytokine signaling through their cognate Jak/STAT pathways is 
reportedly unaffected or even stimulated by GCs. Unexpectedly, we found 
that dexamethasone (Dex) specifically attenuates the IFN-induced gene 
expression in primary macrophages. To identify the Dex-sensitive step in 
the IFN-Jak/STAT signaling pathway, we evaluated the function of the 
heterotrimeric STAT1:STAT2:IRF9 (ISGF3) transcription complex, 
responsible for mediating IFN signals. Interestingly, we found that ISGF3 
utilized the GR cofactor GRIP1/TIF2 as a coactivator. Indeed, dominant 
negative GRIP1, its siRNA-mediated knockdown, genetic disruption or 
depletion by GC-activated GR attenuated ISGF3 promoter occupancy, 
preinitiation complex assembly and ISG transcription, whereas GR 
antagonist RU486, which disrupts the GR:GRIP1 interaction, restored IFN 
response. Thus, type I IFN represents a unique cytokine controlled by GR at 
the levels of both production (e.g., IFN gene transcription) and signaling, 
through the antagonism with ISGF3 effector function, revealing a novel 
facet of the immunosuppressive properties of GCs. 
 
Supported by the Cancer Research Institute, NIH NIAID, Lupus Research 
Institute and Mary Kirkland Center for Lupus Research 
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Nuclear receptor corepressor protein (NCoR) serves as a corepressor for 
nuclear receptors and other factors and recent evidence suggests that 
NCOR1 can be a regulator of metabolism. NCoR represses PPARγ 
(peroxisome proliferator-activator receptor gamma) mediated 
transcriptional activity in 3T3-L1 adipocytes in vitro, but its role in vivo 
remains unclear. We generated adipocyte specific NCoR1 knock-out 
(NCoR-ap2) mice by crossing NCoR f/f with ap2-Cre mice, to investigate 
the function of NCoR in insulin sensitivity. Our data show that NCoR-ap2 
mice gain more weight on a 60% high fat diet (HFD) with increased 
accumulation of subcutaneous and visceral fat. The KO mice also display 
reduced plasma free fatty acid (FFA) and insulin levels. Insulin tolerance 
and glucose tolerance tests showed that NCoR-ap2 mice are more glucose 
tolerant compared with wt HFD mice. Hyperinsulinemic-euglycemic clamp 
studies demonstrate that the NCoR-ap2 mice have higher insulin stimulated 
glucose disposal rate (IS-GDR), suppression of hepatic glucose production 
(HGP) and FFA suppression, showing that NCoR deletion in adipocytes 
leads to improved systemic insulin sensitivity in all three major insulin 
target tissues (liver, muscle and fat). Hepatic triglyceroride content and 
steatosis were reduced in the KO mice, while in adipose tissue, there was 
less macrophage infiltration, reduced inflammatory gene expression 
(including, IL-1β, iNOS and IL-12p40), but greater adipogenic gene 
expression (including, SCD1, FAS, ACC and SREBP-1c) in the KOs. The 
effects of rosiglitazone treatment to improve in vivo insulin sensitivity were 
blunted in the NCoR-ap2 mice, indicating that NCoR-ap2 mice are 
relatively refractory to PPARγ stimulation. Together, these results 
demonstrate that NCoR-dependent transrepression is a key determinant of 
the adipogenic set point as well as an integrator of glucose metabolism and 
whole-body metabolic homeostasis. 
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Cell types and subtypes are specified upon receiving external stimuli and 
also by endogenous programmes. The mechanisms of differentiation and 
subtype specification of certain immune cells such as macrophages are 
critical to understand the regulatory logic and principles of the immune 
system as a whole. It is becoming more and more appreciated that besides 
cytokines lipid signaling also contributes to these processes. Peroxisome 
proliferator-activated receptor γ (PPARγ), a lipid-activated transcription 
factor regulates the interplay of lipid metabolism and inflammation in 
macrophages and dendritic cells (DCs). These immune cells if exposed to 
distinct inflammatory milieu show cell type specification. We will present 
evidence to show one of the the mechanisms how PPARγ signaling is 
regulated in these distinct subsets of cells. We show that proinflammatory 
molecules inhibit, while interleukin-4 (IL-4) stimulates PPARγ activity in 
macrophages and DCs. Furthermore, IL-4 signaling augments PPARγ 
activity through a novel interaction between PPARγ and Signal Transducer 
and Activators of Transcription 6 (STAT6) on promoters of PPARγ target 
genes, including FABP4/aP2. STAT6 acts as a required licensing factor for 
PPARγ by promoting DNA binding and consequently increasing the 
number of regulated genes and also the magnitude of responses. This 
mechanism, underpinning cell type-specific responses, represents a unique 
way of controlling nuclear receptor signaling by inflammatory molecules. 
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The glucocorticoid receptor (GR), like many DNA-binding transcription 
factors, dynamically interacts with response elements (REs) to regulate 
temporal gene expression patterns that are required for development and 
homeostasis. Live cell microscopy studies demonstrate that GR resides on 
glucocorticoid REs (GREs) for time scales of seconds or less, indicating a 
“hit and run” mechanism in which factors stochastically interact with 
binding sites, modify the chromatin, and then rapidly leave the site. In 
contrast, many current interpretations of steady-state chromatin 
immunoprecipitation (ChIP) results suggest that steroid receptors bind on 
time scales of minutes to hours. These longer residency times are proposed 
by others to promote sequential, ordered formation of multi-protein 
regulatory complexes, which are predicted to saturate response elements 
(Degenhardt et al., 2009). Using both microscopy and ChIP approaches, we 
show that the concurrent binding of a second GRE-targeting receptor, the 
estrogen receptor pBox mutant (ER pBox), does not reduce the GRE 
binding of GR or ER pBox compared to the individual receptor steady-state 
binding levels. In mathematical binding simulations, this lack of 
competition is explained by short GR/GRE residency times and relatively 
long times between binding events, which produce GREs that are far from 
saturation. At many genomic sites where GR-binding causes chromatin to 
become more accessible to nuclear proteins, the steady-state levels of 
concurrently binding ER pBox are also increased. This suggests that 
accessible GR-dependent chromatin remodeling states persist after GR has 
left the GRE, providing a mechanism for GR to stimulate transcription 
between intermittent binding events. The prevalence of sparsely occupied 
GREs during transcriptional activation is a novel biophysical condition 
which should be included in future quantitative models of dynamic gene 
expression. These findings further support the “hit and run” transcription 
hypothesis and argue against stable chromatin binding by actively engaged 
regulatory complexes. 
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The effects of global deletion of Peroxisome Proliferator Activated 
Receptor gamma (PPARγ) on development could not be explored so far 
because of the lethality of the germ-line deletion of PPARγ. The presence of 
a major alteration of the placental development seemed the main cause of 
this early embryonic lethality. Therefore, we used an epiblast-specific 
deletion of the PPARγ alleles to preserve PPARγ expression in the 
trophoblast. This allowed us to obtain fully viable PPARγ null mice, 
thereby demonstrating that the placental defect is the unique cause of 
PPARγ-/- early embryonic lethality.  
 
To analyse the activity of PPARγ in the later stage of placental development 
when its expression peaks, we treated pregnant wild-type mice with the 
PPARγ agonist rosiglitazone. This treatment resulted in an aberrant 
placental microvasculature and disorganisation of the placental layers 
accompanied by the decreased expression of proangiogenic genes such as 
PLF, vascular endothelial growth factor and Pecam1. These findings 
demonstrate that PPARγ plays a pivotal role in controlling vascular 
proliferation and contributes to its quiescence in late pregnancy. 
 
As mentioned above, we are now able to obtain a global knockout mouse 
model of PPARγ. The PPARγ null mice are born alive, along the expected 
mendelian ratio. They are totally lacking adipose tissue and are particularly 
fragile before weaning after which their growth not only catch back but 
exceed that of their control littermates. The exploration and main 
observations of this new mouse model will be presented.  
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Estrogens play crucial roles in regulating the expression of hundreds, perhaps 
thousands, of genes in normal physiological states, such as the development of 
reproductive organs, as well as disease states, such as breast cancers. Although 
recent genomic analyses of estrogen-dependent transcription have provided the 
vast amount of information, many aspects of the estrogen-dependent gene 
regulatory network, however, have not yet been elucidated. Foremost among 
these is the set of genes comprising the set of direct or primary estrogen-
regulated targets. This information is critical because the direct estrogen-
regulated transcriptome is likely to define a useful set of biomarkers with 
prognostic value and utility as therapeutic targets in breast cancers.  
 
To define the direct estrogen-regulated transcriptome with greater sensitivity 
than existing genomic analyses, we have applied an innovative new method 
called Global Nuclear Run-On and Massively Parallel Sequencing (GRO-seq) 
to explore the estrogen-regulated transcriptome in MCF-7 breast cancer cells. 
GRO-seq is a deep sequencing-based genomic approach that provides a 
genome-wide map of the location and orientation of transcriptionally engaged 
RNA polymerase II (Pol II). Using GRO-seq as a direct measure of 
transcriptional output, we have produced libraries from MCF-7 breast cancer 
cells in response to short treatments with 17-estradiol (E2) that reveal the 
location of actively transcribing Pol II in human breast cancer cells. Our goals 
are to (1) identify in an unbiased manner the annotated and unannotated 
transcripts that change expression during estrogen signaling, (2) obtain a time-
course of activation for each transcript, and (3) identify the direct estrogen 
target genes. Our results have allowed us to detect E2-regulated transcripts with 
greater sensitivity and at much earlier time points than has been achieved with 
conventional expression microarray platforms. Collectively, these studies are 
revealing many unexpected novel features of E2-regulated gene expression, as 
well as new mechanistic insights. We expect that genome-wide inferences based 
on the direct estrogen-regulated transcriptome will be useful for understanding 
the molecular mechanisms driving the development and progression of breast 
cancers. 
 
Supported by grants from the NIH/NIDDK to W.L.K. 
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Steroid hormone receptors are reliant on the Hsp90 molecular chaperone 
system to establish and maintain both a hormone-binding competent state 
and a dynamic interaction with promoter response elements. By modulating 
the stability of receptor-DNA complexes, molecular chaperones facilitate 
the signaling process by ensuring efficient transitions between the employed 
coactivator complexes and permitting effective sensing of the hormonal 
signal. The Hsp90 cochaperone p23 appears to drive the disassembly of 
receptor-bound coactivator complexes. While dynamic action is likely 
critical for proper gene regulation, the mechanisms used to achieve the fast 
dissociation-kinetics are not fully understood. 
To initially investigate a p23 cochaperone we focused on the yeast homolog 
Sba1 and exploited high-throughput genomic and proteomic approaches to 
gain a global functional map of a p23 protein. Our studies revealed a broad 
nuclear role for Sba1, contrasting with the historical dogma of restricted 
cytosolic activities for chaperones. Importantly, we found that the roles 
were conserved since mammalian p23 also affected the identified pathways. 
To understand how a mammalian p23 cochaperone intersects with a nuclear 
protein we followed up on the synthetic lethal genetic interaction between 
sba1Δ and gcn5Δ; GCN5 encodes for a histone acetyltransferase protein. 
Surprisingly, the connection does not involve chromatin events. Rather, we 
found that p23 and Gcn5 form a regulatory circuit that coordinately 
regulates the DNA-bound state of diverse proteins. Using both the 
Glucocorticoid Receptor (GR) and Heat Shock Factor 1 (HSF1) as model 
targets, we observed that both p23 and Gcn5 inhibited GR and HSF1 DNA 
binding activity. p23 initiated disassembly of DNA-bound transcription 
factors while Gcn5 prolonged the dissociated state by acetylating a lysine 
residue within the DNA binding domain. In addition, p23 can control the 
enzymatic activity of Gcn5, which likely serves to close the regulatory 
circuit. Notably, p23 and Gcn5 affected the DNA binding activities of a 
variety of proteins including other transcription factors and proteins 
required for DNA replication and telomere maintenance. Our data support a 
model in which p23 and Gcn5 constitute a general system for modulating 
protein DNA dynamics across the genome. 
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TLE3 IS A DUAL FUNCTION TRANSCRIPTIONAL COREGULATOR 
OF ADIPOGENESIS 
 
Peter Tontonoz  
 
University of California-Los Angeles, Howard Hughes Medical Institute 
and Department of Pathology and Laboratory Medicine, Los Angeles, CA, 
90095 
 
PPARγ and Wnt signaling are central positive and negative regulators of 
adipogenesis, respectively. Here we identify the groucho family member 
TLE3 as a transcriptional integrator of the PPARγ and Wnt pathways. TLE3 
is a direct target of PPARγ that participates in a positive feedback loop 
during adipocyte differentiation. TLE3 coactivates PPARγ and acts 
synergistically with PPARγ on its target promoters to stimulate 
adipogenesis. At the same time, induction of TLE3 during differentiation 
provides a mechanism for termination of Wnt signaling. TLE3 antagonizes 
TCF4 activation by β-catenin in preadipocytes, thereby inhibiting Wnt 
target gene expression and reversing β-catenin-dependent repression of 
adipocyte gene promoters. Transgenic expression of TLE3 in adipose tissue 
in vivo mimics the effects of PPARγ agonist and ameliorates high fat diet-
induced insulin resistance. Our data suggest that TLE3 acts as a dual 
function switch, driving the formation of both active and repressive 
transcriptional complexes that facilitate the adipogenic program. 
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SUMOYLATION OF C. ELEGANS NUCLEAR RECEPTOR NHR-25 
PROMOTES PROPER ORGANOGENESIS 
 
Jordan D Ward1, Nagagireesh Bojanala2, Teresita Bernal1, Kaveh Ashrafi3, 
Marek Jindra2, Masako Asahina2, Keith R Yamamoto1  
 
1UCSF, Department of Cellular and Molecular Pharmacology, San 
Francisco, CA, 94158, 2Biology Centre ASCR and Univ. South Bohemia, 
Department of Genetics, Budweis, 37005, Czech Republic, 3UCSF, 
Department of Physiology, San Francisco, CA, 94158 
 
We are using C. elegans to deconvolute how NRs govern cell- and tissue-
specific gene regulatory programs. In particular, we focus on the single C. 
elegans NR5A family receptor, NHR-25, and its coordination of diverse 
events such as molting, seam cell differentiation, dauer formation, and 
somatic gonad and vulva formation. To uncover novel co-regulators of 
NHR-25 activity we performed a genome-wide yeast two-hybrid (Y2H) 
screen. NHR-25 interacts strongly with SMO-1, the single C. elegans 
SUMO-1 homolog (SMO-1). To distinguish between covalent sumoylation 
and non-covalent interaction we performed mutational analysis. 
Interestingly, deletion of the SMO-1 C-terminal di-glycine repeat and 
mutations in the SMO-1 beta sheet, which abrogate covalent sumoylation 
and non-covalent binding, respectively, prevented NHR-25 binding in Y2H 
assays. One possible model is that NHR-25 initially binds SMO-1 non-
covalently to promote sumoylation of NHR-25, in a mechanism similar to 
thymine DNA glycosylase sumoylation. smo-1 deletion mutants undergo 
aberrant vulval morphogenesis resulting in a single protrusion at the site of 
the vulva (Pvl). Additionally, smo-1 mutants have a weak multivulva (Muv) 
phenotype where a single proper vulva develops and is surrounded by 
ventral protrusions comprised of vulval tissue. We observed a genetic 
interaction between nhr-25 and smo-1: nhr-25(RNAi) in smo-1(ok359) 
mutant worms exacerbates the smo-1 multivulva phenotype. Interestingly, 
nhr-25(RNAi) prevents the vulval precursor cells from completing full 
rounds of cell division, suppressing the Pvl phenotype. These data suggest a 
critical role for receptor modification by sumoylation in execution of an 
organogenesis program. Given the impact of sumoylation on target gene 
recognition by the vertebrate homologs of NHR-25, SF-1 and LRH-1, these 
studies provide insight into the role of sumoylation on NR5A receptor-
governed physiological programs. 
 
Supported by GACR 204/09/H058, 204/07/0948 TFF postdoctoral 
fellowship 700046, NIH grant CA020535.  
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DYNAMICS OF NUCLEAR RECEPTOR INTERACTIONS AT 
GLOBAL REGULATORY ELEMENTS 
 
Gordon L Hager  
 
National Cancer Inst, NIH, Lab of Receptor Biology & Gene Expression, 
Bethesda, MD, 20892 
 
Multiple cyclical mechanisms are involved in the transcriptional regulation 
of gene expression by nuclear receptors. Live cell imaging analysis 
demonstrates that receptors exchange rapidly with regulatory elements in 
the continued presence of ligand [Mol Cell 35:741 (2009)]. In some cases, 
ligand concentrations in the animal are also subject to oscillatory patterns. 
We have also shown that transcription factors can be actively displaced 
from the nucleoprotein template during chromatin remodeling in vitro [Mol 
Cell 14:163 (2004)]. To examine the complex dynamic of factor/template 
interactions on the global scale, we have carried out a genome-wide analysis 
of nuclear receptor binding events, as well as a global characterization of 
DNaseI hypersensitive transitions (DHS) associated with receptor binding 
[Mol Cell 29:611 (2008)]. We find that receptor/genome interactions are 
universally associated with local chromatin remodeling events. The 
presence of these locally open chromatin regions is highly cell specific, and 
receptor binding correlates well with the presence of these sites. We have 
examined the ability of factors that recognize the same response element to 
compete for binding, by direct imaging of site specific binding events in 
living cells, and by ChIP analysis at genome wide DHS sites. In contrast to 
competition, we observe assisted loading of factors. These findings will be 
discussed in terms of 1) the “hit-and-run” model first proposed for the 
glucocorticoid receptor, 2) the central role for chromatin remodeling in 
genome-wide action by nuclear receptors, and 3) the function of dynamic 
processes operating on multiple time scales in the evolution of complex 
transcriptional programs.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64485 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
